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Serotonin Transporter Inhibitor Ligands: Synthesis of 2-(2-alkyl-piperazin-1-yl)-6- 
nitroquinoline Analogs as Potential Positron Emission Tomography Imaging 
Agents
The pre-synaptic serotonin transporter (SERT) membrane protein is responsible 
for the clearance of the endogenous neurotransmitter serotonin (5-HT) from the 
synaptic cleft. The SERT protein is an established target for serotonin selective 
reuptake inhibitor (SSRI) therapeutic drugs. Alterations in SERT population 
densities and/or function have been implicated in a number of mental health 
disorders, including depression, anxiety, schizophrenia, and Parkinson’s disease. 
Efforts to assess SERT changes in living brain utilizing positron emission 
tomography (PET) have been limited based on the availability of efficacious (as a 
function of in vivo kinetics and nonspecific binding), potent and selective SERT 
PET imaging radioligands. To satisfy the demand for new PET SERT imaging 
agents, investigations have encompassed the interpretation of a SERT 
pharmacophore model of the SSRI binding domain to identify new lead ligands. 
The novel SERT inhibitor 2-(2-methyl-piperazin-1-yl)-6-nitroquinoline has been 
used to design new SERT inhibitors 2-(2-(methoxymethyl)-piperazin-1-yl)-6- 
nitroquinoline and 2-(2-(3-fluoropropyl)-piperazin-1-yl)-6-nitroquinoline, among 
others. The syntheses of these new SERT inhibitors were designed to allow for 
late stage introduction of carbon-11 and fluorine-18 radionuclides. The analogs 
of 2-(2-methyl-piperazin-1-yl)-6-nitroquinoline have been found to be highly 
potent (rSERT Kj = 2-100 pM, [3H]Paroxetine), and selective (relative to 
dopamine and norepinephrine transporters) for SERT. Additionally, specific 
enantiomers of 2-(2-methyl-piperazin-1-yl)-6-nitroquinoline and inhibitors 2-(2- 
(methoxymethyl)-piperazin-1-yl)-6-nitroquinoline are more potent than their 
respective opposing enantiomeric forms. These results provide two new non­
radioactive ligands that are considered as plausible carbon-11 and fluorine-18 
PET SERT imaging agents.
Chairperson: John M. Gerdes
ii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Dedication
I dedicate this thesis to my loving wife Rebecca A. Kusche, my daughter Anika L. 
Kusche and my parents Paul and Teena Kusche. Without their love and support
I could have never achieved so much.
iii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Acknowledgments
I wish to express my sincere gratitude towards Dr. John Gerdes for the 
opportunities he has provided during the course of my graduate work at The 
University of Montana. Dr. John Gerdes has been an excellent mentor, 
colleague and friend.
I have to thank the members of the Gerdes group (past and present) for 
their help and encouragement. In particular I thank Melodie Weller for her 
pharmacological efforts. Most importantly, I have to thank and acknowledge my 
good friend and colleague Dr. David Bolstad. Life in lab and Missoula would not 
have been the same with out him and his encouragement, I could not have asked 
for a better friend and lab partner.
Thank you to Dr. Jim O’Neil at the Lawrence Berkeley National 
Laboratories for giving me the opportunity to experience radiosynthesis first 
hand. The work in this thesis would not be complete if not for all the 
radiochemistry completed with and by Dr. O’Neil.
I would like to express my gratitude to my committee members, Dr. Ed 
Waali, Dr. Keith Parker, Dr. Ed Rosenberg, and Dr. Sean Esslinger, for their 
advice and support through my graduate work at The University of Montana.
Thank you to my family and friends for their love and support throughout 
my college career. I have to thank my parents Paul and Teena for their 
continued encouragement and for providing me the values that have allowed me 
succeed in the career path I have chosen.
iv
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Most importantly I have to thank my wife Becky for her love and support 
throughout life and my graduate work. Her faith in my abilities has provided me 
with the strength to achieve the goals I have set for myself. Of course I have to 
thank my daughter Anika for all of her help during the writing of this thesis, she 
made the late nights easier.
v
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table of Contents
Chapter 1 Introduction and Background.............................................................................................1
1.1 Introduction.....................................................................................................................................1
1.2 The Neurotransmitter Serotonin ......................................................................................2
1.3 Serotonin Neurotransmission at the Synapse..........................................................................4
1.4 Serotonin Reuptake Transporter (SERT)..................................................................................5
1.5 Functional Brain Imaging (FBI)................................................................................................... 8
1.6  Criteria for SERT PET Tracers................................................................................................... 9
1.7 SSRIs as Potential PET Imaging Agents................................................................................ 10
1.8  Current SERT Imaging Agents................................................................................................. 11
1.9 6 -Nitroquipazines as SERT Inhibitor Tracers.........................................................................14
1.10 Pharmacophore Development.................................................................................................. 15
1.11 Me-NQP 28 and (±)-30, Implications to the Pharmacophore...............................................18
1.12 MOM-NQP (±)-31........................................................................................................................21
1.13 R- and S-Me-NQP ((R)-30 and (S)-30)................................................................................... 24
1.14 Proposed Work............................................................................................................................25
Chapter 2 Synthesis of Racemic Targets......................................................................................... 26
2.1 Introduction and Goals............................................................................................................... 26
2.2 Synthesis of [11C]MOM-NQP 31...............................................................................................26
2.3 Synthesis of PROM-NQP (±)-51............................................................................................. 31
2.4 Synthesis of the Radiolabeling Precursor N-formyl-ProTos-NQP 63.................................43
2.5 Nonradioactive Fluorinations of N-formyl-ProTos-NQP 63.................................................. 48
2.6 Radiofluorination of N-formyl-ProTos-NQP 63.......................................................................49
2.7 Synthesis of the Precursor N-Boc-ProTos-NQP 69.............................................................. 50
2.8 Radiofluorination Attempts of N-Boc-ProTos-NQP 69.......................................................... 54
2.9 Radiofluorination Attempts with K222, KHC03 and Ag18F....................................................55
2.10 TBA18F Radiofluorination Attempts.......................................................................................... 57
2.11 Fluorination Control Reactions..................................................................................................62
2.12 Synthesis Pent-NQP (±)-83 and PentF-NQP 8 8 ....................................................................6 6
2.13 Synthesis of BuM-NQP 96.........................................................................................................70
2.14 Summary and Conclusion..........................................................................................................72
Chapter 3 Synthesis of Asymmetric Targets................................................................................... 74
3.1 Chiral Nitroquipazine Ligand Studies.......................................................................................74
3.2 Chiral Piperazine Syntheses..................................................................................................... 76
3.3 Synthesis of Chiral MOM-NQP 31............................................................................................78
vi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3.3.1 Synthesis of N-Boc-N-Bn-glycine...................................................................................... 78
3.3.2 Synthesis of 1-Benzyl-3-(hydroxymethyl)piperazine 113.............................................. 79
3.3.3 Synthesis of Chiral MOM-NQP 31.................................................................................... 81
3.4 Application of the Chiral Synthesis, Chiral PROM-NQP 51................................................ 82
3.5 Alternate Synthesis of Chiral PROM-NQP.............................................................................8 8
3.6 Synthesis of Chiral Pent-NQP 83............................................................................................ 91
3.7 Synthesis of Chiral BuM-NQP 96............................................................................................ 94
3.8 Summary and Conclusions.......................................................................................................95
Chapter 4 Pharmacology..................................................................................................................... 97
4.1 Introduction.................................................................................................................................. 97
4.2 Competitive Inhibition, SERT Pharmacology [3H]paroxetine...............................................98
4.2.1 Discussion of Pharmacology............................................................................................ 100
4.3 Synthesis of n-PROP-NQP 52 and [3H]n-PROP-NQP....................................................... 104
4.4 In Vitro SERT Binding Studies [3H]-n-PROP-NQP 52........................................................ 107
4.5 Determination of the Apparent Equilibrium Dissociation Constant (KD) and Receptor
Density (Bmax)...........................................................................................................................111
4.6 SERT Selectivity of [3H]-n-PROP-NQP 52...........................................................................112
4.7 Summary.............................................................................................................   114
Chapter 5 Conclusions and Future W o rk ....................................................................................... 116
Chapter 6  Experimental Section...................................................................................................... 119
6.1 General Experimental.............................................................................................................. 119
6.2 Racemic Propyl Series............................................................................................................ 120
6.3 Chiral Propyl N-formyl Series..................................................................................................138
6.4 Chiral Propyl N-Boc Series......................................................................................................150
6.5 Racemic n-PROP-NQP Synthesis......................................................................................... 158
6 . 6  Racemic Pent-NQP Series......................................................................................................162
6.7 Chiral Pent-NQP Series...........................................................................................................173
6 . 8  Racemic BuM-NQP Series......................................................................................................187
6.9 Chiral BuM-NQP Series...........................................................................................................195
Appendix...................................................................................................................................................199
Bibliography.............................................................................................................................................207
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
List of Figures
Figure 1-1: Biosynthesis and degradation pathway for serotonin in the CNS..................................... 4
Figure 1-2: Signals from the pre-synaptic neurons to the post-synaptic neurons of the
serotonergic system are linked by the neurotransmitter serotonin (5-HT). Release of
5-HT from the vesicles and subsequent binding with the postsynaptic receptors
induces a response in the postsynaptic neuron and propagates the nerve impulse 5
Figure 1-3: Typical SSRIs and related SERT inhibitors.......................................................................... 7
Figure 1-4: Commercial SSRI analogs developed as potential SERT PET imaging agents.......... 11
Figure 1-5: Radiolabelled derivatives of the potent and selective SSRI MCN5652..........................12
Figure 1-6: The Diarylsulfide SERT inhibitor 403U76 15 and the potential SERT SPECT analogs
IDAM 16 and ADAM 17.......................................................................................................... 13
Figure 1-7: Second generation SERT PET agents................................................................................14
Figure 1-8: SSRI 6 -nitroquipazine............................................................................................................ 14
Figure 1-9: SERT pharmacophore training set SSRIs.......................................................................... 16
Figure 1-10: Superposition of the SERT pharmacophore training set SSRIs (Figure 1-9), and key
SERT binding features............................................................................................................18
Figure 1-11: Structural qualities of 22 related to the SERT pharmacophore features..................... 18
Figure 1-12: Alignment of (S)-Me-NQP 30 with the pharmacophore ligand superposition............. 21
Figure 1-13: Alignment of MOM-NQP 31 with the pharmacophore ligand superposition............... 22
Figure 2-1: Desired fluorine-18 radiolabelled ligand [18F]MeF-NQP 42, tosylate precursor 43 and
the cold fluorinated agent, MeF-NQP 42.............................................................................30
Figure 2-4: Chelating potential of piperazine and related chelator ethylenediame.......................... 40
Figure 2-5: N-protected proposed fluorinating precursor......................................................................44
Figure 2-6: Explanation for the production of the bromide side product formed during BBr3
cleavage of the methyl ether................................................................................................. 45
Figure 2-7: Radioactive TLC analysis after initial fluorination and silica purification of the K222
radiofluorination trial, showing two possible Boc protected fluorinated products......... 57
Figure 2-8: Radioactive TLC analysis of the N-Boc-PROF-NQP 70, co-spotted with radiation at 
the baseline, front and on the product spot to allow for direct comparison to the
radiofluorination attempt.........................................................................................................61
Figure 2-9: Radioactive TLC analysis of the fluorination of 69 after silica gel purification. Two
products are visible with the smaller eluting at the same Rf as 70..................................62
Figure 3-1: Example commercial drugs sold as a racemic mixture.............................................. 75
Figure 3-2: Sedative (f?)-(+)-Thalidomide 101 found to cause birth defects............................... 76
Figure 3-3: Potential chiral piperazine syntheses utilizing amino acid building blocks..............77
Figure 3-4: Potential amino acid starting materials for the chiral PROM-NQP 51 synthesis....83
Figure 3-5: Potential amino acid building block for the synthesis of chiral Pent-NQP 83......... 91
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 4-1: Example single site competition assay plot of %bound radioligand versus the Log of
inhibitor concentration (M)................................................................................................... 100
Figure 4-2: Structure and CLogP comparison of n-PROP-NQP 52 and PROF-NQP 58.............. 105
Figure 4-3: Time course association plots of [3H]-n-PROP-NQP 52 at 21 °C.................................108
Figure 4-4: Time course dissociation plots of [3H]-n-PPOP-NQP 52 at 21 °C................................109
Figure 4-5: Saturation binding isotherm of [3H]-n-PROP-NQP 52 binding with rSERT at 21 °C. 112
ix
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
List of Schemes
Scheme 1-1: Synthesis of 28 and (±)-30, the 2- and 3-alkyl derivatives of 6 -NQP 22.....................19
Scheme 1-2: Synthesis of 2-(2-(methoxymethyl)piperazin-1-yl)-6-nitroquinoline, MOM-NQP (±)-
31............................................................................................................................................... 23
Scheme 1-3: Chiral synthesis of (R)- and (S)-Me-NQP 30...................................................................24
Scheme 2-1: Synthesis of the radiolabeling precursor N-trityl-HOM-NQP 39...................................27
Scheme 2-2: Preparation of the radiolabeling precursor, N-Boc-HOM-NQP 40...............................27
Scheme 2-3: Simulated reaction sequence for the production of the desired radiotracer
[11C]MOM-NQP (±)-31............................................................................................................ 28
Scheme 2-4: Radiosynthesis of [11C]MOM-NQP 31..............................................................................30
Scheme 2-5: Initial synthetic route to the a,|3-unsaturated ethyl ester 45..........................................32
Scheme 2-6: Titration reagent for determining the concentration of organometallic reagents.......33
Scheme 2-7: Initial synthesis of the coupling precursor 3-(3-methoxypropyl)-1-tritylpiperazine 49.
.................................................................................................................................................. 33
Scheme 2-8: Coupling and nitration to give the desired compound PROM-NQP (±)-51.................34
Scheme 2-9: Modified synthesis of the key intermediate 45 for the synthesis of PROM-NQP (±)-
51......................................................................................................................  38
Scheme 2-10: Proposed mechanism for the production of the n-allyl side product that would lead 
to the n-PROP-NQP 52 product after completing the synthetic steps outlined in
Schemes 2-7 and 2-8............................................................................................................. 39
Scheme 2-11: Example of a selective reduction of a conjugated system utilizing Mg°................... 39
Scheme 2-12: Attempted selective reduction of the conjugated alkene of 45.................................. 41
Scheme 2-13: Overall synthesis of PROM-NQP (±)-51........................................................................43
Scheme 2-14: Proposed fluorinated analog 58, to be prepared from PROM-NQP (±)-51..............44
Scheme 2-15: N-formyl protection of PROM-NQP (±)-51.................................................................... 46
Scheme 2-16: Cleavage of the methyl ether of N-formyl-PROM-NQP (±)-51...................................47
Scheme 2-17: Synthesis of N-formyl-ProTos-NQP 63..........................................................................47
Scheme 2-18: Fluorination sequence to prepare PROF-NQP 58...................................................... 48
Scheme 2-19: Initial radiofluorination trial using N-formyl-ProTos-NQP 63 to give [18F]PROF-NQP
58............................................................................................................................................... 49
Scheme 2-20: BBr3 methyl ether cleavage of PROM-NQP and subsequent protection as the N-
Boc to give N-Boc-HOP-NQP 6 6 .......................................................................................... 51
Scheme 2-21: Selective cleavage of the undesired Boc carbonate 6 8 .............................................. 52
Scheme 2-22: Tosylation of N-Boc-HOP-NQP to give the fluorination precursor N-Boc-ProTos-
NQP 69..................................................................................................................................... 52
Scheme 2-23: Trial fluorination of 69 with TBAF Boc group deprotection to give PROF-NQP 58.53
X
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Scheme 2-24: Radiofluorination sequence utilizing K222, KHC03, and Ag18F with the precursor
N-Boc-ProTos-NQP 69...........................................................................................................55
Scheme 2-25: Radiofluorination sequence utilizing TBAF................................................................... 59
Scheme 2-26: Trail nucleophilic fluorine substitution of N-Boc-n-PROP-NQP 71............................63
Scheme 2-27: Trial nucleophilic fluorine substitution with an excess of KF...................................... 64
Scheme 2-28: Trail nucleophilic fluorine substitution using KF as a limiting reagent...................... 65
Scheme 2-29: Example fluoride aromatic nucleophilic substitution of nitropyridines using TBAF . 6 6
Scheme 2-30: Overall synthesis of Pent-NQP (±)-83............................................................................6 8
Scheme 2-31: Synthesis of PentF-NQP 8 8 ............................................................................................ 69
Scheme 2-32: Overall synthesis of BuM-NQP 96..................................................................................71
Scheme 2-33: Synthesis of N-Boc-BuOH-NQP 97................................................................................72
Scheme 3-1: Synthesis of N-Boc-N-Benzyl-glycine 111.......................................................................79
Scheme 3-2: Synthesis of the key synthetic intermediate (S)-113......................................................80
Scheme 3-3: Overall synthesis of chiral MOM-NQP (S)-31................................................................. 82
Scheme 3-4: Potential oxidation of the methyl alcohol according Naylor et al.9 3 ............................ 83
Scheme 3-5: Retrosynthetic analysis for the formation of (/?)-126..................................................... 84
Scheme 3-6: Synthesis of 5-hydroxynorvaline from glutamic acid......................................................84
Scheme 3-7: Potential synthesis of the piperazinedione ring utilizing the lactone (R)-126............ 85
Scheme 3-8: Example peptide coupling using a cyclic lactone derived from 5-hydroxynorvaline
1 2 1 .............................................................................................................................................8 6
Scheme 3-9: Overall synthesis of (R)-PROM-NQP 51, the (S)-enantiomer is afforded according to
the same synthetic sequence starting from L-132.............................................................8 8
Scheme 3-10: Protection of the 2° amine with Boc20 ...........................................................................89
Scheme 3-11: Attempted deprotection of the Boc carbonate (R)-139................................................89
Scheme 3-12: Alternate synthesis of (R)-51 utilizing the N-Boc protected piperazine (/?)-140..... 90
Scheme 3-13: Protection of (R)-134 with benzyl bromide (BnBr).......................................................92
Scheme 3-14: Overall synthesis of (P)-Pent-NQP 83, the (S)-enantiomer was similarly prepared
from (S)-145............................................................................................................................. 93
Scheme 3-15: Initial synthesis of the BuM-NQP precursor (/?)-92, by Wittig olefination technology.
.................................................................................................................................................. 94
Scheme 3-16: Proposed synthesis of chiral BuM-NQP 96 from the synthetic intermediate (/?)-92.
.................................................................................................................................................. 95
Scheme 4-1: Synthesis of 2-(2-propylpiperazin-1-yl)-6-nitroquinoline 52 (n-PROP-NQP)........... 106
Scheme 4-2: Radiosynthesis of [3H]-2-(2-propylpiperazin-1-yl)-6-nitroquinoline 52 ([3H]-n-PROP- 
NQP)................................................................................................................................. 106
xi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table
Table
Table
Table
Table
Table
Table
Table
List of Tables
1-1:10 The different 5-HT receptor families their subtypes and associated therapeutic
potential.......................................................................................................................................3
1-2: Structures of the current 5-halo-6-nitroquipazines and their respective SERT imaging 
radioligands.............................................................................................................................. 15
1-3: SERT binding affinities of the first generation of 6-nitro-alkylpiperazin-1-ylquinolines. 20
2-1: 2-alkylpiperzin-1-yl-6-nitroquinoline products from the initial PROM-NQP synthesis...37 
4-1: Racemic 2-(2-alkyl-piperazin-1-yl)-6-nitroquiolines, compound name and R-group are
given as well as their associated binding inhibition constant (K,), and CLogP(o/w)
value........................................................................................................................................ 1 0 1
4-2: Chiral 2-(2-alkyl-piperazin-1-yl)-6-nitroquiolines, compound name and R-group are 
given as well as their associated binding inhibition constant (Kj), and CLogP(o/w)
value........................................................................................................................................ 103
4-3: Comparison of the kinetically derived dissociation constants (KD), the rate constants of 
association (kon) and dissociation (koff) for [3H]-n-PROP-NQP 52 and select SSRIs at
21 °C....................................................................................................................................... 110
4-4: Inhibition constants (Ki) for select CNS agents inhibiting the binding of [3H]-n-PROP- 
NQP 52 with rSERT..............................................................................................................113
xii
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(COCI)2
5-HT
5-HTT
6-NQP 
9-BBN
A c20
ACE-CI
ACN
AcOH
AgBr
AgF
AgOTs
Ar
BBB
BBr3
bm
B m a x
Bn
Boc
B oc20
bs
BuM-NQP
calcd
CH2CI2
CH3I
CHCI3
CNS
d
5
DAST
DAT
DCE
DCM
dd
DIBAL
DMF
DMSO
DRI
dt
E.O.B. 
EDC HCI 
ee 
El
equiv
List of Abbreviations
oxalyl chloride
5-hydroxytryptamine/serotonin
5-hydroxytryptamine transporter
6 -nitroquipazine 
9-Borabicyclo[3.3.1]nonane 
acetic anhydride
1 -chloroethyl cnloroformate
acetonitrile
acetic acid
silver bromide
silver fluoride
silver tosylate
aromatic group
blood brain barrier
boron tribromide
broad multiplet
binding site density
benzyl group
tert -butoxycarbonyl
di-tert-butyl dicarbonate
broad singlet
2-(2-(4-methoxybutyl)piperazin-1-yl)-6-nitroquinoline
calculated
dichloromethane
iodomethane
chloroform
central nervous system 
doublet
chemical shifts in parts per million 
(diethylamino)sulfur trifluoride 
dopamine transporter 
1 ,2 -dichloroethane 
dichloromethane 
doublet of doublets 
diisobutylaluminium hydride 
N,N-dimethylformamide 
dimethylsulfoxide 
dopamine reuptake inhibitor 
doublet of triplets 
end of bombardment
A/-ethyl-A/-(3-dimethylaminopropyl)carbodiimide hydrochloride 
enatiomeric excess 
electron impact 
equivalent
XIII
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
ESI electrospray ionization
Et ethyl
Et20  diethyl ether
Et3N triethylamine
EtOAc ethyl acetate
EtOH ethyl alcohol
FBI functional brain imaging
g gram
h hour(s)
H2 hydrogen gas
H20 2 hydrogen peroxide
H2S 04 sulfuric acid
HCI hydrochloric acid
HN03 nitric acid
HOM-NQP 2-(2-(hydroxymethyl)piperazin-1-yl)-6-nitroquinoline
HOP-NQP 2-(2-(hydroxypropyl)piperazin-1 -yl)-6 -nitroquinoline
HPLC high performance liquid chromatography
HRMS high resolution mass spectrum
hSERT human serotonin reuptake transporter
Hz hertz
IC50 concentration of a drug that inhibits 50% of a protein (receptor or enzyme) 
IPOH isopropyl alcohol
J  coupling constant (NMR) in hertz
K222 Kryptofix, 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane
K2C 03 potassium carbonate
Ka association constant
KCI potassium chloride
Kd dissociation constant
KF potassium fluoride
Kj inhibition constant
koff dissociation rate constant
kon association rate constant
LBNL Lawrence Livermore National Laboratories
LiAIH4 lithium aluminum hydride
LogP octanol/water partition coefficient
M molarity (moles per liter)
m multiplet
MAO monoamine oxidase
Me methyl
MeF-NQP 2-(2-fluoromethyl-piperazin-1 -yl)-6 -nitroquinoline
Me-NQP 2-(2-methyl-piperazin-1 -yl)-6 -nitroquinoline
MeOH methyl alcohol
mg milligram
Mg magnesium metal
MHz megahertz
min minute(s)
xiv
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
mL milliliter
mM millimolar
|xM micromolar
mmol millimole
mol% percent of reagent used ( 1 0 0  mol% = 1 equiv)
MOM-NQP 2 -(2 -(methoxymethyl)piperazin-1 -yl)-6 -nitroquinoline
NaCI sodium chloride
NaH sodium hydride
NaHC03 sodium bicarbonate
NaN02 sodium nitrite
NaOH sodium hydroxide
n-BuLi n -butyl lithium
NET norepinepherine transporter
nh 4c o 2h ammonium formate
NMR nuclear magnetic resonance
n-PROP-NQP 2 -(2 -propylpiperazin-1 -yl)-6 -nitroquinoline
NQP 6 -nitroquipazine
NRI norepinepherine reuptake inhibitor
PCC Pyridinium chlorochromate
Pd/C palladium on carbon
PDC Pyridinium dichromate
PentF-NQP 2-(2-(5-fluoropentyl)piperazin-1-yl)-6-nitroquinoline
Pent-NQP 2-(2-(5-methoxypentyl)piperazin-1-yl)-6-nitroquinoline
PET positron emission tomography
PG protecting group
pM picomolar
ppm parts per million
PROF-NQP 2-(2-(3-fluoropropyl)piperazin-1-yl)-6-nitroquinoline
PROM-NQP 2-(2-(3-methoxypropyl)-piperazin-1-yl)-6-nitroquinoline
q quartet
rac racemic
R f retention factor
rSERT rat serotonin reuptake transporter
RT°C room temperature
s singlet
SAR stucture activity realationship
SepPak solid phase extraction cartridge
SERT serotonin reuptake transporter
SOCI2 thionyl chloride
SPECT single photon emission computed tomography
SSRI selective serotonin reuptake inhibitor
*1/2 half life
TBAF tetrabutylammonium fluoride
TBOH tetrabutylammonium hydroxide
TEA triethylamine
TFA trifluoroacetic acid
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
THF tetrahydrofuran
TLC thin layer chromatography
TOF-MS time of flight mass spectroscopy
tosylate p-toluenesulfonyl
Tris-HCI Tris(hydroxymethyl)aminomethane hydrochloride
trit triphenylmethane
Trityl triphenylmethane
v2 measure of nonspecific binding
v3" specific-to-nonspecific equilibrium partition coefficient
xvi
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter 1 
Introduction and Background
1.1 Introduction.
Alterations in serotonergic function within the central nervous system 
(CNS) are believed to be associated with a number of neurological and mental 
health disorders, including depression, schizophrenia, anxiety and Parkinson’s 
syndrome.1,2 The serotonin reuptake transporter (SERT) is located on the 
presynaptic neuron cell surface and is responsible for the clearance of serotonin 
(5-HT, 3) from the synaptic cleft after neuronal firing. Presynaptic cell surface 
densities of SERT may be an excellent marker for measuring the integrity of the 
5-HT terminals and 5-HT neurotransmission in relation to neurological and mood 
disorders.3 Visualization and quantification of SERT densities in living tissue can 
be accomplished by positron emission tomography (PET) functional brain 
imaging (FBI) techniques, allowing for the determination of serotonergic system 
integrity. Considering SERT cell densities vary depending on the cerebral 
region, it is important for the understanding of the role of 5-HT 3 and SERT in a 
disease state to be able to image SERT density in high to low regions. There is 
currently a need for new PET imaging probes for the measurement of the brain 
regions with low (e.g. cerebellum) to medium (e.g. limbic system, particularly the 
hippocampus and amygdala) SERT densities.
We are interested in developing new SERT PET imaging agents with 
appropriate properties for the imaging of brain regions implicated in SERT related 
disorders. A desirable imaging agent should have high SERT affinity and
1
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selectivity, good in vivo kinetics (Kd, kon and koff), low nonspecific binding and 
high target to cerebellum ratios (>2, important for imaging low SERT density 
regions). The objective of the Gerdes research group has been to develop new 
PET imaging agents for the in vivo imaging of SERT receptor densities of select 
brain regions.
1.2 The Neurotransmitter Serotonin.
5-hydroxytryptamine (serotonin, 5-HT, 3) is an endogenous
neurotransmitter of the central nervous system (CNS) in addition to peripheral 
tissues. Serotonin 3 was initially described as a substance present in clotting 
blood that acted as a vasoconstrictor (constriction of blood vessels).4 Serotonin 
3 was isolated from beef serum and purified by Rapport et al. in 1948.5 They 
proposed that 3 contained an indole moiety and was likely related in structure to 
tryptophan 1 or tryptamine (not shown).5 In 1951 5-hydroxytryptamine 3 was 
independently synthesized and compared to the vasoconstrictive substance (3) 
isolated by Rapport and was found to possess vasoconstrictive properties and to 
be structurally identical to 3.6 It was later determined that serotonin was involved 
in neurotransmission among other peripheral tissue functions.7 Furthermore, the 
presence of 5-HT receptors was presented by Gaddum and Picarelli in 1957.8 
The existence of two separate 5-HT receptors was shown by Peroutka and 
Snyder in 1979.9 They were able to demonstrate the presence of separate 
receptors utilizing the radioligands [3H]5-HT 3 and [3H]spiperone (not shown) to 
label the different receptor sites termed 5-HT-i and 5 -HT2 respectively.9
2
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Continuing research on the serotonergic system has identified fourteen known 5- 
HT receptors and the 5-HT transporter (5-HTT, known as SERT). Outlined in 
Table 1-1 are the known 5-HT receptors and transporter located peripherally and 
centrally, along with their associated therapeutic potential.10
Table 1-1: 10 The different 5-HT receptor families their subtypes and associated therapeutic 
potential.
Receptor Family Subtype Receptor Type Therapeutic Potential
5-HT! " \
5-HTiA Anxiety
5-HT1b Migraine, Excessive Aggression
5-HT1c
5-HT1d Migraine
5-HT1e Unknown
5-HT1f Migraine
5-HT2 V  G-protein Coupled
5-HT2A Schizophrenia
5-HT2B Migraine
5-HT2C Anxiety, Depression, Obesity
5-HT4 Irritable bowel syndrome
5-HT5 Unknown
5-HT6 Bipolar, Parkinson's
5-HT7 J Sleep disorders, Depression
5 -HT3 Ligand-gated ion channel Irritable bowel syndrome
SERT Transporter (Reuptake) Depression
In the CNS the biosynthesis (Figure 1-1) of 5-HT 3 is accomplished in the
serotonergic neurons from the amino acid tryptophan 1. Tryptophan 1 is 
hydroxylated by the enzyme tryptophan hydroxylase to give 5-hydroxytryptophan 
2. Decarboxylation of 2 by aromatic-L-amino-acid decarboxylase gives 5-HT 3. 
The biosynthesis of 3 is dependent upon the transport of tryptophan 1 across the 
blood brain barrier (BBB). Serotonin 3 is degraded by deamination to 5- 
hydroxyindoleaccetic (5-HIAA, 4) by the enzyme monoamine oxidase (MAO), 
and 4 is then excreted by the urinary tract (Figure 1-1).
3
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Figure 1-1: Biosynthesis and degradation pathway for serotonin in the CNS.
1.3 Serotonin Neurotransmission at the Synapse.
The signaling processes of the body and the brain are propagated through 
neuronal circuitry by electrical action potentials and chemical synaptic potentials. 
The nerve impulse is carried through the axon to the nerve terminus, for the 
nerve impulse to be carried from one neuron to the next the signal must be 
transferred across the synaptic cleft (the junction between the presynaptic and 
postsynaptic cell). The electrical impulse is not simply transferred form cell to 
cell. The process occurring at the nerve terminal is summarized in Figure 1-2. 
As the nerve impulse reaches the nerve terminal there is an influx of calcium ions 
through voltage gated ion channels. The influx of calcium ions causes the 
vesicles to fuse with the presynaptic neuron membrane and release stored 
serotonin 3 neurotransmitters. The neurotransmitters rapidly diffuse across the 
synapse by a concentration gradient where they are bound to receptors on the 
post synaptic terminal. Binding of the neurotransmitters propagates the nerve 
impulse by inducing a change in the membrane potential of the postsynaptic
4
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neuron through a ligand gated ion channel. This can also occur via G-protein 
coupled receptors that activate a second messenger system within the 
postsynaptic neuron to propagate the nerve impulse. Following release the 
neurotransmitters are removed from the synaptic cleft by the serotonin reuptake 
transporter (SERT) located on the presynaptic nerve terminal and then packaged 
again into vesicles to await the next nerve impulse.
Presynaptic Neuron
Voltage-gated 
Ca2+ ChannelMitochondria
Vesicles
Exocytosis
|  ReuptakeV 
® Transporter
Synaptic Cleft
Serotonin
Postsynaptic
Receptor
Response
Postsynaptic Neuron
Figure 1-2: Signals from the pre-synaptic neurons to the post-synaptic neurons of the 
serotonergic system are linked by the neurotransmitter serotonin (5-HT). Release of 5-HT from 
the vesicles and subsequent binding with the postsynaptic receptors induces a response in the 
postsynaptic neuron and propagates the nerve impulse.
1.4 Serotonin Reuptake Transporter (SERT).
The SERT protein is an integral membrane protein and consists of 12 
transmembrane regions with the amino and carboxyl terminals located
5
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intracellularly.11 The SERT protein is a member of the subfamily monoamine 
transporters (which includes, noradrenaline (norepinephrine) and dopamine 
transporters) of the Na7CI" neurotransmitter transporter family.12 After neuronal 
firing, the reuptake transporter is responsible for the termination of 
neurotransmission by uptake of serotonin from the synaptic cleft for later 
packaging into vesicles for use in subsequent neuronal firing events (Figure 1-2). 
The SERT protein actively transports 5-HT from the synaptic cleft with the 
cotransportation of 1 Na+ and 1 Cl", with the counter ion transport of K+ (the 
transport of 5-HT is dependent on the presence of K+ on the cytoplasmic side of 
the membrane).11 The SERT protein is important for the regulation of the levels 
of 5-HT in the synaptic cleft.13 The rat and human SERT proteins are of identical 
length (630 amino acids) and possess 92% amino acid identity.14 The SERT 
protein is a well known target for selective serotonin reuptake inhibitors (SSRIs) 
for the treatment of depression among other disorders (Figure 1-3). By blocking 
SERT uptake of 5-HT, extracellular levels of 5-HT are increased activating 5-HT 
neurotransmission.11
6
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Sertraline, 5 (+)-MCN5652,6 (S)-Citalopram, 7 Indatraline, 8
F
\ —0
NH
o 0
0
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Paroxetine, 9 Fluoxetine, 10 Fluvoxamine, 11
Figure 1-3: Typical SSRIs and related SERT inhibitors.
High SERT density is found in the raphe nuclei, substantia nigra, 
thalamus, hypothalamus and straitum.15'19 Medium SERT densities are 
associated with the limbic and paralimbic structures, including the hippocampus, 
amygdala, and the cingulate cortex.16,18,20 Low to negligible levels of SERT are 
found in the neocortex (occipital, and orbital frontal) and the cerebellum.15,18 The 
cerebellum is used as a reference region for cerebral comparison of non-specific 
binding and for calculation of target-to-cerebellum ratios. Alterations in SERT 
density and function have been attributed to a variety of neuropsychiatric 
disorders, including depression21"23 anxiety,22,24 suicide,20,25,26 schizophrenia,27'30 
and eating disorders,31,32 among others. Studies of the distribution of the SERT 
protein in postmortem human brain samples suggest that the structures of the 
limbic system (including the amygdala, hippocampus, and hypothalamus) are
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connected to the pathology of depression.33"36 To better understand the 
pathology of the diseases related to SERT density changes, in vivo imaging 
studies of SERT densities would be beneficial for diagnosis and monitoring 
therapies of mental health disorders.
1.5 Functional Brain Imaging (FBI).
Non-invasive in vivo analysis of CNS receptor and transporter densities 
can be accomplished by positron emission tomography (PET) and single photon 
emission computed tomography (SPECT).37,38 In vivo imaging techniques refer 
to the use of radioligand tracers containing relatively short lived radionuclides 
(11C, 18F, 76Br and 123l, t-1/2 = 20 -  960 minutes), that are selective for the 
receptor, transporter or enzyme of interest. The PET and SPECT imaging 
techniques can measure receptor protein concentrations in the nanomolar (nM) 
to picomolar (pM) concentration range. These techniques are superior over 
magnetic resonance imaging measures that detect compounds in the micromolar 
(pM) range.39 One benefit of the PET or SPECT imaging technique is that the 
radioligand is used in small amounts reducing the possibility of adverse side 
affects.39 The disadvantages to PET and SPECT imaging is the number of tracer 
exposures for the subject is limited due to radiation exposure (dosimetry) 
restrictions, availability of the radioligand, and in the case of the short lived 
radionuclide (11C and 18F) the proximity of the imaging scanner to the source of 
the radioligand production facility.
8
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1.6 Criteria for SERT PET Tracers.
Radioligand selection criteria for PET and SPECT imaging studies are a 
major hurdle to overcome before any imaging analysis can be accomplished. A 
number of criteria have been delineated in the literature for the selection of the 
appropriate ligand and radioisotope to be used, these include: i) the ligand 
should be selective for the protein of interest, ii) the ligand should have high 
affinity (KD < 1 nM), iii) appropriate ligand lipophilicity (LogP 1.5-4, able to cross 
the blood brain barrier (BBB), but is not so lipophilic the agent suffers from 
nonspecific binding), iv) radioactive metabolites should not be active in the CNS, 
and v) the ligand should be non-toxic.3,13,39 For low density target protein 
measurement a higher affinity agent is required. According to Laruelle et al., a 
ligand with a binding affinity in the range of 1 and 0 .0 1  nM is considered 
sufficient.39 However, the measurement of the ratio of specific-to-nonspecific 
binding may truly define a ligand’s potential as an imaging agent.39
At equilibrium the ratio of specific-to-nonspecific tracer binding is equal to 
V3" (V3” is defined as the specific-to-nonspecific equilibrium partition coefficient). 
A V 3 ”  value of 0.5 in the region of interest is desirable. 3 The partition coefficient 
V3” is equal BmaxA/2KD, where Bmax is the density of the binding site, V2 is a 
measure of nonspecific binding and KD (equilibrium dissociation constant) is the 
affinity of the ligand for the binding site.39,40 The greater the nonspecific binding 
of the radioligand the lower the value of V3” (less desirable). Also as the binding 
site density increases (Bmax) and the ligand’s affinity increases (smaller KD) so 
does V 3 ”  (more desirable). Comparison of V 3 ”  values allows for direct
9
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comparison of potential radioligands. Where the greater the ligands associated 
V3” value corresponds to a lower nonspecific binding (V2) and a better signal-to- 
noise ratio. The signal-to-noise ratio is especially important when attempting to 
measure the density of the tracer binding site in regions of medium density, i.e. 
SERT density in the limbic and paralimbic system implicated as the regions 
related to 5-HT and SERT disorders.
1.7 SSRIs as Potential PET Imaging Agents.
The use of the SSRIs citalopram 7 and paroxetine 9 was investigated as 
potential SERT radiotracers based upon their respective SERT affinities and 
selectivity for SERT. The more biologically active enantiomer (S)-citalopram 7 
has high affinity and selectivity for SERT and a relatively low lipophilicity.41 The 
N-methyl carbon-11 analog [11C]7 was prepared from norcitalopram (not shown) 
and evaluated for its efficacy as a SERT PET imaging agent.42 Ex vivo studies 
of [11C]7 showed low target-to-background ratios and very low specific signal in 
human volunteers in PET studies.42,43 A derivative of the SSRI paroxetine 9 
(Paxil) was prepared [18F]fluoropropylparoxetine 12, by treatment of 9 with 
[18F]fluoropropyltosylate.44 However, the functionalized radiotracer [18F]12 
suffered from reduced affinity for SERT (3 orders of magnitude) and brain 
distribution studies showed no distinct localization in SERT rich regions of the 
brain.
10
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(S)-[11C]Citalopram, 7 N-(3-[18F]Fluoropropyl)paroxetine, 12
Figure 1-4: Commercial SSRI analogs developed as potential SERT PET imaging agents.
1.8 Current SERT Imaging Agents.
Initially, imaging the SERT protein was difficult due to the lack of a specific 
radioligand with suitable in vivo binding kinetics.38 Attempts at utilizing known 
radiolabelled SSRIs (Figure 1-4) have been unsuccessful. The first useful 
radiotracer for SERT imaging in primates was (+)-[11C]MCN5652 6 (Figure 
1-5).38,45,46 Subsequently (+)-[11C]6 became a standard for comparison to 
determine the efficacy of new radiolabeled agents for PET SERT imaging. 3,18,19 
Unfortunately, the in vivo kinetics of (+)-[11C]6 were too slow for the carbon-11 
radionuclide to be useful (carbon-11, t-1/2 = 20.4 min).19 Additionally, nonspecific 
binding was too high for quantification of SERT in low density regions of interest 
(ROI) within the brain, particularly the limbic system.3
Attempts to prepare a radiotracer with a longer half life have been made. 
Suehiro et al. prepared [18F]FET-MCN 13 (Figure 1-5), where the fluorine-18 
radioisotope with a longer half-life might prove to have better in vivo 
characteristics allowing for a longer analysis tim e47 However, [18F]13 did not 
improve upon the lead [11C]6. It actually showed less favorable properties due to
11
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reduced BBB penetrating abilities. Additionally, [18F]FET-MCN showed a lower
tissue to cerebellum ratios than the lead [11C]6 .ia,4/ The fluoromethyl analog 
[18F]14 (Figure 1-5) was also investigated and showed faster kinetics than the 
lead [11C] 6  and higher specific binding in porcine brain, which is suggestive of its 
potential in humans.19,34
19,47
18
(+)-[11C]MCN5652, 6 (+)-[1 8 F]FEt-MCN, 13 (+)-[1 8 F]FMe-MCN, 14
Figure 1-5: Radiolabelled derivatives of the potent and selective SSRI MCN5652.
The second generation SERT imaging agents have been based upon the 
general structure of the diarylsulfide SSRI 403U76 15 (Figure 1-7). The first 
tracer introduced for use as a SERT SPECT imaging agent was [123I]IDAM 
16.48’49 The tracer [123I]IDAM 16 had very good SERT selectivity compared to the 
norepinephrine reuptake transporter (NET) and the dopamine reuptake 
transporter (DAT). The SPECT images had similar distribution compared to 
[11C]6 .49 Following IDAM 16, the iodinated congener of [125I]ADAM 17 was 
prepared and found to have superior in vivo profile compared to 16. The 
[123I]ADAM 17 is expected to be an excellent SPECT imaging tracer.2,50
12
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SSRI 403U76, 15 IDAM, 16 ADAM, 17
Figure 1-6: The Diarylsulfide SERT inhibitor 403U76 15 and the potential SERT SPECT analogs 
IDAM 16 and ADAM 17.
For PET imaging a series of carbon-11 diarylsulfide class of compounds 
have been evaluated and compared to [11C] 6  (Figure 1-7). The diarylsulfide 
ligands (Figure 1-1) have been shown to be selective for rSERT and have the 
appropriate regional distribution in rat brain for SERT.3 Of the four diarylsulfides, 
[11C]DAPA 20 and [11C]ADAM 17 showed no benefit over [11C]6 . However, 
[11C]DASB 19 and [11C]AFM 18 were demonstrated to outperform [11C]6 . The 
radioligand [11C]AFM 18 with a significantly higher V 3 ”  value than the other tracer 
has the potential to be an excellent imaging agent for low to medium SERT 
density regions.3 The excellent profile of [11C]AFM 18, lead to the development 
of [18F]AFM 21, where the inclusion of the fluorine-18 atom has the advantage of 
increased scanning time compared to carbon-1 1  and a fluorine-18 tracer can be 
transported to off-site imaging facilities if needed.3 Biodistribution studies in rat 
of [18F]21, showed high brain uptake and high SERT binding affinity and 
selectivity. Based upon the current in vivo rat studies, [18F]21 has been proposed 
to be an excellent SERT imaging agent.51 It remains to be seen whether the 
benzyl fluoride moiety of [18F]21 will provide suitable imaging performance 
qualities in primates.
13
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[11C]AFM, 18 [11C]DASB, 19 [11C]DAPA, 20
1 8 FH2C
[1 1 C]ADAM, 17 [11C]MCN5652, 6 [1 8 F]AFM, 21
Figure 1-7: Second generation SERT PET agents.
1.9 6-Nitroquipazines as SERT Inhibitor Tracers.
The lead structure 6 -nitroquipazine 22 (6 -NQP, 6-nitro-2-piperazin-1- 
ylquinoline, DU-24565) (Figure 1-8) is known to be one of the more potent and 
selective agents for SERT.1,52,53 It seems plausible that analogs of 6 -NQP 22 
would lead to an efficacious SPECT or PET agent. The current functional brain 
imaging (FBI) analogs of 6 -NQP are outlined in Table 1-1, including: [123l]5-iodo- 
6 -nitroquipazine (INQP) 23,54,55 [76Br]5-bromo-6-nitroquipazine 24,56 [18F]5-fluoro- 
6 -nitroquipazine 25,57 and [11C]5-methyl-6-nitroquipazine 26 (Table 1 ) .58'59
6 -NQP, 22
Figure 1-8: SSRI 6-nitroquipazine.
14
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Table 1-2: Structures of the current 5-halo-6-nitroquipazines and their respective SERT imaging 
radioligands.
x X X*
k / NH
23
24 Br
25 F
26 CH3
123
However, the metabolic dehalogenation fate of INQP 23 in primate brain, 
led to the presence of free [123l] that ultimately obscures the SPECT images. 
Additionally, the BrNQP 24 suffers from high non-specific binding.59 The [18F]5- 
fluoro-6 -nitroquipazine tracer 25, showed lack of selectivity (readily displaced by 
maprotiline (not shown) a norepinephrine re-uptake inhibitor) and lack of binding 
affinity (readily displaced by citalopram 7 ) .57 The [11C]5-methyl-6-nitroquipazine 
radioligand 26, was also shown to be a plausible agent for PET imaging. 
However, the carbon-11 analog suffered from slow binding kinetics,58 where the 
short half life of carbon- 1 1 did not allow the tracer to reach apparent equilibrium 
of binding.
1.10 Pharmacophore Development.
Many of the radiolabeled versions of the SSRIs (Figure 1-1), have 
lipophilic qualities that may interfere with the PET or SPECT imaging through 
non-specific binding. It is our hypothesis that a portion of the non-specific 
binding may be related to SSRIs (and their labeled forms) acting as steroid 
mimics, perhaps interacting at neuroendocrine receptors in the brain.60 Analysis 
of the structural similarities of the various SSRIs currently in the literature (Figure
15
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1-3), 61 shows that each SSRI possess dual aromatic ring moieties connected by 
a central connecting carbon.
It is well known that SSRI treatment can lead to sexual dysfunction, a side 
effect that has profound implication on a patients willingness to stay on the 
treatment course.62 A comparison of the SSRIs in Figure 1-3, shows that 
fluvoxamine 11 is the only SSRI shown to be devoid of a second aromatic 
moiety. Additionally, 11 has a marked attenuated difference in its respective side 
affects.63,64 We believe the presence of the dual aromatic ring structure may lead 
to the side effects observed during SSRI treatment. Recently, SSRIs have been 
shown to be actively involved in the modulation of the neuroendocrine system .60 
It is our hypothesis that in the absence of a second aromatic ring the ability of an 
SSRI to interact with the neuroendocrine system is diminished, resulting in 
decreased side effects and prospectively reduced non-specific binding.
Sertraline, 5 (+)-MCN5652,6  (S)-Citalopram, 7 Indatraline, 8
Figure 1-9: SERT pharmacophore training set SSRIs.
Therefore, we have developed a pharmacophore model constructed from 
a superposition of four semi-rigid SSRI ligands (Figure 1-9), in an effort to 
elucidate key structural features for an efficacious SERT PET tracer.65,66 
Examination of our model suggests there are a number of distinct features
16
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necessary for SERT binding: i) an electronegative region (X group), ii) two 
aromatic regions (Ar1, and Ar2) iii) a heteroatom moiety and iv) a terminal amine 
group. It is our belief, based upon the structural diversity of known SERT 
inhibitor ligands all of the pharmacophore points need not be activated in order to 
maintain high SERT affinity. Our effort has been to develop ligands devoid of the 
Ar2 aromatic moiety which may play a key role in eliminating activity as a steroid 
mimic while maintaining the other structural characteristics of the pharmacophore 
(Figure 1-10).
Of particular interest to us was the SSRI 6 -nitroquipazine 22 that has been 
shown to be potent and highly selective for SERT. The most interesting feature 
of 22 is the structural qualities compared to other SSRIs (Figure 1-1). The 
structure of 22 is composed of one aromatic ring moiety (Ar1), an X-group (Ar- 
NO2), a heteroatom moiety (3° piperazine nitrogen or quinoline nitrogen), 
terminal amine (2 ° piperazine nitrogen), but is devoid of a second aromatic ring 
moiety (Ar2). We then proposed that alkyl-substitution of 22 at the 2- or 3- 
position of the piperazine ring would likely probe the Ar2 binding pocket of our 
model.
17
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Figure 1-10: Superposition of the SERT pharmacophore training set SSRIs (Figure 1-9), and key 
SERT binding features.
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Figure 1-11: Structural qualities of 22 related to the SERT pharmacophore features.
1.11 Me-NQP 28 and (±)-30, Implications to the Pharmacophore.
We became interested in developing new PET imaging radioligands for 
SERT based upon the lead selective and potent SSRI 6 -NQP 22. The current 6 - 
NQP FBI agents described above (Figure 1-8) have been shown in vitro to be 
highly selective for SERT. However, due to variety of factors i.e. dehalogenation,
18
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low ROI-cerebellum ratios and low synthetic yields of the desired agent. The 
aromatic halogenated analogs of 2 2  have failed to be useful for imaging studies. 
We believe that functionalizing 6 -NQP 22 at the piperazine ring with alkyl groups 
that are amenable to late stage introduction of a radioisotope will likely show 
enhanced SERT binding by mimicking the interaction of the Ar2 moiety described 
in the pharmacophore model.
HN NH
CH3
27
2-CI-quinoline 
toluene, A
HN03, h 2 s o 4
0°C
/ = \  / /— H ^NH 55%, 2 steps
02N—̂  ^ —N X—^
X 7  c h 3
28
Trityl-CI, Et3 N, 
CH2 CI2, 0 °C
2-CI-quinoline HN03, h 2 s o 4
0°C
.— i n— N NH 10%, 4 steps
°9N- \  />-N ) —/
x 7  h3c
/~A
Ph3 C—N NH --------------------------- ►
\ — /  toluene, K2 C03, A;
CH3  HCI’ Et0H
29 (±)-30
Scheme 1-1: Synthesis of 28 and (±)-30, the 2- and 3-alkyl derivatives of 6-NQP 22.
To initially determine if alkyl substitution on the piperazine ring of the lead
structure 6 -NQP 22 would increase SERT binding affinity, the racemic forms of 2-
and 3-substituted 2-piperazinyl-6-nitroquinoline (±)-30 and 28 were prepared
(Scheme 1-1) and evaluated for SERT binding against the standard
[3H]paroxetine (Table 1-3) .67
19
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 1-3: SERT binding affinities of the first generation of 6-nitro-alkylpiperazin-1-ylquinolines.
A NH
Y
Cmpd # X Y Ki (nM)a'°
22 H H 0.163 ±0.053
(±)-30 CO
Xo
H 0.081 ± 0.061
28 H c h 3 4.56 ± 2.4
(±)-31 CH2OCH3 H 2.48 ± 0.28 (pM)
aGerdes, 2002. bData determined from competition
assay utilizing rat cortical membrane suspensions 
labeled with [3H]paroxetine, method is discussed in 
Chapter 4.
From this study we were able to determine that substitution at the 2- 
position of the piperazine ring is 56 times more potent for SERT than the 3- 
substituted analog. Additionally, (±)-30 is 2 times more potent than 22, 
suggesting that the alkyl substituent at the 2 -position has added beneficial 
interaction for SERT binding compared to the lead 22. Also, we can deduce from 
the binding data that the 3-position involves negative interaction at the binding 
site leading to its decreased affinity for SERT. As shown in Figure 1-12, an 
overlay of the enantiomer ((S)-2-(2-methylpiperazin-1-yl)-6-nitroquinoline ((S)- 
MeNQP 30) with the SERT pharmacophore shows the methyl group positioned 
for interaction within the Ar2 pocket. This led us to investigate the synthesis of 
an extended alkyl chain version of MOM-NQP (±)-31 that could interact deeper 
within the Ar2 binding region. We also investigated the production of a potential 
radiolabeling precursor by substitution of the piperazine ring at the 2 -position, 
with a substituent that can be later converted to its radiolabeled equivalent.
20
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Figure 1-12: Alignment of (S)-Me-NQP 30 with the pharmacophore ligand superposition.
1.12 MOM-NQP (±)-31.
In an effort to extend the 2-alkyl-piperazine substituent into the Ar2 binding 
pocket, as well as to generate a precursor for the development of a FBI agent for 
SERT, we investigated the synthesis of 2-(2-methoxymethylpiperazin-1-yl)-6- 
nitroquinoline (MOM-NQP) (±)-31. Computational analysis and superposition of 
(±)-31 suggests an excellent fit of the methoxymethyl side chain into the region 
we have defined as Ar2, likely serving as a highly potent SERT inhibitor.
21
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Figure 1-13: Alignment of MOM-NQP 31 with the pharmacophore ligand superposition.
The synthesis of MOM-NQP (±)-31 was accomplished from the starting 
material ethyl 1,4-dibenzylpiperazine-2-carboxylate 32 in six synthetic steps 
(Scheme 1-2) .68"70 The key step of the synthesis was the utilization of the Gilman 
coupling method.71 We have found that the Gilman method is particularly 
sensitive to the ratio of the reagents used. For successful Gilman coupling the 
ratio of reagents must be strictly adhered to (150 mol% of the amine, 150 mol% 
of n-BuLi, and 100 mol% of 2-chloroquinoline). Use of the lithium amide of 
piperazine 36 according to Gilman procedure proved to be a more facile method 
for the preparation of 2-alkylpiperazin-1-yl-quinolines. The method is far superior 
to previous methods of amine 2 -chloroquinoline couplings that required heating 
the two components for extended amounts of time resulting in low yields ( - 2 2 %) 
of the desired product (Scheme 1-2) .67 The Gilman method allowed us to couple
22
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the 2-substituted N-trityl-protected piperazine 36 with 2-chloroquinoline in the 
consistent range of 80-95% yield, as per Scheme 1 _2 .69’72’73
BrKM/ \
V l LiAIH4, Et20  ^  | NaH, CH3 I, N ^  . 2H CI
E,0 Y ^ N' -  -------------- '  H° ^ N'Bn
32 33 HCI(g) 34
HNH2 , 5% Pd/C * 2HCI HIJ ^  C(Ph)3 CI, Et3N ,
abs. EtOH H3C ' CH2 CI2, 0 °C Hz° '  " ° P h 3
35
n-BuLi, 2-CI-quinoline
Et2 0, 0 °C;
6  M HCI, EtOH 
(Gilman Coupling)
h n o 3, h 2 s o 4
N N
36
0 2N
NH
(±)-31
Bn =
Scheme 1-2: Synthesis of 2-(2-(methoxymethyl)piperazin-1-yl)-6-nitroquinoline, MOM-NQP (±)- 
31.
The synthesis of MOM-NQP (±)-31 not only expanded our knowledge of 
coupling piperazines to 2 -chloroquinoline but also further exemplified our study of 
the SAR of the 2-(2-alkyl-piperazin-1-yl)-6-nitroquinoline series. Synthesis of 
MOM-NQP (±)-31 gave us another ligand to further establish that our 
computational model is predictive. Extension of the 2-alkyl-piperazine group into 
the Ar2 region improves the ligands affinity. Table 1-1 shows the binding affinity 
of (±)-31 is 33 times more potent than our lead (±)-Me-NQP 30 and 6 6  times 
more potent than the initial lead 6 -NQP 22.
23
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1.13 R- and S-Me-NQP ((/?)-30 and (S)-30).
Based upon the success found with the methyl (Me-NQP (±)-30) and the 
methoxymethyl (MOM-NQP (±)-31) analogs of 6 -NQP 22 we began to investigate 
the synthesis and subsequent in vitro pharmacological evaluation of the 
enantiomers of (±)-30. The synthesis of (SJ-30 and (R)-30 was accomplished 
utilizing the enantiomeric forms of 2-methyl piperazine available from Sigma- 
Aldrich. Each quipazine enantiomer was prepared according to the methods 
described in the MOM-NQP (±)-30 (Scheme 1-2). Briefly, the desired enantiomer 
of 27 was protected as the N-trityl and coupled to 2-chloroquinoline using the 
Gilman method. Deprotection of the trityl group and selective nitration at the 
quinoline 6 -position gave the enantiomers (fi)-30 ( [ a ] 2 0 D  -62° (EtOH)) and (S)-30 
( [ a ] 2 0 D  = +65° (EtOH)) in 51% and 49% yields, respectively, over four steps 
(Scheme 1-3).
HN
H3C
H
(R)-27 as per scheme 1-2 (R)-30
H
(S)-27 (S)-30
Scheme 1-3: Chiral synthesis of (R)- and (S)-Me-NQP 30.
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1.14 Proposed Work.
The goal of this work has been to utilize our SERT pharmacophore model 
to develop new more selective and potent agents for the SSRI SERT binding 
domain. In particular, we were interested in developing ligands devoid of a 
second aromatic ring moiety (Ar2) in the hopes that SERT ligands with only one 
aromatic moiety would show less nonspecific binding. In doing this we wanted to 
expand our SAR knowledge of the SSRI SERT binding domain by synthesizing 
new 2-(2-alkyl-piperazin-1-yl)-6-nitroquinolines to probe the area defined as Ar2. 
We have shown that functionalizing the 2-position of the piperazine ring with a 
methyl (±)-30 and methoxymethyl group (±)-31 greatly enhances SERT binding 
affinity. In addition to expanding the SAR study of the 2-(2-alkyl-piperazin-1-yl)- 
6 -nitroquinolines, we were interested in preparing potential radiolabeling 
precursors for incorporation of carbon- 1 1 and fluorine-18 radioisotopes to explore 
the development of new PET imaging agents for SERT. We also hoped to show 
that our 2-(2-alkyl-piperazin-1-yl)-6-nitroquinolines are selective for the SERT 
and have appropriate vitro binding kinetics for PET imaging studies of low to 
medium SERT density regions through a kinetic binding study.
25
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Chapter 2
Synthesis of Racemic Targets 
2.1 Introduction and Goals.
The initial SAR study, encompassing synthesis and biological evaluation 
of the racemic and chiral 2-(2-alkyl-piperazin-1-yl)-6-nitroquinolines (Me-NQP (±)- 
30 and MOM-NQP (±)-31), has shown that structural alteration of the lead 6 -NQP 
22 at the piperazine 2-position increases SERT binding affinity of the ligand. 
This chapter describes the synthesis of six new SERT ligands to expand our 
knowledge of the SAR of the SERT binding domain. This work has also 
prompted us to develop new racemic radiolabeled (carbon-1 1  and fluorine-18) 
analogs of our lead (±)-31. Outlined in this chapter are the syntheses of the new 
potential radiotracers [11C]MOM-NQP 31 and [18F]PROF-NQP 58.
2.2 Synthesis of [11C]MOM-NQP 31.
Preliminary work in our group attempted the synthesis of the radiolabeling 
precursor N-trityl-HOM-NQP 39 according to Scheme 2-1. The synthesis began 
by demethylation of MOM-NQP (±)-31 with boron tribromide to give the methyl 
alcohol HOM-NQP 38. Once the alcohol 38 was made, our initial thought was 
that protection of the terminal amine with a trityl group would be the simplest 
protecting group for us to use giving the N-trityl protected HOM-NQP 39.
26
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0,N
C(Ph3)CI
-78 °C 
f, 2) NaHC03(aq)
(±)-31
HCk ^ \ / N H Et3 N, CH2 CI2  
H
H
CPh3
38 39
Scheme 2-1: Synthesis of the radiolabeling precursor N-trityl-HOM-NQP 39.
The synthesis of the 39 from HOM-NQP 38 proved to be more challenging 
than expected. Unfortunately, the mono-N-protected species 39 was difficult to 
prepare due to the formation of the undesired di-protected (terminal amine and 
alcohol) HOM-NQP (not shown). Multiple attempts to selectively protect the 
nitrogen of 39 were preformed at varying temperatures; -78 °C, 0 °C and ambient 
temperature.74
Due to the difficulties of the trityl protecting group, we decided that 
protection of the free amine of HOM-NQP 38 as the f-butyl carbamate (N-Boc) 
may be a viable alternative radiolabeling precursor. We again began by 
demethylation of (±)-31 with BBr3 to give 38. The boron tribromide demethylation 
was followed by Boc protection of the amine using an excess of di-terf-butyl 
dicarbonate in dichloromethane (DCM) to give the carbon-11 radiolabeling 
precursor 40 (Scheme 2-2).
XL X  .NH 2)[(CH3 )3 COCO]2 O,CH2 CI2 ,0°C
1) BBr3, CH2 CI2, -78 °C
40
H
Boc
Scheme 2-2: Preparation of the radiolabeling precursor, N-Boc-HOM-NQP 40.
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To determine the feasibility of the radiolabeling precursor 40, we ran 
control methylation and deprotection reactions that were designed to simulate the 
conditions that would be used during the radiolabeling synthesis (Scheme 2-3). 
Compound 40 was deprotonated in dimethyl formamide (DMF) with sodium 
hydride (NaH) at ambient temperature to give the alkoxide as a bright red 
solution. The alkoxide was quenched with the addition of methyl iodide (CH3I) to 
give the nonradioactive (cold) agent N-Boc-MOM-NQP 41. The cold agent was 
isolated by aqueous workup and extraction with DCM, the resulting dried (K2CO3) 
DCM solution was treated with trifluoroacetic acid at ambient temperature. The 
crude reaction mixture was made basic (pH 12) and the deprotected product (±)- 
31 was extracted with DCM, followed by purification by reversed phase HPLC 
utilizing a C-18 column eluting with 50:30:20:0.2 (methanol/acetonitrile/ 
water/triethylamine).
y  o 2n
\  J  ]  NaH, DMF; TFA, 100°C
HO J ^ N . Boc CH3' H3 C ' ° ^ K - N'Boc CH2 CI2  h 3 C ' ° ^ ^ NH
H H
40 41 (±)-31
Scheme 2-3: Simulated reaction sequence for the production of the desired radiotracer 
[11C]MOM-NQP(±)-31.
Upon completion of the nonradioactive synthesis of (±)-31, the 
radiolabeling precursor N-Boc-HOM-NQP 40 was shipped to our collaborators at 
Lawrence Berkeley National Laboratory (LBNL), Berkeley California to attempt 
carbon-11 methylation of the alcohol with [11C]methyl iodide and subsequent N-
28
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Boc deprotection to give the desired radiolabelled ligand [11C]31. Initial 
experiments performed by our collaborator Dr. James P. O’Neil resulted in a 5% 
decay corrected, end of bombardment (EOB) purified yield of [11C]31. The 
radiosynthesis encompassed the methylation and N-Boc deprotection of [11C]31 
using trifluoroacetic acid, according to Scheme 2-4.75 The N-Boc protected 
HOM-NQP 40 was deprotonated by NaH as a solution in DMF and added to a 
solution of [11C]methyl iodide. The reaction was sealed and heated at 100 °C for 
2-3 minutes. The crude product was isolated by C-18 Sep-Pak eluting with DCM. 
Trifluoroacetic acid (TFA) as a 1:9 mixture in DCM was added to the N-Boc 
protected intermediate [11C]41 and the reaction mixture was concentrated in 
vacuo at 100 °C to give the crude product [11C]31. The crude labelled product 
was purified by reverse phase semipreparative HPLC, eluting w/ 50:30:20:0.2 
(methanol/acetonitrile/water/triethylamine) to provide [11C]31 in a 2-5% end of 
bombardment (EOB) decay corrected yield. The [11C]CH3 l used in the synthesis 
was generated from 14N gas using the LBNL onsite cyclotron. Carbon-11 was 
generated by irradiation of nitrogen-14 in a 14N(p,a)11C nuclear reaction in the 
presence of oxygen giving [11C]C02. The reduction of [11C]C02 over a nickel 
catalyst in the presence of H2 gave [11C]CH4 and the [11C]CH4 is halogenated 
with l2 to give [11C]CH3I.
29
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Scheme 2-4: Radiosynthesis of [11C]MOM-NQP 31.
Later during the investigation it was proposed that due to the binding 
kinetics of a related agent [3H]/>Prop-NQP 52 (preparation and pharmacology 
are discussed in Chapter 4), the time needed to reach apparent binding 
equilibrium with SERT was greater than 100 min which exceeded four carbon-11 
half lives (20.4 min), precluding the effective use of [11C]31 for PET imaging. A 
similar finding has been described for the SERT PET agent [11C](+)McN5652 6 . 19 
Marjamaki et al. proposed that incorporation of the fluorine-18 radionuclide (ti/2 = 
109.8 min) would allow for increased time need to reach apparent binding 
equilibrium.19 We were interested in the preparation of MeF-NQP 42 of a 
fluorinated version of (±)-31 (Figure 2-1). The inclusion of the fluorine-18 
radionuclide would allow us to reach apparent equilibrium of binding by 
increasing the time the radiolabelled agent would be useful for imaging,.
Figure 2-1: Desired fluorine-18 radiolabelled ligand [18F]MeF-NQP 42, tosylate precursor 43 and 
the cold fluorinated agent, MeF-NQP 42.
This led us to try to synthesize the cold agent of [18F]MeF-NQP 42 (Figure
2-1). Initial efforts looked into the preparation of MeF-NQP 42 from the precursor
H
[18F]42 43 42
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N-Boc-HOM-NQP 41 by preparing the O-tosylate 43. The O-tosyl moiety is a 
useful leaving group for radiofluorination. Additionally, our collaborators had an 
efficient process for the generation of [18F"] fluoride that could be used for non- 
aqueous nucleophilic fluoride ion substitution reactions. However, all efforts in 
our lab could not produce the desired tosylate product 43. Furthermore, a 
number of attempts to synthesize the cold 2 -(2 -(fluoromethyl)piperazin-1 -yl)-6 - 
nitroquinoline 42 via other methods, i.e. (diethylamino)sulfur trifluoride (DAST), 
resulted in only the formation of undesired side products.74 With these results, 
we decided that lengthening the carbon side chain by two carbons may increase 
the possibility of making a viable tosylate radiolabeling precursor with reduced 
chances of any side reactions occurring.
2.3 Synthesis of PROM-NQP (±)-51.
Described in this section is the overall synthesis of 2-[2-(3- 
methoxypropyl)-piperazin-1-yl]-6-nitroquinoline (PROM-NQP, (±)-51). With the 
information gained from the one carbon series, efforts in our lab were focused on 
the production of the three carbon 2 -(2 -alkyl-piperazin-1 -yl)-6 -nitroquinoline 
precursor 59 that we believed would be better suited for late stage introduction of 
a fluorine-18 atom. In order to accomplish this task we decided to lengthen the 
piperazine alkyl chain at an early stage in the 2 -(2 -alkyl-piperazin-1 -yl)-6 - 
nitroquinoline synthesis, versus the alternate strategy of a later carbon chain 
extension post quipazine framework formation. The complete synthesis of 
PROM-NQP (±)-51 is shown in Scheme 2-13. This synthesis was afforded in 11
31
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steps with an overall yield of 19%. The following describes the work leading up 
to the optimized synthesis of (±)-51.
As shown in Scheme 2-5, initial experiments were focused on the 
controlled reduction of ethyl 1,4-dibenzylpiperazine-2-carboxylate 32 to its 
corresponding aldehyde 44 using diisobutylaluminum hydride (DIBAL). Following 
reduction the aldehyde 44 would be used in a Horner-Emmons76 type olefination 
reaction to extend the length of the chain by two carbons giving the desired 
piperazine fragment with a three carbon chain length. The ester 32 was reduced 
with DIBAL to the corresponding aldehyde 44 at -78 °C. The resulting 
intermediate was converted to the corresponding a,(B-unsaturated ethyl ester 45 
(74%, 2 steps) using triethyl phosphonoacetate as the Horner-Emmons reagent 
and n-BuLi as the base (Scheme 2-5).
“ y ' 1 — i " T
3 2  4 4  74%, 2 steps 4 5
Scheme 2-5: Initial synthetic route to the a,(3-unsaturated ethyl ester 45.
However, we found it difficult to drive the DIBAL reduction of 32 to 44, 
leaving a portion (10-25 mol%) of the starting material ester 32 remaining. 
Attempts to improve the reduction by titration of the DIBAL reagent before the 
reduction with salicylaldehyde phenylhydrazone did not improve the yield 
(Scheme 2-6).
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v ^ P h  ^  .  ^ v ^ N ' ^ h  ^
OH o©
Salicylaldehyde (ye|low) (red)
phenylhydrazone
Scheme 2-6: Titration reagent for determining the concentration of organometallic reagents.
After the Horner-Emmons homologation we also found that the resulting 
a,(3-unsaturated ethyl ester 45 was difficult to isolate from the starting material 
32 by column chromatography. The successfully purified fraction of the 
unsaturated ester 45 was reduced to the unsaturated alcohol 46 (94%) utilizing 
lithium aluminum hydride (LiAIH4), followed by methylation of 46, forming 47 in a 
53% yield (Scheme 2-7). Subsequent catalytic reduction of the alkene and 
hydrogenolysis of the benzyl groups of 47 gave 2-(3-Methoxy-propyl)-piperazine 
48 (8 6 %). The least hindered nitrogen of 48 was protected with 
triphenylmethane chloride (trityl, CPh3) in DCM giving 49 in a 70 % yield. For this 
reaction an excess of Et3N was used to in situ to give the free base form of the 
starting material, as well as to act as an acid scavenger for the HCI generated in 
the reaction.
45
LiAIH4, Et20
94%
Bru NaH, CH3 I, •2 HCI Bn
Nv .0
Bn DMF, 0 °C; H3C
HCI
46
(g)
53% 
C(Ph)3 CI, Et3NH2, 5% Pd/C * 2  HCI
---------------   - O ^ / ^ K / N H
H CH2 CI2, 0 °C 3Cabs. EtOH H3C 
86% 48 70%
47
CPh3
49
Scheme 2-7: Initial synthesis of the coupling precursor 3-(3-methoxypropyl)-1-tritylpiperazine 49.
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The protected trityl piperazine 49 was coupled to 2-chloroquinoline using 
the Gilman method (discussed in Chapter 1) and purified by column 
chromatography to give the N-trityl-PROM-QP (not shown, 75%). The purified 
coupled product N-trityl-PROM-QP was deprotected by dissolving the material in 
a minimal amount of acetone and treating with 6  M HCI. The deprotected 2-(3- 
methoxypropyl-piperazin-1 -yl)quinoline was easily isolated from any non- 
nitrogenous side products (quinoline and trityl alcohol) by diluting the reaction 
mixture with 1 M HCI and extracting with DCM. The resulting aqueous layer is 
then brought to basic pH and the 2-(3-methoxypropyl-piperazin-1-yl)quinoline 
was extracted from the aqueous layer with DCM. The extracted product was 
found to be of sufficient purity to continue with the nitration step without further 
purification. Compound 50 was selectively nitrated at the 6 -position of the 
quinoline ring using HN03 in H2SO4 at 0 °C to give the 2-[2-(3-methoxypropyl)- 
piperazin-1 -yl]-6 -nitroquinoline (±)-51.
1)n-BuLi, 2-chloroquinoline 
Et2 0, 0 °C
0 2N
2) 6 M HCI, acetone 0°C.0 . NH NH
48% 99% (±)-51
Scheme 2-8: Coupling and nitration to give the desired compound PROM-NQP (±)-51.
The NMR spectra of the final product PROM-NQP (±)-51 (Figure 2-2) when 
compared to a MOM-NQP (±)-31 NMR (Figure 2-3) (our standard for 2-(2-alkyl- 
piperazin-1-yl)-6-nitroquinolines) looked promising. We were intrigued by the
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doubling of the peak at 7.00 (Figure 2-2). We initially attributed the splitting 
pattern to the presence of the longer piperazine side chain. The extend alkyl 
chain was thought to be interacting with and changing the inherent environment 
of the hydrogen at the quinoline 3-position thus affecting its splitting pattern, 
possibly through a rotational barrier. Similar splitting patterns have occurred with 
N-formyl-6 -nitroquinoline compounds. Protection as the N-formyl results in 
splitting of the quinoline signals in the proton spectrum due to amide rotamers 
where the peak (quinoline 3-position) at 7.00 ppm is typically the most influenced 
by the amide rotamer.
o2n
NH
52
.0. NH
H3C '
i— !— I— I— |— I— r  
8.2
i — i— |— i— i— r
7.8
t ' T  i i i i | i 1 i i | i i i i ] i i i i 
7.6 7.4 7.2
i—r
8.08.6 7.0
Figure 2-2: NMR of the Aromatic region of PROM-NQP (±)-51, showing the splitting of the C- 
3 quinoline hydrogen.
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Figure 2-3: NMR of the Aromatic region of MOM-NQP (±)-31 as a comparison to the PROM- 
NQP (±)-51 NMR.
However, analysis of the crude reaction mixture before N-trityl 
deprotection (Scheme 2-8) by thin layer chromatography (TLC) (1:9 
EtOAc/hexanes) showed the presence of three distinct coupled products. 
Suggesting that at some point during the initial reaction sequence (Scheme 2-5, 
Scheme 2-7 and Scheme 2-8) two side products had formed in addition to the 
desired compound (±)-51.
We were able to isolate each coupled product as their respective N-trityl 
protected species from the crude reaction by column chromatography. 
Subsequent deprotection of each purified product ( 6  M HCI, EtOH), followed by 
NMR and mass spec analysis determined that the three products were n-PROP- 
NQP 52, MOM-NQP (±)-31 and the desired product PROM-NQP (±)-51 (Table 
2-1).
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Table 2-1: 2-alkylpiperzin-1 -yl-6-nitroquinoline products from the initial PROM-NQP synthesis.
R Cmpd
rA /N H
c h 2o c h ; (±)-31
52c h 2c h 2c h 3
c h 2c h 2c h 3o c h 3 (±)-51
The methoxymethyl product was determined to be carry over of the 
starting material ethyl ester piperazine 32 due to the incomplete reduction with 
DIBAL. To eliminate the carry over of 32, other methods of preparing the 
aldehyde 44 were investigated; i.e., PCC, PDC, and Swern. We decided that a 
more efficient method of preparing the aldehyde 44 was to fully reduce the ethyl 
ester 32 to the alcohol 33 in a similar manner to a literature procedure,68,70 
followed by oxidation of the methyl alcohol 33 to the desired aldehyde 44.
Outlined in Scheme 2-9 is the modified synthesis of the key intermediate 
45 for the preparation of PROM-NQP (±)-51. The ethyl ester 32 was reduced to 
its corresponding alcohol 33 via LiAIH4 reduction at room temperature in Et2 0  to 
give the alcohol 33 in a 96% yield. This reaction proceeds smoothly in less than 
one hour to give the alcohol, which after quenching the reaction and isolation 
from the inorganic salts was of sufficient purity to continue with the next 
transformation. When necessary, the alcohol can be purified by column 
chromatography over silica gel eluting with 3:2 EtOAc/hexanes. The aldehyde 
44 was generated by Swern oxidation77' 79 (DMSO, COCL and Et3N), according to 
the previous synthesis (Scheme 2-5) the aldehyde 44 was used immediately in 
the Horner-Emmons olefination to give the unsaturated ester 45 in a 64% yield 
over two steps (Scheme 2-9).
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Bn
UAIH4 , Et20 DMSO, (COCI)2,
EtO
O H
Bn Et3 N, CH2 CI2, -78 °C
32 33
n-BuLi,
H
N ^ " '|  (Et0)2 P(Q)CH2 C02Et 
' j ^ NvBn THF, 0 °C
N EtO.
Bn
O O
44 64%, 2 steps 45
Scheme 2-9: Modified synthesis of the key intermediate 45 for the synthesis of PROM-NQP (±)- 
51.
The reaction sequence outlined in Scheme 2-9 proved more facile for the 
preparation of 45 than the previous controlled reduction of the ester with DIBAL 
and subsequent Horner-Emmons homologation. Additionally, the purification of 
the resulting a,(3-unsaturated ethyl ester 45 proved to be much easier, 
considering both the LiAIH4 reduction and Swern oxidation go to completion. 
This eliminated the carryover of any of the starting material ester 32 and the 
presence of MOM-NQP (±)-31 after coupling was no longer detected.
This left us to determine where the n-propyl side product 52 was being 
generated. We proposed that the n-propyl side product 52 may be the result of a
1,4 addition of the hydride to the a,|3-unsaturated system of 45 during the LiAIH4 
reduction of ester to the propenyl alcohol 46. A proposed mechanism for the 1,4 
hydride addition is detailed in Scheme 2-10. To possibly further support this 
mechanism similar conditions of the reaction (Scheme 2-5, Scheme 2-7 and 
Scheme 2 -8 ) could be run using lithium aluminum deuteride (LiAID4). The 
resulting reaction mixture could be analyzed for the presence of the deutero n- 
propyl product at the 1- and 3-position of the propylene side chain.
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Scheme 2-10: Proposed mechanism for the production of the n-allyl side product that would lead 
to the n-PROP-NQP 52 product after completing the synthetic steps outlined in Schemes 2-7 and 
2- 8 .
To eliminate the possibility of the 1,4 hydride addition, saturation of the 
alkyl chain of 45 was necessary before LiAIH4 reduction. If this was to be 
accomplished using catalytic hydrogenation, it would be necessary to reduce the 
alkene selectively and avoid hydrogenolysis of the N-benzyl groups of 45. To 
avoid the possibility of cleaving the N-benzyl protecting groups we looked into the 
reduction of the alkene by a non-catalytic hydrogenation technique. A literature 
search for the reduction of a,0 -unsaturated esters found that the use of 
magnesium metal in methanol reduced unsaturated esters in good yields (65- 
99% ) .80,81 For example, Fadel, et al. were able to selectively reduce an a,(3- 
unsaturated ester in the presence of a non-conjugated alkene by treatment with 
Grignard grade magnesium metal in dry methanol (Scheme 2-11 ) .80
Mg°, MeOH
CO2M6 CO2MS
Scheme 2-11: Example of a selective reduction of a conjugated system utilizing Mg°.
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According to the literature this was a simple process of reacting the 
unsaturated ester with magnesium turnings in methanol, quenching with acid to 
consume any remaining magnesium metal, and isolation of the product by 
aqueous extraction. This is a useful reaction when there are non-conjugated 
alkenes present (as above) as well as other catalytic hydrogenation sensitive 
groups, i.e. cyano and nitrile. The reaction did seem to progress well giving the 
saturated methyl ester 53, although the yields were not as expected, ranging in 
the 26-32% yield (Scheme 2-12). During the reaction progress a large amount of 
baseline material by TLC material was formed, which has been proposed to be 
due to chelation of Mg2+ by the piperazine nitrogen atoms. This is likely, 
considering piperazine is a cyclic version of ethylenediamine, a well known metal 
chelating agent (Figure 2-4) .82
B n-N  N -B n FfeN Nhfc 
\  / ’ /
M g / Ma>+
Figure 2-4: Chelating potential of piperazine and related chelator ethylenediame.
In light of the failed Mg° reduction we attempted a “gentle” hydrogenation 
of 45 using 5% Pd/C and H2 at atmospheric pressure and hydrochloric acid (12 
M). When using 12 M HCI the alkene was easily reduced. Unfortunately the 
cleavage of the benzyl groups also occurred, giving compound 54 in a 95% yield 
(Scheme 2-12). This was both a positive and negative result, we now knew that 
a pressure of 50 psi and 50 °C was not necessary to cleave the benzyl groups, a 
standard method in our group. However, selective reduction of the alkene in the
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presence of the benzyl groups was still elusive. We decided to attempt the 
hydrogenation using acetic acid instead of the typical 12 M HCI. A solution of the 
dibenzyl a,(3-unsaturated ethyl ester 45 was treated with excess of acetic acid 
and a catalytic amount of 5% Pd/C. The reaction was sealed with a septum and 
hydrogen was bubbled through the solution. The reduction in the presence of 
acetic acid allowed us to selectively reduce the alkene leaving the benzyl groups 
intact, thereby giving the saturated ethyl ester 55 in a 78% yield (Scheme 2-12).
Bru
Mg°, MeOH
Bn.
N
EtO
H
45
'Bn
o°c
26-32% 
H2, 5% Pd/C
MeOH, 12M HCI
95%
H2, 5% Pd/C
MeOH, AcOH
67-78%
MeO
Bn
53
•2 HCI H N ^
Et ° Y ^ 4 ^ NH
°  54
EtO.
Bn
Scheme 2-12: Attempted selective reduction of the conjugated alkene of 45.
The saturated propyl ester 55 was reduced to the propyl alcohol 56 with 
UAIH4 in Et2 0  (95%, Scheme 2-13) in a similar manner to the one carbon side 
chain case (Scheme 1-2). The propyl alkoxide was generated in DMF using 
NaH, and then methylated by the addition of CH3I to give 57. The benzyl groups 
of the free-base form of methoxypropyl 57 were cleaved at atmospheric 
pressure and ambient room temperature hydrogenolysis conditions, as a solution
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in MeOH and an excess of 12 M HCI, to give the dihydrochloride salt of the 
piperazine 48 (53%, 2 steps).
The more accessible nitrogen atom was selectively protected with trityl- 
chloride to give the N-trityl-piperazine 49 in a 99% yield. Then 49 was coupled to
2-chloroquinoline utilizing the Gilman coupling conditions and the resulting crude 
material was purified by column chromatography (1:9 EtOAc/hexanes). The N- 
trityl protected product (not shown) was deprotected in acetone with 6  M HCI, 
aqueous workup afforded the desired compound 50 in an 82% yield over two 
steps. Selective nitration at the quinoline six position gave the desired 2 -(2 -alkyl- 
piperazin-1-yl)-6-nitroquinoline (±)-51 (99%). The overall synthesis is shown in 
Scheme 2-13 and was accomplished in 11 steps with an overall yield of 19%.
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Scheme 2-13: Overall synthesis of PROM-NQP (±)-51.
2.4 Synthesis of the Radiolabeling Precursor N-formyl-ProTos-NQP 63.
Upon completion of the synthesis of (±)-51, the focus was turned towards 
generating a fluorinated analog with the intent of preparing a radiolabeling 
precursor for the introduction of a fluorine-18 atom (Scheme 2-14). The goal
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(±)-51 58
Scheme 2-14: Proposed fluorinated analog 58, to be prepared from PROM-NQP (±)-51. 
was to prepare a stable fluorination precursor that was amenable to late stage 
incorporation of the fluorine atom by Sn2 displacement technology. We set out to 
generate an N-protected-propyl-O-tosylate 59 (Figure 2-5) of compound HOP- 
NQP 146 (not shown).
Figure 2-5: N-protected proposed fluorinating precursor.
Our specific approach encompassed the nucleophilic displacement of the 
proposed tosylate 59 by F" and subsequent nitrogen deprotection would give the 
desired radiolabelled compound 58. To prepare the O-tosyl precursor, PROM- 
NQP (±)-51 needed to be demethylated and the 2° nitrogen atom had to be 
protected. Earlier work within the MOM-NQP (±)-31 series found that the MOM 
group could be easily deprotected using boron tribromide in good to moderate 
yields (Scheme 2-1). Furthermore the nitrogen could be protected with a BOC 
group as part of the purification procedure after demethylation. What remained 
unknown was whether the propyl version could undergo tosylation reaction, this 
would be in contrast to the one carbon side chain version that failed to tosylate.
59
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Our prediction was that by extension of the carbon chain by two additional 
carbons would make the oxygen more available for reaction with tosyl chloride.
When PROM-NQP (±)-51 was treated with boron tribromide under similar 
conditions to the MOM-NQP demethylation procedure (Scheme 2-2), we found 
that the desired alcohol 146 was generated; additionally a second more non­
polar product was also formed. Mass spectra analysis showed that the side 
product was the corresponding alkyl-bromide 62. The mechanism shown in 
Figure 2-6 below provides a rationale for the formation of the two products under 
the BBr3 conditions. Unfortunately, due to the high polarity of the 6 -NQP analogs 
the bromide could not be easily separated from the desired product by silica gel 
chromatography. It was necessary to use a high percentage of methanol in DCM 
to elute the products and the resulting separation was poor.
Figure 2-6: Explanation for the production of the bromide side product formed during BBr3 
cleavage of the methyl ether.
62
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In order to simplify the purification of the BBr3 reaction we decided that 
protection of the terminal amine with a group that is stable to BBr3 conditions 
would be beneficial. Therefore, the free amine of PROM-NQP (±)-51 was 
protected as the N-formyl according to Scheme 2-15. Treatment of (±)-51 with 
acetic anhydride (AC2O) as a solution in 8 8 % formic acid gave the desired N- 
formyl-PROM-NQP 60 in a 91% yield.83 Protection of the amine as the N-formyl 
group made the purification simple and the use of column solvents that contained 
a high percent of MeOH were avoided. The resultant N-formyl-2-(3- 
methoxypropyl-piperazin-1 -yl)-6 -nitorquinoline was purified using silica gel eluting 
with 0.01:5 MeOH/CHCI3.
N N N N
8 8 % Formic acid 
Ac20  
91%
Scheme 2-15: N-formyl protection of PROM-NQP (±)-51.
The N-formyl-PROM-NQP 60 was treated with BBr3 according to the 
procedure developed in the MOM-NQP synthesis (Scheme 2-2). In brief a 
solution of N-formyl-quipazine in DCM at -78 °C was treated with a solution of 
BBr3 (500 mol%) then allowed to warm to room temperature, the reaction was 
quenched by the addition of a saturated solution of NaHCOs, and the organic 
portions were extracted with DCM. We found the N-formyl protecting group to be 
stable to the BBr3 reaction conditions. Importantly, by having the terminal amine 
tied up as the N-formyl allowed for easy separation of the desired alcohol product
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from any unreacted starting material 60 or bromide side product 62. We found 
that the BBr3 demethylation of PROM-NQP (±)-51 as the N-formyl amide gave 
consistent results where the product alcohol 61 was easily isolated from any side 
products by column chromatography with silica gel (6 6 %).
o2n
1) BBr3, CH2CI2. -78 °C
0 2N
H
60
N N
2) NaHC03(aq) ^  ^
66% X = OH 61 and Br 62
Scheme 2-16: Cleavage of the methyl ether of N-formyl-PROM-NQP (±)-51.
The N-formyl-HOP-NQP 61 was then treated with tosyl chloride in the 
presence of pyridine in DCM at 0 °C for 24 hours to give the O-tosylate 63 in a 
53% yield. However, we found that the resulting O-tosylate 63 was very reactive 
to nucleophiles present in the reaction mixture. For example, chloride ion that 
was generated during the reaction quickly converted 63 to the alkyl chloride 64.
° 2N
k  J L  A  ^  Tosyl-CI, pyridine
H0^ - ^ k ^ 0  CH2CI2, o - rt  °c
H HH 51%
61 X = OTs 63 and Cl 64
Scheme 2-17: Synthesis of N-formyl-ProTos-NQP 63.
This result was not surprising considering the mixture of products formed 
during demethylation with BBr3. With NMR analysis it was determined that the 
reaction gave a 1:1 mixture of tosylate 63 to chloride 64. The two products could 
be carefully separated by column chromatography (1:1 EtOAc/CHCh). However,
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the mixture was typically carried forward to the fluorination step (Scheme 2-17), 
and extensive purification was undertaken only when the precursor was to be 
shipped to LBNL for radiofluorination.
2.5 Nonradioactive Fluorinations of N-formyl-ProTos-NQP 63.
To investigate the usefulness of 63 as a radiolabeling precursor, trial 
fluoride ion substitutions (tetrabutylammonium fluoride, TBAF) and subsequent 
deprotections (4 M H2S 04) were performed. We found that N-formyl-ProTos- 
NQP 63 was readily fluorinated with TBAF in THF at 60 °C. The crude reaction 
was subsequently concentrated in vacuo and then quickly purified by flushing 
through a silica plug. The N-formyl group was removed using 4 M H2SO4, at 50 
°C, to give the desired fluorinated product PROF-NQP 58 in a 58% yield over 2 
steps (Scheme 2-18).
TBAF, THF
55 °C r
H
H
64% 65
THF, 55 °C NH
90%
Scheme 2-18: Fluorination sequence to prepare PROF-NQP 58.
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With the fluorination and deprotection steps accomplished the tosylate 
precursor 63 was purified and shipped to our collaborator Dr. O’Neil at LBNL for 
trial radiofluorination and deprotection.
2.6 Radiofluorination of N-formyl-ProTos-NQP 63.
Based upon successful non-radioactive fluorination of the O-tosylate 63, 
the precursor was shipped to LBNL for radiofluorination trials. Outlined in 
Scheme 2-19, is an overview of the radiofluorination attempts to give [18F]58. 
The synthesis of [18F]58 was accomplished in 2 synthetic steps from the N-Boc- 
tosylate precursor 63.
N" 'N '
H
N N
ACN, 100 °C
I 1 0 min 
H [ F]65
80% Activity
100 °C, Vacuum
Silica plug 
EtOAc
H18F
40% Activity
4 N H 2 S04, 80-100 °C; 10min 
Sep-Pak;
C-18 HPLC
N N
[18F]58 
8-10% Actvity
Scheme 2-19: Initial radiofluorination trial using N-formyl-ProTos-NQP 63 to give [ F]PROF-NQP 
58.
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Displacement of the O-tosylate with [18F“] is afforded utilizing tetrabutyl 
ammonium [18F]fluoride (TBA18F) in acetonitrile (ACN) at 100 °C (80-90% 
incorporation). After heating the reaction mixture was purified from any inorganic 
material by elution through a silica plug with ACN, radioactive survey showed 
80% activity. Concentration of the eluent under vacuum at 100 °C and 
subsequent survey showed 40% activity and a 40% loss in activity. The loss of 
activity was attributed to defluorination of the fluoroalkyl to give H18F. The crude 
material containing [18F]65 was deprotected with 4 N H 2 S O 4  at 100 °C, quenched 
with NaOH(aq) and initially purified using a C-18 Sep-Pak, eluting the desired 
fraction containing [18F]58 with MeOH. Purification of the eluent by 
semipreparative HPLC (65:35:0.2 Me0 H/H2 0 /Et3N) isolated the desired 
radioactive fraction containing [1SF]58 in a 8-10% EOB decay corrected yield.
We were concerned with the large loss in radioactivity when the silica plug 
eluent was concentrated and during the deprotection of the N-formyl protecting 
group. It seemed that at high temperatures (80-100 °C) a large amount of H18F 
was produced. Attempts to circumvent high temperature deprotection conditions 
(4 N H2SO4 and 16 M H2SO4 at ambient temperature, as well as basic 
deprotection with NaOH) resulted only in incomplete deprotection of [18F]65 to 
give the desired product [1SF]58.
2.7 Synthesis of the Precursor N-Boc-ProTos-NQP 69.
The losses of activity during heating cycles and during deprotection of the 
N-formyl group lead us to investigate the preparation of a similar precursor with a 
protecting group that would be removed under more facile conditions. The
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
nitrogen protecting group ferf-butyl carbamate (N-Boc) was used with relative 
ease in our laboratory as a tool for purifying polar compounds, i.e. HOM-NQP 38 
and MOM-NQP (±)-31. For example, we had found that deprotection of N-Boc 
compounds with H2S0 4 routinely gave the desired amine product in excellent 
purity in 5 minutes or less. Using the same BBr3 procedures as already outlined 
for MOM-NQP (±)-31 and N-formyl-PROM-NQP 60 (Scheme 2-16), PROM-NQP 
(±)-51 was treated with BBr3 accordingly and the reaction was quenched and the 
product was extracted with DCM. The DCM portion was dried, filtered and 
concentrated to a 5-10 ml volume and an excess of di-ferf-butyl-dicarbonate was 
added (Scheme 2-20).
° 2 N s / ^ v ^  °2N
1) BBr3, CH2 CI2, -78 °C
N N
2) [(CH3 )3 C0C0]2 0, CH2 CI2, 0 °C .
H H B“
44%, 2 steps
X = OH 6 6 , Br 67, and di-Boc 6 8
Scheme 2-20: BBr3 methyl ether cleavage of PROM-NQP and subsequent protection as the N- 
Boc to give N-Boc-HOP-NQP 66.
Examination of the crude reaction by TLC after treatment with Boc20  
showed the expected N-Boc protected alcohol 66 and bromide 67. However, 
upon concentrating in vacuo any excess unreacted Boc20  reacted with the 
alcohol group forming the respective carbonate product 68. Thus, with this 
reaction workup three products were formed, including the mono-Boc-HOP-NQP 
66, the di-Boc-HOP-NQP 68 and Boc-bromo-NQP 67. In other experimental 
attempts when there was a large excess of Boc20  used all of the alcohol was 
protected as the carbonate giving di-Boc-HOP-NQP 68 and the Boc-bromo 67
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in the workup mixture. The presence of the N-Boc made purification of these 
quipazines very easy (silica gel), where the three products could be separated by 
column chromatography eluting with a mixture of EtOAc/hexanes. The 
carbonate group of 6 8  could then be selectively deprotected over the carbamate 
moiety by heating to 50 °C in MeOH with an excess of powdered K 2 C O 3 ,  to give 
the desired N-Boc-HOP-NQP 6 6  in a 72% yield (Scheme 2-21).
Scheme 2-21: Selective cleavage of the undesired Boc carbonate 6 8 .
The N-Boc protected HOP-NQP 6 6  could then be tosylated in a similar 
fashion to the N-formyl case, giving N-Boc-ProTos-NQP 69 in a 76% yield 
(Scheme 2-22). However, the reaction conditions were improved to limit the 
amount of propyl chloride side product formed, by simply increasing the amount 
of pyridine to 600 mol% and tosyl chloride to 420 mol%.
76%
66 69
Scheme 2-22: Tosylation of N-Boc-HOP-NQP to give the fluorination precursor N-Boc-ProTos- 
NQP 69.
K2 C03, MeOH
72%
68 66
Tosyl-CI, pyridine
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The excess pyridine acts as a scavenger of the chloride generated during 
the reaction. The resulting Boc protected tosyl quipazine 69 was fluorinated 
using the technology developed for the N-formyl case (Scheme 2-23). A solution 
of 69 in dry THF was treated with 150 mol% of TBAF and heated to 55 °C. The 
crude reaction mixture was concentrated, purified (silica gel) to give N-Boc- 
PROF-NQP 70. The benefit gained from the new protecting group was that the 
Boc group could be removed in under 5 minutes at room temperature using 
concentrated sulphuric acid to give the desired fluorinated product PROF-NQP 
58 in a 78% yield. The ease by which the Boc group could be removed was 
thought to be very useful for the radiolabeling protocol.
Scheme 2-23: Trial fluorination of 69 with TBAF Boc group deprotection to give PROF-NQP 58.
An important caution and downfall of this method is that when quenching 
the deprotection, one must be diligent in maintaining a cool temperature or risk 
defluorination. The need to maintain a cool temperature for deprotection further 
substantiates the results from the LBNL fluorination trials with 63. We have 
found the fluorinated product 58 is very easy (under aqueous acidic conditions) 
to form a very polar oxidized species. The side product has been hypothesized 
to be the result of elimination of the fluoride and possibly further oxidation of the
TBAF, THF, 55 °C;
69 78% 58
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alkene. However, the polar side product to date has not been formally isolated to 
determine its identity.
2.8 Radiofluorination Attempts of N-Boc-ProTos-NQP 69.
After the successful preparation of nonradioactive PROF-NQP 58 by 
utilizing the nitrogen protecting group Boc, we shipped the tosylated precursor 69 
to LBNL for further [18F'] fluorination attempts. Two separate fluorination 
methods were attempted. The first trial, as outlined in Scheme 2-24, used 
Kryptofix 222 (K222), KHC03, Ag18F in ACN at 100 °C, followed by Boc 
deprotection (H2SO4) and purification. The second trial outlined in Scheme 2-25 
was attempted according to the N-formyl case (Scheme 2-19) utilizing TBA18F in 
ACN at 100 °C, and similarly deprotected.
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2.9 Radiofluorination Attempts with K222, KHCO3 and Ag18F.
KHCO3 , K222, Ag18F
ACN, 100 °C, 11 minTsO.
'Boc 'Boc
Silica plug 
ACN
16 M H2 S04, 4 min 
Sep-Pak, MeOH elutionWater Fraction 
43% Activity 
H18F
36% Activity
K222 = n \ oV o\ n
C-18 HPLC
OoN
N N
[18F]58 
1.6 % Actvity
Scheme 2-24: Radiofluorination sequence utilizing K222, KHC03, and Ag18F with the precursor 
N-Boc-ProTos-NQP 69.
As outlined in Scheme 2-24, a dry solution of K222, KHCO3, and Ag18F in 
ACN was prepared in a 4 mL vial and transferred to a vial containing a solution of 
tosylate 69 in ACN. The reaction mixture was heated at 100 °C for 11 min and 
then cooled on ice. The cooled reaction mixture was treated directly with H2SO4 
(16 M) to deprotect [18F]70, after 4 min the deprotection was quenched by adding 
to a dilute solution of NaOH (1%), and loaded onto a C-18 SepPak. The SepPak 
was washed with water and radioactive survey showed 43% activity in the wash. 
The desired fraction eluted from the SepPak with methanol afforded the fraction 
containing [18F]58 with 36% activity. Further purification of the SepPak eluent by 
semi-preparative reverse phase HPLC (65:35:0.2 MeOH/Water/TEA) gave the
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desired fraction (eluting at 7.6-9.5 min) containing [18F]58, radioactive survey 
showed 1.6% activity. Analytical HPLC (70:30 MeOH/O.17 M NH4CO2H, 0.5% 
AcOH) confirmed the product eluting at 4.6 min. The synthesis was successful in 
generating the desired radiolabelled product [1SF]58 in a 1.6% EOB decay 
corrected yield. However, the yield was considerably lower than earlier trials 
using the N-formyl protecting group (8-10% EOB decay corrected yield, Scheme 
2-19).
A second fluorination attempt was made using the same procedure 
outlined above (Scheme 2-24). However, TLC analysis of the initial fluorination 
was performed to determine if incorporation of the radionuclide was giving the 
expected product [18F]70. As before, a dry solution of K222, KHC03, and Ag18F 
in ACN was prepared in a 4 mL vial, treated with a solution of tosylate 69 in ACN, 
heated at 100 °C for 11 min and then cooled. The crude mixture was purified by 
elution through a silica plug with ACN. Radioactive TLC analysis showed the 
presence of two radioactive products eluting close to the expected product 
[18F]70 Rf, product one, Rf = 0.422 and product two, Rf = 0.584 (2:3 
EtOAc/hexanes) (Figure 2-7). We were concerned with the presence of two 
radioactive products and decided that returning to the original conditions 
(TBA18F) attempted with the N-formyl case (Scheme 2-19) would be beneficial.
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Rgn 1 12.2 29.6 22.2 0.020 75911.0 15182.2 11.63 11.95
Rgn 2 28.7 47,9 37.8 0.167 114717.0 22943.4 17,58 18.06
Rgn 3 55.7 74.0 65,1 0.422 194335,0 38867.0 29.78 30.59
Rgn 4 73.2 94.9 82,5 0.584 250245.0 50049.0 38.35 39.40
4 Peaks 635208.0 127041.6 97.33 100.00
Figure 2-7: Radioactive TLC analysis after initial fluorination and silica purification of the K222 
radiofluorination trial, showing two possible Boc protected fluorinated products.
2.10 TBA18F Radiofluorination Attempts.
As outlined in Scheme 2-25, a solution of the tosylate 69 in ACN was 
treated with a solution of TBA18F in dry ACN and the reaction was heated at 100
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°C for 12 min. The reaction was cooled and flushed through a silica plug with 
acetonitrile, with the desired fraction having 49% activity by radioactive survey. 
Analysis of the silica plug eluent by radioactive TLC (3:2 EtOAc/hexanes) 
showed one major spot (Rf = 0.59) and one minor spot (Rf = 0.48)(Figure 2-9). 
The eluent was treated with H2SO4 (16 M) at 0 °C for 9 min, quenched by dilution 
into 1% NaOH (30 ml_), and loaded onto a C-18 SepPak. The water flush 
contained 41% of the radioactivity, and elution of the SepPak, to isolate the 
product fraction, contained 3.6% of the original radioactivity. At this point we 
were already at a lower possible yield of [18F]58 than the N-formyl trials utilizing 
TBA18F or the K222 trial with the N-Boc-ProTos-NQP 69 precursor (Scheme 2- 
24). Purification of the SepPak methanol eluent by HPLC gave the desired peak 
[18F]58 eluting at 8.5-9 min with 0.6% EOB decay corrected yield.
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Scheme 2-25: Radiofluorination sequence utilizing TBAF.
A second trial was performed and the reaction process was stopped after 
silica gel purification of the fluorination mixture (Scheme 2-25). Again we 
analyzed the purified reaction mixture by radioactive TLC. Included on the TLC 
plate was a lane for the nonradioactive standard 70 and a lane for the silica gel 
eluent expected to contain [18F]70. This allowed us a direct comparison of 
[19F]58 and [18F]58 and any other radiofluorinated Boc protected compounds. To 
enable direct comparison, the solvent front, baseline and UV active spot 
corresponding to [19F]58 were spotted with a sample of radiation to enable the 
use of the radioactive TLC analyzer. The TLC analysis of the nonradioactive 
standard [19F]70 is shown in Figure 2-8. From the nonradioactive lane we 
determined that the desired product [18F]70 should have an Rf = 0.516. Figure
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2-9 shows the second lane containing the silica gel plug ACN eluent. 
Comparison of the two TLC lanes shows the desired product is only 20% of the 
mixture. The other TLC spot was 54% of the mixture {R f  = 0.631), could be a 
second fluorination product with a similar elution profile as the desired product.
Producing only 20% of the desired product [18F]70 during the fluorination 
attempt, helps to explain why we were only able to produce 0.6% of the desired 
labelled compound in the first TBA18F trial. Additionally if the compound is labile 
to acidic conditions as we saw in the N-formyl case, then treatment of the ACN 
eluent from the silica gel plug would likely cause a further decrease in the yield of 
[18F]58.
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Figure 2-8: Radioactive TLC analysis of the N-Boc-PROF-NQP 70, co-spotted with radiation at 
the baseline, front and on the product spot to allow for direct comparison to the radiofluorination 
attempt.
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Figure 2-9: Radioactive TLC analysis of the fluorination of 69 after silica gel purification. Two 
products are visible with the smaller eluting at the same Rf as 70.
2.11 Fluorination Control Reactions.
To explain the second fluorinated product observed in the K222 and 
TBA18F radiofluorination attempts we set out to attempt to reproduce the results 
in our lab. It was hypothesized that at the high temperature of the fluorination 
reaction that nucleophilic aromatic substitution (SnA^  could occur. To determine
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if the aromatic system of the 2 -(2 -alkyl-piperazin-1 -yl)-6 -nitroquinolines was 
susceptible to fluoride attack, N-Boc-n-PROP-NQP 71 was used as a test ligand. 
Outlined in Scheme 2-26 is the nonradioactive control reaction with 71. 
Treatment of 71 with NaHC03 (600 mol%), K2 2 2  (1000 mol%) and KF (800 
mol%) and heating at 100 °C for 10 min produced a new spot by TLC (R f  = 0.44, 
3:2 EtOAc/hexanes), purification by silica gel pipette column (2:3 
EtOAc/hexanes) the fluoride substitution product 72 was isolated in a 25% yield. 
Proton NMR of the new product shows a distinct change in the aromatic system 
that is consistent with substitution at the quinoline 6 -position.
Boc
K222 , NaHC03, KF
ACN, 100 °C, 10 min
Boc
72
Scheme 2-26: Trail nucleophilic fluorine substitution of N-Boc-n-PROP-NQP 71.
With successful incorporation of a fluoride atom onto the 2-(2-alkyl- 
piperazinyl)-6 -nitroquipazine system we looked to repeat the results using the 
radiolabeling precursor 69 in two separate control reactions. Scheme 2-27 
describes the fluorination control reaction according to the procedure used with 
the N-Boc-n-PROP-NQP 71 control reaction. Accordingly, 69 was heated as a 
solution in ACN at 100 °C for 10 min with K222 (1000 mol%), NaHC0 3  (600 
mol%), and KF (1000 mol%). This gave two products by TLC analysis and 
separation of the products was afforded using silica gel chromatography (2:3 
EtOAc/hexanes). NMR analysis of the more nonpolar product (R f  = 0.5, 3:2 
EtOAc/hexanes) suggests the product is the result of nucleophilic fluoride
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substitution of the tosylate in addition to the aromatic substitution to give 73. The 
more polar product ( R f  =  0 .4 , 3:2 EtOAc/hexanes) by NMR comparison to 
standards is the expected fluorination product N-Boc-PROF-NQP 70.
Scheme 2-27: Trial nucleophilic fluorine substitution with an excess of KF.
We were then interested as to what a control reaction would give using the 
ratios resembling the radiolabeling protocol (K222 (1000 mol%), NaHC0 3 ( 6 0 0  
mol%), but KF (50 mol%)) was used as a limiting reagent (Scheme 2-28). Using 
the same procedures outlined above tosylate 69 was heated at 100 °C for 10 
min, giving two products by TLC analysis of the crude reaction. The products 
were purified by silica gel pipette column (1:3 EtOAc/hexanes to elute 70, and 
3:2 EtOAc/hexanes to elute 66) and analyzed by NMR. The product with an Rf of 
0.55 was N-Boc-PROF-NQP 70, the more polar product ( R f  = 0.2) is the result of 
nucleophilic fluoride attack at the sulfur of the tosyl group to give the alcohol 66 .
NaHC03, K222, KF
70
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Scheme 2-28: Trail nucleophilic fluorine substitution using KF as a limiting reagent.
Based upon the fluorination control reactions it seems likely that the 
difluoro species 73 is the anomalous radiofluorinated product observed during 
the TBA18F and Ag18F radiofluorinations. As shown in Scheme 2-29, TBAF has 
been used with successfully to displace aromatic nitro groups in the preparation 
of fluoro-substituted pyridines 75 from 2, 3, and 4 nitropyridines 74, and as an 
alternative for the Balz-Schiemann reaction (Scheme 2-29).84 Additionally, the 
use of KF has been also been shown to give aromatic substitution by 
fluorodenitration of nitropyridines.85 In order to determine if the difluoro 73 is the 
unknown product of radiofluorination a standard sample would need to be sent to 
LBNL, the radiofluorination attempted again and isolation of the side product for 
HPLC comparison completed.
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TBAF, DMF
R
74 75
DN-fN H 2 2) A
Balz-Schiemann reaction
1)NaN02, HBF4
Scheme 2-29: Example fluoride aromatic nucleophilic substitution of nitropyridines using TBAF.
Based upon the three trial radiofluorinations, it is likely that the N-formyl 
precursor 63 would be more suited for the preparation of the radioligand PROF- 
NQP 58. The N-formyl case resulted in a much higher yield (8-10% EOB decay 
corrected yield) of [18F]58 compared to either fluorinations using the Boc 
precursor 69. In addition to a better radiofluorination yield the preparation of the 
N-formyl tosylate precursor 63 is far more facile to produce, especially 
considering the nitrogen protecting group (N-CHO) is in place before 
borontribromide cleavage of the ether. Also, BBr3 demethylation of the N-formyl- 
PROM-NQP 60 is more consistent than the Boc series (Scheme 2-22). With the 
improvements of the tosylation conditions the likelihood of generating the 
chloride side product 64 (Scheme 2-17) is diminished, thus improving the 
tosylate yield and eliminating the need for cautious purification of 63.
2.12 Synthesis Pent-NQP (±)-83 and PentF-NQP 88.
As shown in Scheme 2-30 the universal starting material ester 32 for our 
quipazine syntheses was reduced by LiAIH4 to give the alcohol 33 in 96% yield. 
Swern oxidation of the alcohol followed Horner-Emmons olefination furnished the
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unsaturated ester 76 in a 6 6 % over 2 steps. Catalytic hydrogenation at 
atmospheric pressure with 5% Pd/C in MeOH and acetic acid gave the saturated 
ester 77 in 78% yield. The ester was reduced with UAIH4 to give the pentyl 
alcohol 78 (95%). Subsequently, the alkoxide was generated with NaH in DMF 
and alkylated with iodomethane to give 79 in a 60% yield. Hydrogenolysis of the 
benzyl groups utilizing 5% Pd/C in MeOH and HCI gave the pentyl piperazine 
dihydrochloride 80 (quantitative yield), which was protected at the least hindered 
amine with trityl chloride to give the N-trityl piperazine 81 (99%). The protected 
piperazine was coupled to 2-chloroquinoline using the typical Gilman coupling 
and subsequent deprotection with 6  M HCI in acetone gave the pentyl quipazine 
82 (58%, 2 steps). Selective nitration with HNO3 in sulphuric acid gave the 
desired 2-pentyl-nitroquipazine (±)-83 (quantitative yield). Together, (±)-83 was 
afforded in 11 steps in an overall yield of 16%.
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Scheme 2-30: Overall synthesis of Pent-NQP (±)-83.
The free amine of Pent-NQP (±)-83 was protected as the N-formyl 
according to the procedures described in the propyl synthesis (Scheme 2-31) to 
give 84 in a 97% yield. Treatment with BBr3 to generate the desired alcohol for
68
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
subsequent tosylation, only gave the bromide product 85 in a 93% yield. To 
generate the tosylate from the bromide a new technique was used. We found 
that the pentyl bromide could be transformed to the tosylate 86 by treatment with 
silver tosylate (AgOTs),86 in a Finkelstein-like reaction. For this reaction, the 
nucleophilic O-tosylate group displaces the bromide affording the AgBr solid. 
Treatment of N-formyl-PentBr-NQP 85 with an excess of AgOTs at 50-60 °C 
gave the desired tosylate 86 in a 88% yield. Fluoride ion displacement of 
tosylate 86 was accomplished using TBAF conditions developed for the propyl 
series to give 87 in a 84% yield. Subsequent N-formyl deprotection with 4 M 
H2SO4 at 50 °C gave 88 (91%). To date, no further work has been attempted to 
examine radiofluorination of 86.
(—)-83
H
NH
8 8 % Formic acid
97%
84
B B f3, C H 2C I2
AgOTs, CH3CN TBAF, THF
H H
85 88% 86 84%
HH 91%87 88
Scheme 2-31: Synthesis of PentF-NQP 88.
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2.13 Synthesis o f BuM-NQP 96.
The BuM-NQP analog 96 was synthesized from the common dibenzyl 
starting material 32 according to Scheme 2-32. The dibenzyl alcohol 33 was 
oxidized by Swern oxidation, followed by Horner-Emmons olefination (64%, 2 
steps) to give the a,p-unsaturated ester 45. The alkene of 45 was reduced with 
H2 and 5% Pd/C (78%), then the ester 55 was reduced with LiAIH4 to provide the 
propyl alcohol 56 (95%). Swern oxidation of 56 gave the aldehyde 89 and 
subsequent Wittig olefination with ethyltriphenylphosphonium bromide gave the 
butylene 90 in 74% yield over 2 steps. The butyl alcohol 91 was prepared by 
hydroboration of 90 with 9-BBN followed by oxidation gave 91 in a 73% yield. At 
this stage we found that careful purification of the dibenzyl alcohol away from any 
1,5-cyclooctanediol (see inset) that is generated after quenching of the borane 
reagent was necessary. If 91 is not carefully purified by chromatography, the 
following methylation reaction results in a much lower yield (6-10%). We found 
that monitoring the column chromatography of the alcohol product by TLC and 
staining with vanillin aided in determining the presence of the 1,5- 
cyclooctanediol.
After purification, the alcohol 90 was methylated with iodomethane (DMF, 
NaH, 61%). The benzyl groups were cleaved catalytically with H2 and 5% Pd/C 
to give the desired piperazine hydrochloride 93 in 98% yield. The least hindered 
amine of the piperazine was protected as the N-trityl and the protected 
piperazine 94 (94%).
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Scheme 2-32: Overall synthesis of BuM-NQP 96.
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The trityl piperazine was coupled to 2-chloroquinoline according to the 
method of Gilman. Deprotection gave 95 in a 63% yield (2 steps). Selective 
nitration at the 6 -position of the quinoline ring gave the desired methoxybutyl 
quipazine 96 in 8 8 % yield. The BUM-NQP target ligand was prepared from the 
dibenzyl ester 32 in 14 steps in an overall 7.7% yield.
The Boc protected alcohol N-Boc-BuOH-NQP 97 was prepared from BuM- 
NQP 96 by treatment with BBr3, treatment of the crude workup mixture with di- 
ferf-butyl-dicarbonate gave 97 in a 44% overall 2 step yield (Scheme 2-33). The 
N-Boc-BuOH-NQP intermediate is ready for tosylation and subsequent 
fluorination when needed.
Scheme 2-33: Synthesis of N-Boc-BuOH-NQP 97.
2.14 Summary and Conclusion.
The syntheses of new 2-(2-alkyl-piperazin-1-yl)-6-nitroquinolines have 
been described, including PROM-NQP (±)-51, PROF-NQP 58, Pent-NQP (±)-83, 
PentF-NQP 88, and BuM-NQP 96. The syntheses of these analogs has 
furthered our SERT SAR study by expanding upon the lead compound 6 -NQP 
22. We are interested how the 2-alkyl-piperazine substitutions affect SERT 
binding affinity, particularly to probe the Ar2 binding domain described by the 
pharmacophore model. The in vitro competitive binding studies of a select group
NH 2) [(CH3)3C0C0]20, CH2CI2, 0 °C
Boc
96
44%, 2 steps
97
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of the ligands prepared here is described in Chapter 4. Furthermore, the PROM- 
NQP (±)-51 ligand was useful in the preparation of two radiofluorination precursor 
N-formyl-ProTos-NQP 63 and N-Boc-ProTos-NQP 69. The synthesis of the 
precursors 63 and 69, along with the initial nonradioactive and radioactive 
fluorinations were used as foundational synthetic sequences and 
radiofluorination experiments for the analogous radioligand MePROF-NQP 148.74 
The initial radiofluorination results with the N-formyl-ProTos-NQP 63 suggests 
that [18F]PROF-NQP 58 is a plausible PET radioligand. The radiosynthesis using 
63 should be revisited now that we have more knowledge from the N-Boc- 
ProTos-NQP 69 radiolabeling trials. There is more work to be accomplished in 
understanding the major side product formation from the N-Boc-ProTos-NQP 69 
radiolabelling trials. It would be very intriguing to determine if fluoride substitution 
of the aromatic nitro group is really occurring. If indeed there is aromatic fluoride 
substitution occurring, perhaps a second generation of our compounds could be 
prepared that possesses a dual fluorine-18 label.
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Chapter 3
Synthesis of Asymmetric Targets
3.1 Chiral Nitroquipazine Ligand Studies.
Described in this chapter are the chiral syntheses of 6 -NQP SERT 
analogs previously prepared in racemic form, including, MOM-NQP (±)-31, 
PROM-NQP (±)-51 and Pent-NQP (±)-83. The chiral syntheses utilize the amino 
acids glycine, serine and glutamate to form the piperazine ring structures. The 
use of the optically pure forms of serine and glutamate eliminates the need for 
later separation of a racemic mixture by HPLC or diastereomeric salt formation. 
Chiral pharmaceuticals are commonplace in the drug industry. A number of 
commonly used drugs are sold as the racemic mixture, including ibuprofen 
(Advil), citalopram HBr (±)-7 (Celexa), cetirizine HCI 99 (Zyrtec), methylphenidate 
100 (Ritalin), and fluoxetine HCI 10 (Prozac) (Figure 3-1). The application of 
chiral drug development as well as “chiral switches” 87 (the development of chiral 
drugs from their racemic mixture) has become a major focus to industry as more 
studies show the importance of stereoisomer distinction within many 
pharmacological therapies.88,89 Of the racemates mentioned above (98, (±)-7, 
99, 100) all except fluoxetine 10 are currently licensed to be sold as their more 
potent or preferred enantiomeric form under new brand names. The benefits of 
producing enantiomerically pure forms of a racemic drug include diminished side 
affects, reduction in dose, among other features. For example, the active form of
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ibuprofen, (S)-ibuprofen has a markedly faster onset of action than the racemic 
form and is currently licensed in Austria and Switzerland.
CHg
h3c  ^ f = 0
c h 3  ho
Ibuprofen, 98
CH
(±)-Citalopram, 7
O HN
F,C
Cl
Cetirizine, 99
Methylphenidate, 100 Fluoxetine, 10
Figure 3-1: Example commercial drugs sold as a racemic mixture.
One of the most historically noteworthy examples on the differences 
between enantiomeric drug forms is that of thalidomide. In the early 1960’s the 
racemic form of thalidomide was given to pregnant mothers during their first 
trimester of pregnancy as a sedative. Sadly, it was later determined that 
thalidomide resulted in the birth of ‘thalidomide babies’ that were characterized 
by incomplete or missing arms and legs. The discovery of thalidomide birth 
defects lead to the removal of the drug from use. It was later proposed that the 
teratogenic properties of thalidomide were attributed only to the (R)-(+)~ 
thalidomide enantiomer 101 (Figure 3-2).
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(R)-(+)-Thalidomide, 101 
Figure 3-2: Sedative (R)-(+)-Thalidomide 101 found to cause birth defects.
The work with the chiral forms of fluoxetine 10 and citalopram 7 are 
especially interesting for our research. The difference in binding potency to the 
SERT target for their enantiomers suggests that the synthesis of chiral analogs of 
our 2 -(2 -alkyl-piperazin-1 -yl)-6 -nitroquinolines may result in more potent and 
selective agents. Each enantiomer of fluoxetine 10 have progressed through 
phase II clinical development for their separate pharmacological actions; (R)- 
fluoxetine 1 0  for its antidepressant qualities and associated fast tissue washout 
and (S)-fluoxetine 10 for the prevention of migraines. Particularly interesting is 
the enantiomer (S)-citalopram 7 (escitalopram) that is -150 times more potent 
than the enantiomer (R)-citalopram 7 for rat SERT (rSERT) 90 and -30 times 
more potent for human SERT (hSERT) .90,91
3.2 Chiral Piperazine Syntheses.
As in many pharmacologically active agents, including the 2-(2-alkyl- 
piperazin-1 -yl)-6 -nitroquinolines we have prepared, the racemic qualities of the 
ligand is due to alkyl-substitutions of the piperazine ring. The piperazine ring 
system is an integral part of a number of biologically active ligands, that include: 
c-receptor agents,92 K-opiod receptor antagonists,93 farnesyltransferase 
inhibitor,94 and an H1-receptor antagonist.95 Considering the selectivity of
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receptors for specific piperazine ring ligand enantiomers, the synthesis of 
enantiomerically pure piperazine ring structures is important.
A brief review of the literature found multiple articles focusing on the 
preparation of chiral piperazine rings for a number of pharmacological ligands. 
The literature includes diastereomeric salt formation,96,97 the use of chiral building 
blocks i.e. amino acids, 92_94’98 diastereoselective hydrogenation,99 and kinetic 
resolutions with bacterial cells and enzymes.100,101 Of particular interest to our 
group was the preparation of chiral piperazines utilizing amino acids as the chiral 
building blocks (Figure 3-3) .93,94,98
h3co
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H V -0 H
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Figure 3-3: Potential chiral piperazine syntheses utilizing amino acid building blocks.
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3.3 Synthesis of Chiral MOM-NQP 31.
The rSERT binding potency ( K j )  of the racemic forms of Me-NQP (±)-30, 
MOM-NQP (±)-31, and PROM-NQP (±)-51, and also the evidence of preferred 
transporter binding site selectivity for enantiomerically pure ligands (escitalopram 
(S)-10) led us to investigate the synthesis and biological potencies of the related 
enantiomers for our ligand series. The synthesis of (R)-30 and (S)-30 were 
accomplished utilizing the commercially available (R )- and (S)-2- 
methylpiperazine hydrochloride salts (Sigma Aldrich), according to procedures 
used in the Gerdes laboratory (Scheme 1-3) .72 Attempts at preparing the (R )- 
and (S)-2-methoxymethyl-piperazine diastereomeric salts using D- and L-tartaric 
acid according to the procedure of Kawachi et al. failed.96 Following their 
procedure our efforts to generate the diastereomeric salts resulted in the 
formation of oils. The diastereomeric salt formation method of producing analogs 
of (R)- and (S)-2-methoxymethyl-piperazine was abandoned. However, we 
opted to utilize the method of Naylor et al. (Scheme 3-3) to synthesize the 
piperazine ring structure using amino acids as chiral building blocks. The 
synthesis of chiral MOM-NQP 31 outlined in Scheme 3-3 is adapted from a 
synthesis of 2-hydroxymethyl-4-benzylpiperazine (S)-113 according the 
procedure developed by Naylor et al. as described below.93
3.3.1 Synthesis of N-Boc-N-Bn-glycine.
To begin the synthesis of chiral MOM-NQP, we needed to prepare the 
starting material N-Boc-N-Bn-glycine 111 from glycine 109 (Scheme 3-1 ) .102,103
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H2 N ^ C 0 2H -------------------► ''N C02H  ► "N X 0 2H
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MeOH, HCI
109 110 111
Scheme 3-1: Synthesis of N-Boc-N-Benzyl-glycine 111.
A warm solution of glycine 109 in 1:1 EtOH/hkO is treated with potassium 
hydroxide (KOH) and benzyl-bromide (BnBr), then heated to reflux for 2 hours. 
The crude solution is concentrated by 20%, then the reduced solution is boiled 
while acetic acid (AcOH) is added, to give the free acid of dibenzyl-glycine (not 
shown) as a white precipitate (79% ) . 102 Dibenzyl-glycine is converted to mono- 
benzyl-glycine 110 by catalytic hydrogenolysis with a Parr hydrogenator (5% 
Pd/C in methanol (MeOH) and 12 M HCI) at an initial pressure of 50 psi.102 The 
catalyst is removed by filtration and the reaction mixture is concentrated giving 
the mono-benzyl-glycine HCI 110 in a 98% yield. Product 110 was converted to 
N-Boc-N-Bn-glycine 111 by treatment with B0 C2O as a basic solution in 1:1 
H2O/1 ,4-dioxane gave 111 in a 6 6 % yield according to the method of Bail et al.103
3.3.2 Synthesis of 1-Benzyl-3-(hydroxymethyl)piperazine 113.
The preparation of the chiral piperazine (S)-113 from D-serine 
hydrochloride is shown in Scheme 3-2; the (#?)-113 enantiomer is prepared in a 
similar procedure from L-serine hydrochloride.93 The methyl ester of D-serine D- 
102 is coupled to the pentafluorophenol activated ester of N-Boc-N-Bn-glycine 
111 (EDC hydrochloride and pentafluorophenol (PFP) ) .93 The dipeptide is easily
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purified by column chromatography eluting with 3:2 EtOAc/hexanes, to give (R )- 
N-Boc-N-Benzyl-glycyl-D-serine methyl ester (/?)-112 in a 96% yield. The Boc 
group of the dipeptide is removed by treatment with SOCb in MeOH and 
concentration in vacuo, and then triturated with Et2 0  to give the corresponding 
HCI salt (not shown). The N-Boc deprotected dipeptide is dissolved in MeOH 
and treated with NH4OH, aqueous workup and extraction with 4:1 IPOH/CHCI3 
gives the cyclized piperazinedione (/?)-103. Reduction of (#?)-103 with LiAIH4 in 
refluxing THF affords the desired 2-hydroxymethyl-4-benzylpiperazine (S)-103 
(note the stereochemistry switch from R to S after reduction). We considered 
(S)-2-hydroxymethyl-4-benzylpiperazine to be a chiral structural equivalent to the 
racemic 1,4-dibenzyl-2-hydroxymethyl-piperazine 33, requiring only protection of 
the 2° nitrogen and the alcohol group for Gilman coupling to 2-chloroquinoline 
according to the racemic syntheses (Scheme 1-2 and Scheme 2-13).
CO2M6 EDC —  
N-Boc SOCI2, MeOH;
D-102
O
Et3 N, CH2 CI2  Bn O H
(R)-112
NH4OH, MeOH
reflux
(R)-103 (S)-113 33
Scheme 3-2: Synthesis of the key synthetic intermediate (S)-113.
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3.3.3 Synthesis of Chiral MOM-NQP 31.
After completion of the synthesis of chiral 2-hydroxymethyl-4- 
benzylpiperazine (R)-113 and (S)-113, we extended the methodology of the 
racemic synthesis of (±)-31 to the chiral synthesis of (/?)-31 and (S)-31 (Scheme 
3-3).74 The N-formylation of the free amine (S)-113, using acetic anhydride in 
formic acid, gave the N-formyl-monobenzyl-HOM (S)-114. Treatment of (S)-114 
with NaH (300 mol%) in DMF gave the alcoxide, which was subsequently 
methylated with methyl iodide ( C H 3 I )  gave (S)-115. The N-formyl group was 
deprotected with 4 M H2SO4 at 60 °C. The resulting piperazine (S)-116 was 
coupled to 2-chloroquinoline according to the standard Gilman procedure, to give 
the N-benzyl-MOM-QP (S)-117. Deprotection of the benzyl group was preformed 
by heating (S)-117 with 1-chloroethyl chloroformate (ACE-CI) in 1,2- 
dichloroethane at 80 °C, with cleavage of the intermediate carbamate (structure 
not shown) by heating in methanol, thereby affording the debenzylated product 
MOM-QP (S)-31. Nitration of (S)-31 at the 6-position of the quinoline ring gave 
the desired product (S)-31 typically with a 40% yield overall in seven steps. 
Repeating the synthesis using L-serine gives the alternate enantiomer (R)-MOM- 
NQP (/?)-31 also in 40% overall yield.74
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Scheme 3-3: Overall synthesis of chiral MOM-NQP (S)-31.
3.4 Application of the Chiral Synthesis, Chiral PROM-NQP 51.
With the success of the chiral MOM-NQP synthesis we turned our focus to 
using the technology developed for the production of (R)- and (S)-PROM-NQP 
((/?)-51 and (S)-51, respectively. Naylor et al. were successful in using a Swern 
oxidation of 118 to generate the corresponding aldehyde (not shown).93 To 
minimize racemization during the oxidation, N-methylmorpholine was used by 
Naylor, instead of employing EtsN amine as a base. After oxidation, Naylor was 
successful in using the aldehyde in a reductive amination with pyrrolidine to give 
119. According to Naylor et al. they were able to accomplish the oxidation and 
reductive amination with minimal racemization giving the desired compound 119 
in a >99% ee (HPLC).93
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Scheme 3-4: Potential oxidation of the methyl alcohol according Naylor et al.93
We examined the possibility of using the Naylor method to oxidize a N- 
protected version of (S)-113 followed by a Horner-Emmons olefination according 
to the racemic PROM-NQP (±)-51 synthesis (Scheme 2-13). However, we 
thought that it would be more beneficial to investigate the use of other amino 
acids with the appropriate piperazine side chain all ready in place as the amino 
acids side chain (R) group. We were particularly interested in the methyl esters 
of D- and L-glutamate 120, as well as the D- and L- forms of 5-hydroxynorvaline 
121 (an equivalent to serine for the three carbon case) for the synthesis of (#?)-51 
and (S)-51.
Figure 3-4: Potential amino acid starting materials for the chiral PROM-NQP 51 synthesis.
If 5-hydroxynorvaline 121 could be readily prepared in our lab, we could 
utilize all the procedures developed with the earlier chiral MOM-NQP (±)-31
o o o
5-hydroxynorvaline, 121glutamate, 1 2 0
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synthesis. Scheme 3-5 shows the retrosynthetic strategy for the synthesis of the 
propyl (f?)-126 equivalent to the methyl hydroxy (R)-103.
o
HÔ
NH'2
*  N ' ^ Y lNl̂ X ^ 0 H = >  h o ^ ^ o h
'Bn Bn O H
O
(R)-126 (R)-123 (R)-121
O
Scheme 3-5: Retrosynthetic analysis for the formation of (R)-126.
A search of the literature found that 121 could be synthesized from D- or 
L-glutamic acid 120 by selective protection of the a-carboxylate as the 
boroxazolidone and reduction of the terminal carboxylate, according to Scheme 
3-6. The a-carboxylic acid of glutamic acid 120 is protected as the 
boroxazolidone according to the procedures of Nefkens and Gong.104,105 The 5- 
carboxylate was selectively reduced with borohydride-THF complex (BH3-THF) to 
give the alcohol and the boroxazolidone was cleaved by refluxing in 1.5M HCI, 
purified by ion exchange to give 5-hydroxynorvaline (/?)-121 according to the 
procedure of Garcia.106
l_l H Et,
-  o-Et
0  0  THF' A O O 1.5MHOI.A a
OH
D-120 (R)-122 (R)-121
Scheme 3-6: Synthesis of 5-hydroxynorvaline from glutamic acid.
Attempts to generate the methyl ester of 5-hydroxynorvaline (/?)-121 
resulted in the formation of the cyclized lactone (/?)-124 according to Scheme
3-7. The lactone (/?)-124 was posed as a possible substrate for the peptide 
coupling to give compound (R)-126, where the lactone of dipeptide (f?)-125
84
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HN
HO.
(R)-126
would act as the methyl ester of (/?)-112 for the cyclization to the piperazine ring 
in the chiral MOM-NQP synthesis (Scheme 3-2).
© ft EDC HCI, PFP O
H3 N v J ^ q  N-Boc-N-Bn-glycine BrK .  N _________
9 C l O  Et3 N,CH2 CI2  nv^ ^ V " ' B n
(R)-124 (R)-125
l Sr°V J  Bn ^
(R)-127 (R)-128
Scheme 3-7: Potential synthesis of the piperazinedione ring utilizing the iactone (R)-126.
As shown in Scheme 3-8 the lactone form of 5-hydroxynorvaline (S)-130 
has been prepared and similarly used in a dipeptide coupling with N-Boc 
protected amino acids, including alanine, glycine among others to give the 
peptide (S)-131 after deprotection of the N-Boc group.94,107 While only the (S)- 
enantiomer of the lactone (prepared from L-glutamic acid) was used in the 
preparation of the dipeptide, the (R)-lactone can be afforded using the same 
procedure.105 The missing experiment in our research would be to attempt a 
cyclization to the piperazine (/?)-126 as solution in MeOH and NH4OH according 
to Scheme 3-8. However, due to the expense and labor intensive process of 
preparing large quantities (>10 g) of 5-hydroxynorvaline 121 and its associated 
lactone 124, we decided on using a more economical route.
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EDC, HOBt HCI
129 (S)-130 (S)-131
Scheme 3-8: Example peptide coupling using a cyclic lactone derived from 5-hydroxynorvaline 
121.
As shown in Scheme 3-9, the dimethyl ester of D-glutamic acid D-132 
easily couples with N-Boc-N-Bn-glycine 111, according to the chiral MOM-NQP 
31 synthesis (Scheme 3-2), to give the dipeptide (/?)-133 in an 87% yield. 
Dipeptide (/?)-133 was deprotected (SOCI2, MeOH) and cyclized to give 
compound (/?)-134 in an 84% yield. The cyclization required stirring overnight at 
room temperature to achieve complete conversion. This is in contrast to the 
MOM-NQP synthesis where 2-3 hours were required to complete the cyclization, 
suggesting the kinetic differences for the reactions is a function of side chain 
length or substitution, i.e. alcohol vs. ester. The cyclized piperazinedione (/?)- 
134 was reduced with LiAIH4 and the crude material was treated with acetic 
anhydride in formic acid to give the N-formyl-piperazine (/?)-136 in a 63% yield 
over 2 steps. The N-formyl-piperazine (/?)-136 was treated with NaH (300 mol%) 
as a solution in DMF to generate the alkoxide that was quenched by the addition 
of CH3I to give compound (ff)-137 in a 59% yield. Deprotection of the N-formyl 
protecting group of (/?)-137 was afforded by treatment with 4 M H2S 0 4 as a 
solution in THF to give (/?)-138.
Importantly, the mono-benzyl propyl ester (ft)-138 was not coupled to 2- 
chloroquinoline as in the chiral MOM-NQP 31 synthesis (Scheme 3-3), due to 
difficulties at that time to get consistent benzyl group deprotection results.74
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Instead, we opted to remove the benzyl group of (/?)-138 by catalytic 
hydrogenolysis conditions at atmospheric pressure, to give PROM-piperazine 
dihydrochloride (/?)-48 in a 93% yield. The least hindered nitrogen was protected 
with trityl-chloride (97%) and the resulting protected piperazine (/?)-49 was 
coupled to 2-chloroquinoline by the standard Gilman conditions and according to 
the earlier racemic PROM-NQP (±)-51 synthesis (Scheme 2-13). The coupled 
product was purified accordingly and deprotected to give PROM-NQP (/?)-50 in a 
75% yield. Nitration at the 6-postion gave the desired chiral agent (R)-PROM- 
NQP (R)-51 in a quantitative yield. The R- and S-enantiomers of PROM-NQP 
were prepared from D- and L-glutamic acid dimethyl esters, respectively in 11 
steps in a 17% and 23% overall yield, respectively.
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Cl,©  ffi
H3CO
EDC HCI, PFP H r n  u *
OCHa N-Boc-N-Bn-glycine B o c ^ / \ ^ , N  ' 2 SOCI2, MeOH;
0 O
D-132
HN
Bn
Et3 N, CH2 CI2  
87%
LiAIH4, THF
Bn O H C02Me NH4 OH, MeOH 
84%
reflux
(R)-133
Ac2 0, „  _ „2  ̂ H N
'Bn formic acid H O v . - N -
H63%, 2 steps
O
NaH, CH3 I, A .
3r H N ^  ______
DMF A  THF
H3C Bnrl
(R)-135
4M H2 S0 4
HaC'
59% 93%
(R)-137
C(Ph)3 CI, Et3N
(R)-138
(R)-48
CH2 CI2, 0 °C h 3 C' 
97%
CPh
(/?)-49
(R)-136
H2, 5% Pd/C 
'Bn MeOH, 12M HCI 
93%
1) n-BuLi, 2-chloroquinoline 
Et2 0, 0 °C
13 2) 6 M HCI, acetone
75%, 2 steps
HN03 ,H2 S0 4
h3c
N N
quantitative
(R)-50
0 2N
NH
(R)-51
Scheme 3-9: Overall synthesis of (R)-PROM-NQP 51, the (S)-enantiomer is afforded according 
to the same synthetic sequence starting from L-132.
3.5 Alternate Synthesis of Chiral PROM-NQP.
The alternate synthesis of (R)-51 and (S)-51 utilized the nitrogen 
protecting group Boc for the protection the 2° amine of (/?)-135. To accomplish 
this, the ester and the amides of (/?)-134 were reduced with LiAIH4 in refluxing 
THF. Attempts to selectively protect the nitrogen of the piperazine with a Boc 
group were moderate at best (25-40% yield). For example, treatment of (/?)-135 
with 98 mol% of di-ferf-butyi dicarbonate (Boc20 ) according to Scheme 3-10
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gave the N-Boc-N-Bn-propylpiperazine (R)-140 in a 40% yield. Unfortunately, 
the Boc protection of the free amine was not selective and the crude reaction 
workup gave a mixture with of the unprotected starting material (#?)-135, the 
desired product (R)-140, and the diprotected species (/?)-139. These results 
were not surprising, considering the problems associated with Boc protection of 
the racemic form of HOP-NQP 146 (Scheme 2-20).
(k )-135
Boc2 0, NaOH(aq)
THF, 0 0  - RT °C Boc'
(R)-135
Rl-139
(R)-140
10%
40%
Scheme 3-10: Protection of the 2° amine with Boc20 .
Attempts to selectively deprotect the side chain carbonate according to 
the racemic synthesis of 66 failed ( K 2 C O 3 , MeOH, Scheme 2-21).
BoCv.
Boc
(R)-139
K2 C03, MeOH Boc
R)-140
50 °C
Scheme 3-11: Attempted deprotection of the Boc carbonate (R)-139.
Despite the selectivity problems with Boc protection the chiral synthesis 
was completed as proof of concept as shown in Scheme 3-12. The Boc
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protected piperazine (R)-140 was methylated (DMF, NaH and CH3I) according to 
the N-formyl series to give (/?)-141 in a 68% yield. The Boc group was 
deprotected (4 M H2SO4, THF) (87%) and the resulting monobenzyl piperazine 
(/?)-138 was coupled to 2-chloroquinoline by the standard Gilman method to give 
(R)-142 in a 55% yield. The coupled product (R)-142 was nitrated (H2S0 4 , 
HNO3, 0 °C) at the 6-position of the quinoline ring and the 2 and 4 positions of 
the benzyl group (R)-143 giving a mixture of regioisomers of the phenyl ring in a 
92% yield. Cleavage of the nitro-benzyl groups with 1-Chloroethyl chloroformate 
(ACE-CI) gave the desired enantiomers of 51, (R)-51 and (S)-51 in 49% and 62% 
yields, respectively. Scheme 3-12 details the overall synthesis of (R)-51and (S)- 
51 from (R)-135 in 6 steps and an overall yield of 6% yield for (R)-51 and 11% 
yield for (S)-51.
R)-135
B0 C2 O, NaOH(aq) 
N' Bn THF, 0 ° - R T ° C  H0
40%
Boc
(ft)-140
NaH, CH3 I,
N'Bn DMF h 3 C" 0  
68%
Boc
/?)-141
4M H2 S0 4
87%
n-BuLi, 2-chloroquinolineHN
"Bn
Bn
55%
0,N
Ace-CI, DCE 
0 - 80 °C;
HNO3 , H2 S0 4
0°C NHMeOH, 80 °C
92% (R)-5149%
Scheme 3-12: Alternate synthesis of (/?)-51 utilizing the N-Boc protected piperazine (/?)-140.
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3.6 Synthesis of Chiral Pent-NQP 83.
To further explore the application of the chiral synthetic approach, the 
synthesis of (R )- and (S)-Pent-MOM 83 were explored. Initially, we looked into 
using an unnatural amino acid with a carbon chain of the appropriate length that 
could be used in the peptide coupling and cyclization procedures. A survey of 
the literature and chemical supplier catalogs found (±)-2-aminoheptanedioic acid 
(Figure 3-5). However, 144 Is only available as the racemate, and a chiral 
synthesis for the enantiomeric forms 144 was not available.
o o
2-aminoheptanedioic acid, 144
Figure 3-5: Potential amino acid building block for the synthesis of chiral Pent-NQP 83.
Our second option was to use an intermediate of the chiral propyl 
synthesis and perform the carbon extension via Swern oxidation and Horner- 
Emmons olefination (/?)-135. In order to accomplish the carbon extension, the 
free amine of (R)-135 needed to be protected with a protecting group stable to 
the Swern and Horner-Emmons conditions. An examination of protecting groups 
used routinely in our lab and comparison of their respective stabilities to the 
reagents utilized in Swern and Horner-Emmons was performed.108 The ease of 
the protecting group deprotection procedures was also taken into 
consideration.108
Considering the questionable success of protecting the chiral piperazine 
(f?)-135 as the N-Boc (A?)-140 we decided a benzyl group protection of the 
piperazinedione (/?)-134 (Scheme 3-13) would be the preferred route. The N-
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benzyl protecting group was also preferred, considering that after reduction of the 
amides and the ester of (/?)-145 we would be afforded a chiral piperazine 
matching the synthesis of the racemic propyl and pentyl series (compound 33,
Scheme 2-13 and Scheme 2-30). Thus, we would now be able to apply all the
technologies developed in those series for the preparation of chiral Pent-NQP 83. 
Initial trials of the benzylation reaction using NaH and benzyl bromide in DMF 
resulted in only moderate yields (54-70%) of product (/?)-145. Supplementing 
the reaction with a catalytic amount (40 mol%) of tetrabutylammonium Iodide 
(TBAI) improved the yields (89-93%), by changing the leaving group from a 
bromide to an iodide.109
o o
h n A ] Bn-Br,Bu4NI B n ^ A ^
Me0 2 C ^ / x ^ A ^ N U Bn NaH, DMF, 0°C Me0 2C\ / \ < ^ | - N' Bn
O O
(R)-134 89% (R)-145
Scheme 3-13: Protection of (R)-134 with benzyl bromide (BnBr)
As shown in Scheme 3-14, piperazinedione (/?)-145 was reduced with
U A I H 4  in refluxing THF to give the dibenzyl propyl alcohol (/?)-56 (92%). Swern
oxidation and Horner-Emmons olefination with triethylphosphonoacetate gave
the unsaturated pentyl ester (/?)-146 (60%, 2 steps). Subsequent saturation was
accomplished by catalytic hydrogenation using 5% Pd/C in MeOH and acetic
acid (AcOH) (60%). The saturated ester (R)-77 was reduced with LiAIH4 in Et20
(99%) and the resultant alcohol (/?)-78 was methylated as the alkoxide (NaH) in
DMF with C H 3 I to afford (/?)-79 (56%). Hydrogenolysis of the benzyl groups gave
the Pent-MOM piperazine dihydrochloride (/?)-80 in a 83% yield, which was
92
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protected using trityl-chloride (99%). The N-trityl-pentyl-piperazine (/?)-81 was 
coupled to 2-chloroquinoline according to the Gilman method, deprotected with 6 
M HCI in acetone to give (R)-82 (53%, 2 steps). Nitration at the 6-position of the 
quinoline ring gave Pent-NQP (/?)-83 in a quantitative yield. The synthesis of 
(/?)-83 and (f?)-83 were accomplished in 8% and 5% yield, respectively, in 11 
steps.
B r uUAIH4 , THF
(/?).145-------— _  H0
reflux
92%
n-BuLi 
(Et0)2 P(0)CH2 C02Et
THF, 0 °C 
60%, 2  steps
UAIH4 , Et20 
99%
(R)-146
DMSO, (COCI)2, 
Bn Et3 N, CH2 CI2, -78 °C
H2, 5% Pd/C
B r u
'Bn
(R)-89
Bn^
Bn MeOH, AcOH 
60%
NaH, CH3 I,
(R)-78
DMF H3 C' 
56%
(R)-79
H2, 5% Pd/C 
MeOH, 12 M HCI H3 C' 
83%
, 2  HCI C(Ph)3 CI, Et3N
-NH --------------------- ►
CH2 CI2, 0 °C h 3 C
(R)-80 99% (R)-81
1) fi-BuLi, 2-chloroquinoline 
Et2 0, 0 °C
2) 6  M HCI, acetone
h3o
53%, 2 steps
N N
(R)-82
h n o 3, h 2 s o 4
NH 0°C 
quantitative
N N
Scheme 3-14: Overall synthesis of (/?)-Pent-NQP 83, the (S)-enantiomer was similarly prepared 
from (S)-145.
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3.7 Synthesis of Chiral BuM-NQP 96.
Preliminary accomplishments for the synthesis of the chiral butyl variant 
(/?)-91 have been realized, as shown in Scheme 3-15. However, at the time of 
this writing this (R )- and (S)-BuM-NQP 96 have not been prepared. The 
intermediate chiral dibenzyl-HOP (R)-56 was prepared as described above in the 
chiral pentyl synthesis from the cyclized piperazinedione (f?)-145 (Scheme 3-13). 
Swern oxidation of alcohol (/?)-56 to the aldehyde (R)-89 was followed by Wittig 
olefination with methyltriphenylphosponium and n-BuLi gave the terminal alkene 
(/?)-90 in a 49% yield over two steps. Hydroboration of (/?)-90 with 9-BBN 
followed by oxidation gave the desired butyl alcohol (R)-91 (94%). For this 
reaction careful purification was required to remove the side product 1,5- 
cyclooctanediol by column chromatography, before the subsequent methylation 
reaction. Attempts to methylate the alcohol (/?)-91 after aqueous acid-base 
workup gave low yields (<10%) of the desired product (/?)-92.
Scheme 3-15: Initial synthesis of the BuM-NQP precursor (/?)-92, by Wittig olefination 
technology.
Completion of the synthesis of (R)- and (S)-BuM-NQP 96, can be afforded 
during the future by repeating the reaction sequence for the preparation of the 
(±)-BuM-NQP 96 as outlined in Chapter 2. Briefly as per Scheme 3-16, the
HO
Bn Et3 N, CH2 CI2, -78 °C
DMSO, (COCI)2,
m-m
n-BuLi, [(Ph)3 P+CH3]|-
THF, 0 °C BnH
(R)-56 49% (R)-90
H
9-BBN THF, 50 °C;
H2 0 2, NaOH, 0 °C HO
94% (R)-91 (R)-92
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alcohol (/?)-91 would be methylated and the benzyl groups cleaved. The less 
hindered nitrogen of the piperazine can be protected as the N-trityl group. The 
N-trityl piperazine (/?)-94 would be coupled to 2-chloroquinoline, then 
deprotected and nitrated to give the desired (R)- and (S)-BuM-NQP 96.
NaH, CH3I
(R)-91
C(Ph)3CI, Et3N 
CH2CI2, 0 °C
H3Cv
h n o3, h2s o 4
o°c
H2, 5% Pd/C
w  H3C__
Bn MeOH, 12 M HCI 0
1) n-BuLi, 2-chlororquinoline 
HN' ^  Et20, 0°C
' CPh3 2) 6 M HCI, acetone
• 2  HCI H N ^
(R)-94
NH
(/?)-1
N N
Scheme 3-16: Proposed synthesis of chiral BuM-NQP 96 from the synthetic intermediate (/?)-92.
3.8 Summary and Conclusions.
Typically, the synthesis of the chiral forms of a SERT agent results in an 
enantiomer with higher SERT affinity compared to the opposing enantiomer. For, 
example the synthesis of (R ) and (S)-citalopram 7 resulted in discovering a more 
potent SSRI in (S)-7. This chapter summarizes our efforts to prepare the 
enantiomeric forms of PROM-NQP (±)-31, Pent-NQP (±)-83 and the initial 
synthesis of BuM-NQP 96. Further work is required to accomplish the 
enantiomers of 96. Chapter 4 discusses the pharmacology of the enantiomers of 
Me-NQP (±)-30 and MOM-NQP (±)-31, as it has been our goal to further the SAR
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of the 6-NQP 22 analogs according to their respective SERT binding affinities. 
The synthesis of the longer chain derivatives of the 2-(2-alkyl-piperazin-1-yl)-6- 
nitroquinolines furthers our understanding of the affects of chain length and 
chirality of the 6-NQP analogs and their selectivity for SERT binding. The 
synthesis of the radiolabeling precursors and the cold fluorinated analogs 58 and 
88 should be accomplished to benefit the SAR studies allowing direct 
comparison of binding affinities of the enantiomeric forms of the ligands to the 
racemic forms.
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Chapter 4
Pharmacology
4.1 Introduction.
The pharmacological evaluation of the prepared 2-(2-alkyl-piperazin-1-yl)- 
6-nitroquinoline analogs for their respective competitive binding affinities at the 
serotonin reuptake transporter (SERT) is outlined in Table 4-1 and Table 4-2. 
Our focus was to develop a more detailed understanding of the structure-activity 
relationship (SAR) of the 2-(2-alkyl-piperazin-1-yl)-6-nitroquinoline analogs that 
would afford the most favored SERT ligand binding. By doing so we would be 
able to describe the pharmacological profile of the proposed PET imaging agents 
58 and 148.
The alkyl side chain groups of the 2-(2-alkyl-piperazin-1-yl)-6- 
nitroquinoline ligands are designed to probe the area of the binding domain (Ar2) 
that is shared by the alkyl side chain of the antidepressant fluvoxamine (Figure 
1-3). We have also proposed that this binding area is also shared by an aromatic 
ring of other serotonin selective reuptake inhibitors (SSRIs) that contain two 
aromatic moieties. It is thought that one of the two aromatic moieties is critical 
for SERT binding (Chapter 1 ).67
Our research group utilizes a published in vitro competitive ligand binding 
assay for the determination of the inhibition constant ( K i )  as a comparative 
analog SAR measurment.67,110 Described below is the competitive inhibition 
pharmacology measures, a summary of the SAR of the 2-(2-alkyl-piperazin-1-yl)-
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6-nitroquinoline ligands based upon their respective Ki values. Additionally the 
synthesis of [3H]n-PROP-NQP 52 is provided, as well as the kinetic binding 
profile of [3H]52. Kinetic analysis of [3H]/i -PROP-NQP 52 will allow us to gain a 
better understanding of the rate constants kon (association) and koff (dissociation) 
and also kinetic and the related equilibrium dissociation constants (Kd).
4.2 Competitive Inhibition, SERT Pharmacology [3H]paroxetine.
The in vitro inhibition binding constants (K) of the ligands outlined in Table
4-1 and Table 4-2 were determined using an established radioligand competition 
binding assay (rat cortical SERT (rSERT), [3H]Paroxetine 9 )67110 which is a 
modified method of Habert.111 The measured K  data (mean ± s.e.m., n = 3 or 
more runs) is summarized in Table 4-1 and Table 4-2, where a lower Kj value is 
indicative of higher SERT ligand binding affinity.
The in vitro assays were performed with aliquots of partially purified male 
rat cortex membrane tissue (Pel-Freeze Biologicals, Inc.). The cerebral cortex 
was dissected from adult rat brains. The cortex was homogenized using a 
Polytron tissue homogenizer in Tris-HCI buffer. Centrifugation of the crude 
homogenate isolated the desired membrane fraction. The pellet material was 
suspended in assay buffer (50 mM Tris-HCI, pH 7.4, 120 mM NaCI, and 5 mM 
KCI). The suspensions were incubated with 0.25 nM [3H]Paroxetine (DuPont- 
NEN, specific activity of -19.5 Ci/mmol) and decreasing concentrations (10"6 M to 
10"11 M) of the inhibitors. After 3 hours, the incubations were terminated by 
dilution with ice-cold buffer and then filtered using S & S glass filter papers
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(Schleicher and Schuell #32 glass fiber filter paper) under vacuum (Brandel cell 
harvester). To minimize nonspecific binding of the radioligand, the filter papers 
were presoaked in a 0.05% v/v solution of polyethyleneimine. The filter papers 
were washed rapidly with cold Tris-HCI buffer and transferred to scintillation vials. 
To the vials was added 10 ml_ of Ecolume scintillation fluid (ICN, Irvine, CA), the 
vials were shaken 24 hours and the radioactivity was counted with a Packard 
scintillation counter.
Specific binding was determined as the binding difference between total 
binding and non-specific binding. Non-specific binding was defined as the 
residual binding in the presence of 1pM 6-Nitroquipazine 22 to the incubation 
media. Total binding is described as the level of radioactivity of the assay 
medium in the absence of unlabeled competitive inhibitor. Binding data was 
analyzed using the software program Prism (GraphPad, Inc.) where percent of 
total specific binding vs. -log molar concentration of inhibitor (six or more data 
points per curve) were plotted. The inhibitor concentrations ( I C 5 0 )  required to 
obtain 50% inhibition of [3H]paroxetine 9 binding were determined.112 Assay data 
points were done in triplicate and the experiments were repeated a minimum of 
three times on different days. The Kj value was calculated according to the 
equation: K j  = I C 5 o / ( 1 + [ L ] / K d ) ,  where [ L ]  is the concentration of the unbound 
[3H]paroxetine 9 (0.25 nM), and Kd is the equilibrium dissociation of paroxetine 
(0.15 nM).111,112 An example plot for the binding of 9 is given below (Figure 4-1).
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Figure 4-1: Example single site competition assay plot of %bound radioligand versus the Log of 
inhibitor concentration (M).
4.2.1 Discussion of Pharmacology.
Based upon the lead structure 6-nitroquipazine (6-NQP) 22 a number of 
racemic (Table 4-1) and chiral (Table 4-2) 2-(2-alkyl-piperazin-1-yl)-6- 
nitroquinolines have been prepared, and their respective binding affinities ( K j )  for 
rSERT have been determined. Included in the table are their structural 
differences from the lead 6-NQP 22 and their calculated lipophilicity values 
(LogP).113
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Table 4-1: Racemic 2-(2-alkyl-piperazin-1-yl)-6-nitroquiolines, compound name and R-group are 
given as well as their associated binding inhibition constant ( K j ) ,  and CLogP(o/w) value.
rA ^ nh
Name R Ki (pM) CLogP(o/w)** Ref
22 NQP H 160 ± 50 1.9 67
(±)-30 (±)-Me-NQP c h 3 81 ±61 2.42 II
(±)-31 (±)-MOM-NQP CH2OCH3 2.48 ± 0.28 1.94 72
38 HOM-NQP CH2OH 12.65 ±3.00 1.19 74
(±)-51 PROM-NQP (CH2)3OCH3 2.12 ± 1.13 2.21 This Work
147 HOP-NQP (CH2)3OH 50.25 ± 35.76 1.5 This Work
58 PROF-NQP (CH2)3F 2.48 ±0.19 2.75 This Work
52 n-PROP-NQP c h 2c h 2c h 3 41.48 ± 19.87 3.48 This Work
(±)-83 PentOM-NQP (CH2)5OCH3 1.02* 3.26 This Work
148 MePROF-NQP CH20(C H 2)3F 3.96 ± 0.88 2.28 74
88 PentF-NQP (CH2)5F 79.6 ±21.2 3.81 This Work
‘ Preliminary Value “ Daylight Software (http://www.daylight.com/daycgi/clogp)
Early work by Gerdes et al. has shown that methyl group substitution of 
the piperazine ring at the 2-position Me-NQP (±)-30 is 56 times more potent for 
rSERT than methyl substitution at the 3-position 3-Me-NQP 28.67 Additionally 
binding potency of Me-NQP (±)-31 was 2 times (81 pM) more potent compared to 
the lead 6-NQP 22 (160 pM). The next generation ligand MOM-NQP (±)-31 was 
obtained by extending the alkyl chain by two atoms as the methoxymethyl, 
increased binding affinity to 2.5 pM (64 times more potent than 22). The 
increase in binding of (±)-31 suggests that the piperazine substitution is 
interacting deeper in the Ar2 binding pocket (Figure 1-10). Comparison of (±)- 
MOM-NQP (±)-31 to the all carbon case n-PROP-NQP 52 (similar chain length) 
shows that in the absence of an oxygen binding potency is decreased (Ki = 42 
pM). The addition of an oxygen as the propyl methyl ether PROM-NQP (±)-51,
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showed an increase in binding affinity (Ki = 2.1 pM) that is equivalent to the 
affinity of (±)-31. A similar comparison can be made between PentF-NQP 88 
(void of oxygen) and MePROF-NQP 148 (oxygen present). The all carbon case 
88 (79.6 pM) has the same potency as (±)-30 (81 pM). The introduction of an 
oxygen atom in MePROF-NQP 148 (oxygen location is the same as (±)-31) 
results in an increase in binding affinity that is consistent with the ligands 
containing an ether functionality (±)-31 and (±)-51 (Ki = 4.0 pM). The increase in 
binding of the alkyl chains containing an ether functional group is suggestive that 
the Ar2 binding region may prefer hydrogen bonding acceptors, i.e. oxygen and 
perhaps fluorine.
When comparing the binding affinities of the all carbon substitutions there 
is a doubling in potency by increasing the carbon length from one carbon (±)-30 
to three carbons (±)-52 Kj = 81 pM and 42 pM, respectively. The increase in chain 
length may enhance potency through lipophilic interactions within the Ar2 
domain. It is interesting to note that there is relatively no change in potency 
between PROM-NQP (±)-51 and (±)-MOM-NQP (±)-31 ( K j  = 2.12 and 2.48 pM, 
respectively), perhaps the presence of a hydrogen bond acceptor far out weighs 
the chain length. Replacement of a terminal hydrogen of n-PROP-NQP 52 with a 
fluorine atom to give PROF-NQP 58 (Kj = 2.5 pM) increased potency by 17 times 
further substantiating the benefit of an H-bonding acceptor. It is interesting to 
note that the propyl hydroxyl version HOP-NQP 147 shows a -25 times drop in 
potency ( K j  = 50 pM) compared to PROM-NQP (±)-51 and (±)-MOM-NQP (±)-31. 
Additionally the methyl alcohol HOM-NQP 38 showed a 6 fold decrease in
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potency compared to MOM-NQP (±)-31. It seems that the presence of a 
hydrogen bonding donor is not well tolerated in the Ar2 binding domain. The 
binding potency of PROF-NQP 58 and MePROF-NQP 148 bode well for their use 
as potential PET imaging agents.
Table 4-2: Chiral 2-(2-alkyl-piperazin-1-yl)-6-nitroquiolines, compound name and R-group are 
given as well as their associated binding inhibition constant ( K i ) ,  and CLogP(o/w) value.
Q j N .
r^ N H
H
Name R Ki (pM) Ref
(±)-30 (±)-Me-NQP c h 3 81 ±61 67
( R )-30 (R )-(-)-Me-NQP II 91 ± 16 73
(S )-30 (S)-(+)-Me-NQP II 68 ±21 11
(±)-31 (±)-MOM-NQP CH2OCH3 2.48 ± 0.28 72
(R )-31 (R )-(+)-MOM-NQP 11 47* 74
(S)-31 (S)-(-)-MOM-NQP ll 1* ll
‘ Preliminary Values
To further expand upon our SERT SAR the enantiomeric forms of (±)-Me- 
NQP 30 and (±)-MOM-NQP 31 were evaluated for their respective SERT binding 
affinities (Table 4- 2 ) .  Comparison of the enantiomers (/?)-30 and (S)-30 binding 
affinity at rSERT ( K j  =  91 ± 1 6  pM and 68 ±  21 pM) shows no significant 
difference in SERT preference for either enantiomer. Perhaps the methyl group 
is not long enough to evoke a definite preference at the SSRI binding domain. 
Initial binding affinity values of the (/?)-31 and (S)-31 enantiomers ( K j  =  47 pM 
and 1 pM, respectively) shows a 47 times higher affinity for (S)-31. This is 
encouraging; suggesting that in there is a receptor preference for one 
enantiomer, which is similar to the results seen for citalopram 7 and fluoxetine 
10.
103
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4.3 Synthesis of n-PROP-NQP 52 and [3H]n-PROP-NQP.
Our interests in developing a PET imaging agent for SERT lead us to 
investigate the binding kinetics of our 2-(2-alkyl-piperazin-1-yl)-6-nitroquinoline 
analogs with the SERT protein. In addition we wanted to assess the selectivity of 
our ligands for SERT relative to the other biogenic amine transporter targets 
within the CNS. To accomplish these evaluations we investigated the possibility 
of generating a tritium labeled compound based upon our 2-(2-alkyl-piperazin-1- 
yl)-6-nitroquinoline analog series. When examining our library of compounds we 
decided that n-PROP-NQP 52 would be an excellent analog for the preparation 
of a tritiated [3H]2-(2-alkyl-piperazin-1-yl)-6-nitroquioline. Since 52 was complete 
with a propyl side chain it could act as a good representative analog compared to 
the balance of our compound library, particularly 58.
Initially n-PROP-NQP 52 was considered a side product of the PROM- 
NQP (±)-51 synthesis. However, the synthesis of 52 and related binding affinity 
for SERT was fortuitous. We proposed that 52 could be used as a 
pharmacological tool for assessing the binding kinetics of our ligand series as 
well as selectivity of our ligand series for SERT over other monoamine 
transporters, i.e. DAT and NET. Additionally, 52 is good replacement for PROF- 
NQP 58 based upon the similarity of the side chain length and lipophilicity 
between 52 and 58 (Figure 4-2).
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Figure 4-2: Structure and CLogP comparison of n-PROP-NQP 52 and PROF-NQP 58.
Determination of the in vitro binding kinetics using the [18F]PROF-NQP 58 
agent would be more desirable,114 but due to the difficulties of preparing 
[18F]PROF-NQP 58 analog at the time of this study, n-PROP-NQP 52 was a 
more desirable agent.
As shown in Scheme 4-1, the synthesis of the 52 began with the Swern 
oxidation of dibenzyl alcohol 33 to the aldehyde 44, followed by Wittig olefination 
with ethyl-triphenylphosphonium bromide to give 149 (71%, 2 steps). 
Hydrogenolysis of the benzyl groups and simultaneous hydrogenation of the 
alkene with 5% Pd/C and HCI in MeOH, (atmospheric pressure) gave the n- 
propyl piperazine dihydrochloride 150 in a 92% yield. The piperazine was 
protected with triphenylmethane chloride to give 151, then coupled to 2- 
choroquinoline, deprotected (152, 45%, 2 steps) and then selectively nitrated at 
the 6-position to give the desired n-PROP-NQP 52 in a quantitative yield. The n- 
PROP-NQP 52 target was synthesized from the common intermediate dibenzyl- 
alcohol 33 affording 2-(2-propylpiperazin-1-yl)-6-nitroquinoline 52 in 7 steps and 
a 29% overall yield.
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n-BuLi, [(Ph)3P+Et]Br- Bn .
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quantitative
"CPh3
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0 2N
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Scheme 4-1: Synthesis of 2-(2-propylpiperazin-1-yl)-6-nitroquinoline 52 (n-PROP-NQP).
Upon completion of the synthesis of 52, it was shipped to SibTech, Inc. 
(Newington, CT) and radiolabeled labeled with tritium. This was accomplished 
by aromatic halogenation of the quinoline ring, followed by dehalogenation-tritium 
exchange to give [3H]52, with a specific activity of 17.5 pCi/mmol, and a chemical 
purity of 99% (Scheme 4-2).
3h
o2n^
SibTech, Inc.
NH 17.5 pCi/mmol 
99% pure
52 [3H]52
Scheme 4-2: Radiosynthesis of [3H]-2-(2-propylpiperazin-1-yl)-6-nitroquinoline 52 ([3H]-n-PPOP- 
NQP).
N N
N N
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4.4 In Vitro SERT Binding Studies [3H]-n-PROP-NQP 52.
In this study our aim was to examine the in vitro binding characteristics 
and receptor selectivity of the radiolabeled SERT inhibitor [zH ]n -P R O P -N Q P  52 
prepared according to Schemes 4-1 and 4-2. We were interested in determining 
the equilibrium dissociation constant (KD), binding site density (Bmax), association 
and dissociation rate constants (kon and k0ff), and to assess the selectivity of 
[3H]52 for rSERT. The equilibrium dissociation constant (Kd) is useful to describe 
a ligand’s affinity for a given binding domain, considering Kd is the reciprocal of 
binding affinity KA (KA = 1/KD).115 A lower the KD value represents higher affinity 
of the ligand for the receptor and at equilibrium if the KD value is small the 
dissociation of the ligand-protein complex will be slower. The association rate 
constant (kon) is a measure of how fast the ligand-receptor complex is formed. 
The dissociation rate constant (k0ff) is a measure of how tightly the ligand is 
bound to the receptor. A low Kd and a slow dissociation (k0ff) of the ligand- 
receptor complex are thought to be favorable for a SERT imaging agent. 
Additionally, fast association is desirable to establish binding equilibrium at the 
receptor relatively quickly to benefit the imaging experiment. The Kd values can 
be determined kinetically from the rate constants kon and k0ff where Kd = k0ff/k0n 
and from saturation equilibrium binding studies.
ôn
Ligand + SERT -  Ligand-SERT
^off
— ôn ! koff — 1 / Ka
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Measurement of the dissociation constants (KD) were performed according to 
the published procedures.13,110,111 The association rate constant (kon) and the 
time to reach binding equilibrium was determined by incubation of the radioligand 
[3H]52 (200 pM) with the rSERT membrane preparation at 21 °C and 37 °C for 
varying amounts of time (10 minutes -  4 hours). From the plot of association 
(Figure 4-3), the apparent equilibrium time was determined to be between 2-3 
hours. The time to reach apparent equilibrium is in agreement with a structurally 
related compound [125l]5-iodo-6-nitroquipazine 23 as previously reported.110 The 
observed association constant (kobs) of [3H]52 was determined from the formula 
ln[Be / (Be -  Bt)] = kobs’t, where Be is specific binding at equilibrium, and Bt is 
specific binding at time t (Figure 4-3).
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—
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Figure 4-3: Time course association plots of [ H]-n-PROP-NQP 52 at 21 °C.
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The dissociation rate constant ( k o f f )  was determined by treatment of the 
incubation medium with 1.0 |j M of the non-radioactive from 52, 3 hours after the 
addition of [3H]52 (Figure 4-4). The dissociation rate constant ( k 0 ff )  was 
calculated from the formula; ln[Bt / Be] = - k 0f f * t  and the results are shown in Figure 
4-4.
120-1
©
.E 110- 
■o S 1 0 0 -
Dissociation at21°C
£  50-
0 30 60 90 120 150 180 210 240 270 300 330 360 390 420
Time (min)
Figure 4-4: Time course dissociation plots of [3H]-/7-PROP-NQP 52 at 21 °C.
The association rate constant was determined from the relationship kon = 
( k 0 bs -  k0ff) / [L], where [L] is the concentration of unbound 52. From k o n and k0ff 
the kinetically derived dissociation constant (KD) can be calculated according to 
Kd = (k0ff / kon). The calculated values for KD, kon and koff are outlined in Table 4-3 
and compared to the SERT selective 6-nitroquinoline analog [125l]5-iodo-6- 
nitroquinoline 23 ([125I]INQP) and the SSRIs (+)-MCN5652 6 and (S)-citalopram 
7.
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Table 4-3: Comparison of the kinetically derived dissociation constants (KD), the rate constants of 
association (kon) and dissociation (koff) for [3H]-n-PROP-NQP 52 and select SSRIs at 21 °C.
°c Name Kd (PM) ^  (moT'min'1) koff (min1) Ref
21° [3H]52 n-PROP-NQP 8.5 1.1 x 10B 9.4 x 10-4 Weller, 2003
[125l]23 INQP 7.9 4.8x10® 3.8x1 O'4 Mathis, 1993
[3H]6 (+)-MCN5652 80 3.6x10® 3.1 x 10'3 Elfving, 2001
[3H]7 (S)-Citalopram 310 4.9x10 ' 1.2 x 10"2 Elfving, 2001
Comparison of the Kd value determined for [3H]n-PROP-HQP 52 (8.42 
pM) to the Kd values of other SSRIs ([125I]INQP 23, [3H]-(+)-MCN5652 6, and 
[3H]-(S)-citalopram) showed [3H]52 had comparable binding potency to the 
structurally related quipazine agent INQP 23 (7.9 pM) at 21 °C (Table 4-3). Also, 
[3H]52 has a much higher affinity for rSERT (lower K d ) compared to the SSRIs 
MCN5652 6 and citalopram 7 (21 °C). The rate of association (kon) at 21 °C of 
[3H]52 is essentially equivalent to that of [125I]INQP 23 and [3H]-(+)-MCN5652 6, 
but was an order of magnitude faster than [3H]-(S)-citalopram 7. The dissociation 
rate (k o f f )  of [3H]52 was slightly faster than [125I]INQP 23, but slower than [3H]-(+)- 
MCN5652 6, and [3H]-(S)-citalopram 7 (21 °C). The comparison of binding 
potency (KD), association rate (kon) and dissociation rate (koff) at 21 °C suggest 
that the 2-(2-alkyl-piperazin-1-yl)-6-nitroquinoline analogs will have good in vitro 
binding properties for use as PET imaging agents.39 The slower dissociation 
rate of [3H]52 at 21 °C compared to [3H]-(+)-MCN5652 6 and [3H]-(S)-citalopram 
7, is thought to be important for the imaging of medium to low SERT density 
regions.
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4.5 Determination of the Apparent Equilibrium Dissociation Constant 
(Kd) and Receptor Density (Bmax)-
Determination of the receptor density (Bmax) and the apparent equilibrium 
dissociation constant (KD) were determined from saturation studies of the crude 
rat brain membrane preparation with the radiolabeled compound [3H]52, 
according to the methods of Mathis and Habert.110,111 In brief, the crude 
membrane preparations were treated with increasing concentrations of [3H]52 
(0.001 -  2.5 nM) in the absence and presence of 1 mM paroxetine (to establish 
non-specific binding) and incubated for three hours at 21 °C. The samples were 
filtered and counted as described above. An example plot of the saturation 
experiments is shown (Figure 4-5). From the saturation binding isotherm we 
were able to calculate the apparent equilibrium Kd = 38 pM and Bmax = 395 
fmol/mg of protein, using the iterative least squares curve fitting program Prism 
(Graphpad).
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Figure 4-5: Saturation binding isotherm of [3H]-a7-PROP-NQP 52 binding with rSERT at 21 °C.
The Kd (38 pM) determined for [3H]52 is similar to the equilibrium derived 
Kd determined for the structurally related analog [125I]INQP 23 (23 pM) and 
slightly larger than that of the kinetically derived KD for [3H]52 (8.5 pM). The Bmax 
value determined in our saturation studies is consistent with other rSERT 
saturation measures (-400 fmol/mg protein).13,110
4.6 SERT Selectivity of [3H]-n-P/?OP-NQP 52.
The labeled form of [3H]52 was also useful for examining and estimating 
the selectivity of the 2-(2-alkyl-piperazin-1-yl)-6-nitroquioline ligands for the 
SERT binding site. The SERT selectivity assays are outlined in Table 4-4, the 
ligand name, competitive binding affinity (K) and ligand classification are 
included. For the selectivity assays we used known selective agents for the
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biogenic amine transporters, these are classified as either a serotonin selective 
reuptake inhibitor (SSRI), dopamine reuptake inhibitor (DRI), norepinephrine 
reuptake inhibitor (NRI), or SSRI (quipazine). The assays were performed by 
adding a solution of the unlabelled test agent to the rat membrane preparation 
containing [3H]52 and assay buffer. Total binding was determined by treatment 
of the membrane preparation with [3H]52 in the absence of any competitive 
ligand. Competitive drugs were screened at varying concentrations (1 pM -  10 
pM), the results were plotted and the Kj values were determined using Prism, 
utilizing the kinetically derived Kd of [3H]52 at 20 °C (8.42 pM). Non-specific 
binding was determined in the presence of 1 pM 6-NQP 22. The ligands tested 
are summarized in Table 4-4 with their associated inhibition constants.
Table 4-4: Inhibition constants (K) for select CNS agents inhibiting the binding of [3H]-n-PROP- 
NQP 52 with rSERT.
Cmpd # Name K; (nM)
6 (+)-MCN5652 0.19 ±0.04 SSRI
7 (S)-Citalopram 1.96 ± 0.59 SSRI
9 Paroxetine 0.27 ± 0.08 SSRI
153 GBR12935 >500 DRI
154 Nisoxetine > 10,000 NRI
58 PROF-NQP 0.0056 ± 0.0002 SSRI (Quipazine)
52 n -PROP-NQP 0.0018 ±0.0005 SSRI (Quipazine)
(±)-31 MOM-NQP 0.03 ± 0.01 SSRI (Quipazine)
The ligands tested include the SSRIs (+)-MCN5652 6, citalopram 7 and 
paroxetine 9 the selective DAT inhibitor GBR-12935 (not shown) and the 
selective NET inhibitor nisoxetine (not shown). Included in this study were a 
select group of 2-(2-alkyl-piperazin-1-yl)-6-nitroquinolines prepared in our lab, 
including; PROF-NQP 58, MOM-NQP (±)-31, and PROP-NQP 52. The results 
shown in Table 4-4 are indicative that [3H]52 is binding at the same SERT
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binding domain as the known SSRIs, (+)-MCN5652 6, citalopram 7 and 
paroxetine 9. Additionally, [3H]52 is selective for SERT based upon challenging 
with known selective DAT and NET inhibitors. Also, based upon the potent 
inhibition constants (low nanomolar range) of the 2-(2-alkyl-piperazin-1-yl)-6- 
nitroquinolines (±)-31, 52 and 58, it is indicative that those ligands have potent 
rSERT affinity. The selectivity and binding profiles of the quipazine ligands 
indicate that these ligands will likely show very good in vivo characteristics for 
PET imaging of low SERT density regions of the brain.
4.7 Summary.
Competition assay ([3H]paroxetine, 9) of the 2-(2-alkyl-piperazin-1-yl)-6- 
nitroquinolines (Table 4-1 and Table 4-2) show an overall increase in binding 
affinity compared to the lead agent 6-NQP 22. From these studies we can infer 
that a hydrogen bonding acceptor located in the alkyl chain will benefit binding 
affinity. For example (±)-31, (±)-51, 58, and (±)-83 all showed affinity for SERT in 
the 2 pM range. This is a much higher affinity when compared to the all carbon 
analogs 52, and (±)-30 whose affinities were >20 times less potent. We can also 
comfortably say that the presence of a hydrogen bonding donor is detrimental to 
binding, HOM-NQP 38 and HOP-NQP 147 both show a decrease in binding 
affinity compared to their respective ether analogs. The in vitro studies of [3H]52 
demonstrate the selectivity and binding affinity of [3H]52 for SERT. The in vitro 
kinetic data (KD, kon and koff) for [3H]52 is representative of the kinetics we expect 
for our analog series. This data suggests that a fluorine-18 radioligand derivative
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of a 2-(2-alkyl-piperazin-1-yl)-6-nitroquioline analog, such as PROF-NQP 58 
could prove to be a useful ligand for PET imaging studies; especially considering 
that 58 exhibits a higher binding affinity (2.5 pM) compared to 52 (42 pM), in 
addition to its implied SERT selectivity.
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Chapter 5
Conclusions and Future Work
The syntheses of seven new 2-(2-alkyl-piperazin-1-yl)-6-nitroquinoline 
racemic analogs of 6-NQP 22 have been completed, including PROM-NQP (±)- 
51, HOP-NQP 147, PROF-NQP 58, n-PROP-NQP 52, Pent-NQP (±)-83, PentF- 
NQP 88, and BuM-NQP 96. Of these analogs all except BuM-NQP 96 have 
been evaluated for their in vitro binding affinity for rSERT by radioligand 
competition assay (rSERT, [3H]paroxetine 9) as outlined in Chapter 4. The 2-(2- 
alkyl-piperazin-1-yl)-6-nitroquinolines ligands tested show higher binding affinity 
( K i  = 1-80 pM) for rSERT compared to the lead SSRI 6-NQP 22 ( K i  = 160 pM). 
This initial SAR study of the quipazine ligands prepared during this work 
suggests that probing of the Ar2 binding domain of our pharmacophore model, 
with alkyl chain moieties at the piperazine 2-postion of the quipazine base 
structure, is a useful method for preparing new more potent quipazine ligands.
The presence of hydrogen bonding acceptor moieties (methoxy ether and 
alkylfluoride) in the alkyl chain is beneficial to ligand binding and the inverse is 
seen for the presence of hydrogen bond donating moieties, i.e. hydroxyl. 
Overall, the presence of any alky chain results with increased binding affinity of 
the analogs for rSERT. At this time, the SAR indicates that a chain length of 3-5 
atoms is acceptable as can be seen in the respective binding affinities of MOM- 
NQP (±)-31 and the propyl series ligands (±)-51, 52, 58, and 147 (Table 4-1). 
Further assessments of the racemic butyl and pentyl series will extend our 
knowledge of the chain length limits for SERT binding.
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To expand our SAR studies the (R)- and (S)-enantiomers of MOM-NQP 
(±)-31, PROM-NQP (±)-51 and Pent-NQP (±)-83 were synthesized. 
Unfortunately, only the enantiomers of MOM-NQP (R)-31 and (S)-31 have been 
evaluated for their associated rSERT affinity at the time of this writing. The initial 
studies show a difference in potency of (/?)-31 and (S)-31, suggesting that the 
(S)-enantiomer (Ki = 1 pM) is more potent for SERT than the (R)-enantiomer (Ki = 
47 pM). This trend could be further evaluated using the enantiomers of PROM- 
NQP and Pent-NQP ((/?)-51, (S)-51, (/?)-83 and (S)-83). The syntheses of the 
chiral forms of PROF-NQP 58, PentF-NQP 88, BuM-NQP 96 and the related 
BuF-NQP (not shown) should be accomplished to afford a complete ligand 
series. As per the experimental section the final compounds of the chiral propyl 
and pentyl series ((/?)-51, (S)-51, (R)-8Z and (S)-83) have been analyzed for their 
optical rotations. The measures are indicative that the final compounds have 
retained their enantiomeric purity within reasonable experimental error. The final 
chiral forms of the pentyl series ((R)-B3 and (S)-83) require more analysis when 
larger quantities have been prepared. However, more rigorous determination of 
enantiomeric purity should be completed by chiral HPLC, gas chromatography 
(GC) or spectroscopically (Mosher amide). Furthermore, each enantiomer and 
the untested racemic forms should be analyzed for their respective SERT binding 
affinities. Completion of the analog series and pharmacological analysis will give 
a more complete understanding of our SERT ligand SAR studies.
The tritium labelled ligand [3H]52 was prepared as a representative ligand 
to asses the in vitro binding characteristics and receptor selectivity of our
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quipazine ligand family. Ligand [3H]52 was shown to have superior in vitro 
kinetic values (KD, kon and koff) for SERT binding than the SSRIs (+)-MCN5652 6 
and (S)-citalopram 7. Comparison of [3H]52 to the structurally related analog 
[125I]INQP 23 shows a similar equilibrium dissociation constant (KD) value. This 
suggests that our ligand family will show similar receptor selectivity and the in 
vitro kinetic data looks promising for in vivo imaging. We believe that a 
radioligand, i.e. [18F]PROF-NQP 58 will show far superior in vivo characteristics 
based upon the lipophilicity of 58 (LogP -2.5) and binding affinity for rSERT (Ki =
2.5 pM).
Furthermore, based on the radiofluorination trials with N-Boc-ProTos-NQP 
the N-formyl-ProTos-NQP radiolabeling precursor should be reevaluated for its 
potential to provide the radioligand [18F]PROF-NQP 58. Also, it would be very 
interesting to determine if the fluoride substitution of the aromatic nitro group is 
occurring during the radiofluorination. This could be accomplished by 
synthesizing more of the nonradioactive side product 73 and having it 
chromatographically tested against the crude mixture from the radiofluorination of 
N-Boc-ProTos-NQP 69, under the K222 conditions that gave a 1:1 mixture of the 
two fluorinated products (based upon radioactive TLC) and with the TBAF 
conditions that favored the formation of the side product (based upon radioactive 
TLC).
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Chapter 6
Experimental Section
6.1 General Experimental.
Reactions utilizing dry solvents were performed in oven-dried glassware 
under an atmosphere of argon. Reagent grade chemicals and solvents were 
purchased from commercial suppliers (Aldrich, Fisher and VWR) and used 
without further purification or treatment unless otherwise noted. 
Methyltriphenylphosphonium Iodide was prepared according to the method of 
McCortney, 1990.116 Tosyl chloride was purified according to Armarego.117 Dry 
solvents (ACN, THF, Et2 0 , DMF and CH2CI2) were purchased from J.T. Baker, 
EMD science, and Acros, and used without further treatment. The concentration 
of n-BuLi (Aldrich) was estimated according to the method of Kofron.118
NMR spectra 1H and 13C were obtained using a Varian-Unity spectrometer 
operating at 400 MHz and 100 MHz respectively. Chemical shifts were recorded 
in parts per million (ppm, 5) and were reported relative to the solvent peak of 
CHCI3 (7.26 ppm). High resolution mass spectra (HRMS) were obtained using 
an electrospray ionization (ESI) Micromass LCT connected to a Water 2790 
HPLC. Optical rotations were determined at ambient temperature utilizing a 
Perkin-Elmer 241 polarimeter at the sodium D-line (589 nm) and a 10 cm (1 dm) 
cell. Specific rotations were calculated using the relationship [a]20D = a / L*c; 
where a is the observed rotation, L is the path length and c is the concentration 
in grams solute / solution volume (g/mL). Column chromatography was
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performed using EM Science, Silica gel 60 (230-400 mesh ASTM). Reactions 
were monitored by TLC using EM Science 20 x 20 cm Silica gel 60 F254 
aluminum backed plates. Compound spots were detected visually by ultraviolet 
light at 254nm and 365 nm or by staining with ninhydrin (0.3 g ninhydrin, 100 mL 
EtOH, 3 mL AcOH) or vanillin (15 g vanillin, 250 mL EtOH, 2.5 Ml H2SO4) 
developed by heating. Reactions were performed at room temperature 21-25 °C 
(RT °C) unless otherwise specified. All pH determinations were performed using 
EM ColorpHast pH strips. All organic extractions were dried with K2CO3 and 
filtered before concentration unless otherwise specified. Biotage purification was 
carried out on a Biotage Sp1 high-performance flash chromatography system 
(Biotage, Charlottesville, VA) equipped with a Biotage NH normal phase Flash 
column (12-M). Elution solvents were; solvent A: hexanes and solvent B: EtOAc. 
The flash column was pre-equilibrated with 10% B at 10 mL/min.
6.2 Racemic Propyl Series
1,4-Dibenzyl-2-hydroxymethylpiperazine (33). A suspension of LiAIH4 (1.53 g,
40.3 mmol) in dry ether (80 mL) was treated with a solution of ethyl 1,4- 
dibenzylpiperazine-2-carboxylate 32 (11.4 g, 33.6 mmol) in dry ether (30 mL) at 0 
°C under argon, maintaining a gentle effervescence. The reaction was stirred for
LiAIH4, EtoO
O
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30 min and the ice bath was removed. Stirring was continued at 25 °C for 1 hour. 
The reaction was quenched by consecutive addition of H20  (1.5 mL), NaOH (3 
mL 3 M) and H20  (1.5 mL); the inorganic salts were filtered over a pad of Celite, 
and the pad was rinsed with EtOAc. The filtrate was concentrated in vacuo to 
give 33 as a clear oil (9.45 g, 96%): TLC Rf = 0.33 (1:9 MeOH/CH2CI2); 1H NMR 
(CDCIs, 400 MHz) 5 2.30-2.73 (3m, 7H), 2.95 (m, 1H), 3.39-3.67 (m, 4H), 3.93- 
4.14 (m, 2H), 7.20-7.40 (m, 10H); 13C NMR (CDCI3, 100 MHz) 5 49.8, 52.4, 56.0,
58.0, 58.5, 62.1, 63.1, 127.0, 127.2, 128.3, 128.8, 129.1, 137.5, 138.0.
1,4-Dibenzyl-piperazine-2-carboxaldehyde (44). DMSO (3.5 g, 44.6 mmol) in 
dry CH2CI2 (15 mL) was added dropwise to a solution of oxalyl chloride (2 M in 
CH2CI2, 17.7 mL, 35.4 mmol) in dry CH2CI2 (80 mL) at -78 °C (dry ice, acetone 
bath). After 5 min a solution of 1,4-dibenzyl-2-hydroxymethyl-piperazine 33 (9.45 
g, 32.14 mmol) in dry CH2CI2 (30 mL) was added dropwise, the solution was 
allowed to stir for an additional 20 min. The reaction was treated with Et3N (16.3 
g, 160.7 mmol), forming a tan precipitate and allowed to stir for 5 min. The 
mixture was allowed to warm to room temperature and stir for 1 hour. The 
reaction was quenched by the addition of water (100 mL), the organics were 
separated and the aqueous phase was extracted with CH2CI2 (75 mL). The 
combined organics were washed with saturated NaHC03 (50 mL), dried with
DMSO, (COCI)2
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K2 CO3  and concentrated in vacuo. The aldehyde was used in the next step 
without further purification: TLC R f  = 0.69 ( 1 :9 MeOH/Ch^C^).
3-(1,4-Dibenzyl-piperazin-2-yl)-acrylic acid ethyl ester (45). A stirred solution 
of n-BuLi (17 mL, 2.45 M in hexanes, 40.8 mmol) in dry THF (30 mL) was treated 
with triethylphosphonoacetate (9.1 g, 40.8 mmol) at 0 °C under argon, to give a 
light yellow solution. After 15 min a solution of 1,4-dibenzyl-piperazine-2- 
carbaldehyde 44 (6.0 g, 20.4 mmol) in dry THF (10 mL) was added dropwise to 
the cooled solution. The reaction mixture was allowed to warm to room 
temperature and to stir for 20 h. The reaction was quenched by the addition of 
water (25 mL) and concentrated in vacuo to remove THF. The aqueous layer 
was treated with 20 mL of sat. NaHCOs and extracted with CH 2 CI2  (3 x 20 mL). 
The combined organics were washed with brine (20 mL), dried (K2 CO 3 ) and 
concentrated in vacuo. The crude orange oil was purified by column 
chromatography over silica gel (80 g) loaded with CHCI3  eluted with 1:9 
EtOAc/hexanes followed by 1:3 EtOAc/hexanes to elute 45 as a light tan oil (4.6 
g, 64% 2  steps): TLC R f = 0.63 (MeOH:CH 2 CI2, 1:9) or R f = 0.36 (2:3
EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 6  1.29 (t, J = 7.1 Hz, 3H), 2.10- 
2.30 (2m, 3H), 2.60-2.77 (2m, 3H), 3.12 (m, 1H), 3.50 (dd, J = 13.3 and 17.5 Hz, 
2H), 3.91 and 3.12 (2d, J = 13.6 Hz, 2H), 4.19 (q, J = 7.1 Hz, 2H), 6.04 (d, J =
15.9 Hz, 1H), 6.98 (dd, J = 8.4 and 15.9 Hz, 1H), 7.20-7.35 (m, 10H); 13C NMR
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n-BuLi, Triethylphosphono-
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(CDCb, 100 MHz) 5 50.6, 52.8, 58.0, 59.7, 60.4, 62.8, 123.8, 126.9, 127.1,
128.1, 128.2, 128.9, 129.1, 137.7, 138.3, 148.6, 166.1.
H2, 5% Pd/C Bn' N ^
EtO.
N 'Bn A c0H ’ Me0H EtQ Bn
O O
3-(1,4-Dibenzyl-piperazin-2-yl)-propionic acid ethyl ester (55). 5% Pd/C (0.9 
g was added to a solution of 3-(1,4-Dibenzyl-piperazin-2-yl)-acrylic acid ethyl 
ester 45 (4.5 g, 12.4 mmol) in HPLC grade MeOH (60 mL) and acetic acid (3.7 g, 
61.8 mmol). The reaction flask was sealed with a septum, fitted with a hydrogen 
balloon and a bleed needle. One balloon of hydrogen was bubbled through the 
stirred solution the needle was removed and a second balloon was attached. The 
reaction was stirred overnight, then filtered over a pad of Celite, rinsing with 
MeOH and concentrated in vacuo. The oil was dissolved in CH 2 CI2 , free based 
with 4M NaOH to pH 12 then buffered to pH 10 with sat. NaHC 0 3 - The organics 
were separated and the aqueous layer was extracted with CH 2 CI2  (3 x 20 mL). 
The organic portions were combined, dried (K2 CO 3 ) and concentrated in vacuo. 
The crude oil was purified by column chromatography over silica gel (44 g) 
loaded with CHCI3  and eluted with 1:3 EtOAc/hexanes to give 55 as clear oil (3.5 
g, 78%): TLC Rf = 0.26 (2:3 EtOAc/hexanes) or Rf = 0.5 (3:2 EtOAc/hexanes); 
1H NMR (CDCI3 , 400 MHz) 5 1.23 (t, J = 7.3 Hz, 3H), 1.88-2.8 (5m, 12H), 3.23 
and 4.02 (2d, J = 13.2 Hz, 2H), 4.11 (q, J = 7.3 Hz, 3H), 7.20-7.40 (m, 10H); 13C 
NMR (CDCI3 , 100 MHz) 5 14.2, 24.4, 30.2, 50.3, 52.7, 56.8, 57.5, 58.5, 60.3,
63.0, 126.7, 126.9, 128.1, 128.7, 129.0, 138.1, 139.0, 173.7.
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EtO.
Bn' N ^
o
Bn
UAIH4, Et20
HO
H Bn
1,4-Dibenzyl-2-(3-hydroxypropyl)-piperazine (56). A suspension of LiAIH4 
(0.41 g, 10.9 mmol) in dry ether (20 mL) was treated with a solution of 3-(1,4- 
dibenzyl-piperazin-2-yl)-propionic acid ethyl ester 55 (3.3 g, 9.1 mmol) in dry 
ether (15 mL) at 0 °C under argon, maintaining a gentle effervescence. The 
reaction was stirred for 5 min and the ice bath was removed. Stirring was 
continued at 25 °C for 35 min. The reaction was quenched by consecutive 
addition of H20  (0.41 mL), NaOH (0.82 mL, 4 M) and H20  (0.41 mL). The 
inorganic salts were filtered over a pad of Celite and the pad was rinsed with 
EtOAc. The filtrate was concentrated in vacuo to give 56 (2.8 g, 95%): TLC R f  = 
0.1 (3:2 EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 6  1.52-1.95 (3m, 4H), 
2.12-2.37 (2m, 3H), 2.48-2.80 (3m, 4H), 3.20 and 4.19 (2d, J = 12.8, 2H), 3.48 
(dd, J = 17.9 and 13.2 Hz), 3.66 (m, 2H), 7.20-7.40 (m, 10H); 13C NMR (CDCI3, 
100 MHz) 6  27.6, 28.6, 50.5, 52.2, 56.4, 57.8, 59.4, 62.8, 63.0, 126.9, 127.1,
128.1, 128.3, 129.0, 129.3, 137.8, 138.0
1,4-Dibenzyl-2-(3-methoxypropyl)-piperazine (57). A cooled (0 °C) stirred 
solution of 1,4-dibenzyl-2-(3-hydroxypropyl)-piperazine 56 (1.7 g, 5.2 mmol) in 
dry DMF (15 mL) was treated NaH powder (0.38 g, 15.7 mmol) to give a turbid
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white suspension. The flask was placed under argon and stirring was continued 
for 20 min. iodomethane (0.78 g, 5.5 mmol) was added dropwise to the cooled 
solution, the reaction was allowed to stir on ice for 20 min, followed by room 
temperature for 3.5 h. The reaction was quenched by the addition of water (20 
mL) followed by sat. NaHC0 3  (20 mL). The aqueous layer was extracted with 
Et20 ( 4x10  mL), dried ( K 2 C O 3 ) ,  and concentrated in vacuo to give a tan oil. The 
oil was purified by column chromatography over silica gel (45 g) loaded with 
C H C I 3  and eluted with 1 column length 1:3 EtOAc/hexanes followed by 2:3 
EtOAc/hexanes to give a clear oil 57. The oil was pumped briefly and used in the 
next step without further purification: Rf = 0.33 (3:2 EtOAc/hexanes); 1H NMR 
( C D C I 3 ,  400 MHz) 5 1.44-1.85 (m, 4H), 2.08-2.35 (m, 3H), 2.37-2.87 (3m, 4H),
3.20 and 4.03 (2d, J = 13.2 Hz, 2H), 3.31 (s, 3H), 3.35 (m, 2H), 3.48 (q, J = 13.2 
Hz, 2H), 7.18-7.40 (m, 10H); 13C NMR (CDCI3, 100 MHz) 5 25.6, 26.1, 50.7,
52.8, 57.48, 57.53, 58.5, 59.3, 63.1, 72.9, 126.7, 126.9, 128.1, 128.9, 129.0,
138.2, 139.1.
2-(3-Methoxypropyl)-piperazine dihydrochloride (48). A solution of 1,4- 
dibenzyl-2-(3-methoxypropyl)-piperazine 57 in HPLC MeOH (20 mL) and HCI 
(12 M, 12.4 mmol, 1 mL) was treated with 5% Pd/C (0.21 g). The flask was 
sealed with a septum and a hydrogen balloon was bubbled through the stirred 
solution. The reaction mixture was filtered over a pad of Celite rinsing with
H2, 5% Pd/C
12 M HCI, MeOH
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MeOH and concentrated in vacuo to give a white solid 48 (0.50 g, 53% 2 steps): 
1H NMR (DMSO, 400 MHz) 5 1.40-1.85 (m, 4H), 2.92-3.62 (4m, 11H, overlapped 
singlet 3.21, 3H), 4.14 (bs, 1H), 9.79-10.31 (2bs, 4H); 13C NMR (DMSO, 100 
MHz) 6 24.3, 26.8, 39.3, 39.9, 43.4, 51.5, 57.9, 71.0.
•2  HCI H N ^  CIC(Ph>3, EI3N Hf ^ l
CH2CI2,0 ° C  H3c " '  h  ' cph3
H
3-(3-Methoxypropyl)-1-tritylpiperazine (49). A solution of 2-(3-methoxypropyl)- 
piperazine dihydrochloride 48 (0.44 g, 1.9 mmol) in dry CH2CI2 (16 mL) and dry 
EtaN (0.77 g, 1.1 mL, 7.6 mmol) at 0 °C, was treated with dropwise addition a 
solution of trityl chloride (0.53 g, 1.9 mmol) in dry CH2CI2 (5 mL). The ice bath 
was removed and the reaction stirred for 3 h at room temperature. The reaction 
mixture was transferred to a separatory funnel, diluted to 15 mL with CH2CI2. The 
organics were washed with saturated NaHCC>3 (25 mL) and brine (25 mL), dried 
(K2CC>3) and concentrated in vacuo to give an amorphous white foam 49 (7.3 g, 
99% yield): TLC Rf = 0.33 (1:9 MeOH/CH2CI2). The product was used without 
further purification, or characterization.
CPh,
n-BuLi, 2-chloroquinoline 
_______ Et2Q, 0 °C;
6 M HCI, acetone H,C
2-[2-(3-Methoxypropyl)-piperazin-1-yl]-quinoline (50). A cooled (0 °C) 
solution of 3-(3-methoxypropyl)-1-tritylpiperazine 49 (0.50 g, 1.24 mmol) in dry
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Et2 0  (20 mL) under argon, was treated by a dropwise addition of a solution of n- 
BuLi (0.51 mL, 2.45 M in hexanes, 1.24 mmol), giving a white precipitate. The 
resulting suspension was allowed to stir for 20 min. A solution of 2- 
chloroquinoline (0.14 g, 0.83 mmol) in dry Et2 0  (5 mL) was added dropwise to 
the cooled solution under argon to give a purple solution. The purple solution 
was allowed to stir for 20 min and the ice bath was removed. The reaction was 
allowed to stir overnight under argon giving a red-purple solution. The reaction 
was quenched by the addition of saturated NaHC 0 3  (20 mL). The organics were 
separated and the aqueous phase was extracted 1 x 20 mL with Et2 <D. The 
organic portions were combined, washed with water (50 mL), brine (50 mL), dried 
(K2 CO 3 ), and concentrated in vacuo to give an amorphous foam. The foam was 
purified by column chromatography over silica gel (50 g) loaded with CHCI3  and 
eluted with 1:3 EtOAc/hexanes to give a clear yellow oil. The trityl protected 
quipazine (not shown) was dissolved in acetone (3 mL) with stirring. To the 
stirred solution was added 6  M HCI (1 mL) giving an orange solution that slowly 
generated a white precipitate, stirring continued for 10 min. The reaction was 
diluted out to 25 mL with 1 M HCI, the crude aqueous mixture was extracted with 
CH2 CI2  (4 x 25 mL). The aqueous layer was brought to pH 14 with 4 M NaOH, 
and buffered to pH 10 with saturated NaHCOs. The aqueous layer was then 
extracted with CH2 CI2  (4 x 30 mL), dried (K2 CO 3 ), filtered, and concentrated in 
vacuo, giving a yellow oil 50 (0.36 g, 82%): TLC R f = 0 . 1  ( 1 :9 M eO H /C ^C h); 1H 
NMR (CDCI3 , 400 MHz) 5 1.50-1.70 (m, 2H), 1.72-2.00 (2m, 2H), 2.37 (bs, 1H), 
2.88 (dt, J = 3.2 and 12.0 Hz, 1H), 2.95-3.25 (m, 4H), 3.30 (s, 3H), 3.38 (m, 2H),
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4.38 (bd, 1H), 4.52 (bs, 1H), 6.94 (d, J = 9.1 Hz, 1H), 7.20 (ddd, J = 1.3 and 7.1 
Hz, 1H), 7.52 (ddd, J = 1.7 and 6.8 Hz, 1H), 7.58 (dd, J = 1.3 and 7.8 Hz, 1H), 
7.84 (d, J = 8.4 Hz, 1H); 13C NMR (CDCI3, 100 MHz) 6 24.7, 26.7, 40.0, 46.0,
47.9, 51.4, 58.6, 72.6, 109.3, 122.0, 122.8, 126.4, 127.1, 129.4, 137.4, 147.9,
157.0.
o 2n
h n o 3, h 2s o 4
NH RT°C NHH3C
H H3C H
2-[2-(3-Methoxypropyl)-piperazin-1-yl]-6-nitroquinoline ((±)-51). A cooled (0 
°C) stirred solution of 2-[2-(3-methoxypropyl)-piperazin-1-yl]-quinoline 50 (0.35 g,
1.2 mmol) in H2SO4 (16 M, 15 mL) was treated with HN03 (15.4 M, 0.32 mL) by 
dropwise addition. The resultant solution was allowed to stir for 20 min, then 
quenched by pouring onto ice. The acid was neutralized with 4 M NaOH to give 
a bright yellow solution. The resulting solution was buffered to pH 10 with sat. 
NaHC03. The aqueous solution was extracted with CH2CI2 until minimal yellow 
color persisted in the aqueous layer. The organics were dried (K2C03), and 
concentrated in vacuo to give a bright yellow oil (±)-51 (0.40 g, 99% yield): TLC 
Rf = 0.14 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 1.46-1.68 (m, 2H), 
1.78-2.00 (m, 2H), 1.92 (bs, 1H), 2.82 (dt, J = 3.6 and 12.0 Hz, 1H), 2.96 (dd, J =
3.9 and 12.3 Hz, 1H), 3.03-3.15 (m, 2H), 3.15-3.26 (m, 1H), 3.29 (s, 3H), 3.38 
(m, 2H), 4.45 (bd, 1H), 5.59 (bs, 1H), 7.01 (d, J = 9.4 Hz, 1H), 7.57 (d, J = 9.4 
Hz, 1H), 7.87 (d, J = 9.4 Hz, 1H), 8.24 (dd, J = 2.6 and 9.4 Hz, 1H), 8.47 (d, J =
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2.6 Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 25.6, 26.7, 40.1, 46.0, 48.1, 51.6, 
58.8, 72.7, 111.0, 121.1, 123.8, 124.4, 127.2, 138.8, 141.9, 151.8, 158.6; HRMS 
(ESI-TOF) m/z (M + H)+ calcd. for C 1 7 H2 3 N4 O 3  331.1770 found 331.1770.
o 2n o 2n
88% Formic acid
NH AC2O h 3ch 3c -
H H
N-Formyl-3-(3-methoxypropyl)-4-(6-nitroquinolin-2-yl)piperazine (60). A
solution of 2-[2-(3-methoxypropyl)-piperazin-1-yl]-6-nitroquinoline (±)-51 (0.19 g, 
0.58 mmol) in 88% formic acid (1.5 mL) was treated with acetic anhydride (Ac20 )  
(0.54 g, 0.5 mL, 5.2 mmol) and the reaction stirred for 30 min. The reaction was 
quenched by pouring onto ice, then brought to basic pH with 4 M NaOH, buffered 
to pH 10 with sat. NaHCC>3 . The basic portion was extracted with CH2CI2 ( 3 x 1 0  
mL). The organic portions were combined, dried (K2CC>3 ), and concentrated in 
vacuo to give 60 as a yellow oil (0.19 g, 91%): TLC R f  = 0.65 (1:9
MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) (1:1 mixture of amide rotamers) 5 
1.45-1.90 (m, 4H), 2.9 (dt, J = 4.2 and 12.6 Hz, 0.5H), 2.98 (dd, J = 3.9 and 13.3, 
0.5H), 3.14-3.43 (m, 7.5H), 3.44-3.51 (m, 0.5H), 3.58 (bd, 0.5H), 3.70 (bd, 0.5H), 
4.45 (bt, 1H), 4.74 (bs, 0.5H), 4.91 (bs, 0.5H), 7.70 (dd, J = 7.4 and 9.1 Hz, 1H), 
7.63 (d, J = 9.1 Hz, 1H), 7.98 (d, J = 9.4 Hz, 1H), 8.09 (s, 0.5H), 8.2 (s, 0.5H), 
8.28 (dd, J = 2.6 and 9.1 Hz, 1H), 8.51 (d, J = 2.6 Hz, 1H).
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o 2n o 2n
BBr3, CH2CI2
h 3c
H
Y °  -78 °c
H H
N-Formyl-3-(3-hydroxypropyl)-4-(6-nitroquinolin-2-yl)piperazine (61). A
solution of N-formyl-3-(3-methoxypropyl)-4-(6-nitroquinolin-2-yl)piperazine 60 
(0.19 g, 0.53 mmol) in dry CH2CI2 (25 mL) was cooled at -78 °C in a dry ice 
acetone bath. A solution of BBr3 (2.6 mL, 1 M in CH2CI2, 2.6 mmol, Aldrich) was 
added dropwise under argon giving a dark purple suspension. After 2 h the 
reaction was warmed to RT °C and stirred for 2.5 h giving a yellow-orange 
suspension. The reaction was quenched by the addition of sat. NaHC0 3  (20 mL), 
the organic portion was separated and the aqueous was extracted with CH2CI2 (3 
x 20 mL). The organic portions were combined, dried (K2C 03), filtered and 
concentrated in vacuo. The crude material was purified by column 
chromatography over silica gel (8 g) eluting with 4:1 EtOAc/CHCI3 to elute the 
bromide side product 62, followed by 1:19 MeOH/EtOAc to elute the product, 
concentration in vacuo gave 61 as a yellow foam (0.12 g, 66% yield): TLC R f =  
0.43 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) (mixture of amide
rotamers) 6 1.48-1.96 (m, 5H), 2.88-3.08 (m, 1H), 3.24-3.45 (m, 1.5H), 3.50 (dd, 
J = 3.9 and 13.6 Hz, 0.5H), 3.61 (bd, J = 13.3 Hz, 0.5H), 3.66-3.84 (m, 2.5H), 
4.24-5.15 (bm, 3H), 7.11 (d, J = 9.4 Hz, 1H), 7.76 (bs, 1H), 8.04 (d, J = 9.1 Hz, 
1H), 8.12 (s, 0.5H), 8.26 (s, 0.5H), 8.33 (dd, J = 2.6 and 9.4 Hz, 1H), 8.57 (d, J =
2.6 Hz, 1H).
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2-[2-(3-Hydroxypropyl)-piperazin-1-yl]-quinoline (147). A solution of N-formyl-
3-(3-hydroxypropyl)-4-(6-nitroquinolin-2-yl)piperazine 61 (0.029 g, 0.084 mmol) 
in THF (1 mL) was treated with H2SO4 (4 M, 0. 5 mL) and heated at 55 °C for 1 
hour. The reaction was quenched by pouring onto ice. The mixture was brought 
to a basic pH with 4 M NaOH, and buffered to pH 10 with sat. NaHC0 3 . The 
aqueous layer was extracted with CH2CI2 ( 3 x 1 0  mL), the organic portions were 
combined, dried (K2C03) and concentrated in vacuo to give 147 as yellow oil 
(0.021 g, 90%): 1H NMR (CDCI3, 400 MHz) 5 1.61 (m, 2H), 1.80 (m, 1H), 2.07 
(m, 1H), 2.49 (bs, 2H), 2.86 (td, J = 3.6 Hz, 12.3 Hz, 1H), 2.97 (dd, J = 3.9 Hz,
12.3 Hz, 1H), 3.04-3.18 (m, 2H), 3.27 (td, J = 3.6 Hz, 12.6 Hz, 1H), 3.74 (m, 2H),
4.20 (bd,1H), 4.74 (bs, 1H) 7.04 (d, J = 9.4 Hz, 1H), 7.67 (d, J = 9.4 Hz, 1H), 
7.93 (d, J = 9.4 Hz, 1H), 8.26 (dd, J = 2.6 Hz, 9.1 Hz, 1H), 8.49 (d, J = 2.6 Hz, 
1H); 13C NMR (CDCI3, 100 MHz) 524.7, 28.4, 41.1, 46.1, 47.7, 50.7, 62.4, 111.0,
120.9, 123.8, 124.1, 126.6, 138.7, 141.8, 151.4, 158.3; HRMS (ESI-TOF) m/z (M 
+ H)+ calcd. for C16H21N4O3 317.1614 found 317.1604.
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o 2n o 2n
Tosyl-CI, pyridine
H
CH2 CI2, 0 - RT °C
H X = OTs, Cl H
3-(4-Formyl-1-(6-nitroquinolin-2-yl)piperazin-2-yl)propyl-4- 
methylbenzenesulfonate (63). In an 8  mL vial a solution of N-formyl-3-(3- 
hydroxypropyl)-4-(6-nitroquinolin-2-yl)piperazine 61 (0.081 g, 0.24 mmol) in dry 
CH2CI2 (0.5 mL) and dry pyridine (0.029 g, 0.37 mmol) was cooled at 0 °C. To 
the solution was added tosyl chloride (0.062 g, 0.33 mmol). The vial was flushed 
with argon and sealed with a cap and Para film. The solution was allowed to stir 
at RT °C for 3 h. The crude reaction mixture was purified by column 
chromatography over silica gel (12 g) loaded with CHCI3, eluting with 1:1 
EtOAc/hexanes followed by 4:1 EtOAc/CHCI3 to give the product 63 as a yellow 
foam (0.060 g, 51% yield): TLC Rf = 0.71 (1:9 MeOH/ChbCb); Determined by 
NMR to be a 1:1 mixture of N-formyl-ProTos-NQP 63 and N-formyl-ProCI-NQP 
64. 1H NMR (CDCI3, 400 MHz) (mixture of amide rotamers) 5 1.70-2.02 (m, 8 H), 
2.44 (s, ArCH3, 3H), 2.90 (dt, J = 4.2 and 12.6, 1H), 3.03 (dd, J = 3.9 and 13.3 
Hz), 3.20-3.60 (m, 10H), 3.73 (bd, 1H), 4.30-4.70 (4m, 4H), 4.88 (bs, 1H), 5.10 
(bs, 1H), 7.07 (dd, J = 2.9 and 9.1 Hz, 2H), 7.33 (d, J = 7.8 Hz, 2H), 7.66 (dd, J =
4.5 and 9.4 Hz, 2H), 7.78 (d, J = 8.1 Hz, 2H), 8.03 (d, J = 9.4 Hz, 2H), 8.12 (s, 
1H), 8.26 (s, 1H), 8.31 (dd, J = 2.6 and 9.4 Hz, 2H), 8.55 (d, J = 2.6 Hz, 2H).
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N Y °  55 °c
H
F-
H
H
N-Formyl-3-(3-fluoropropyl)-4-(6-nitroquinolin-2-yl)piperazine (65). In an 8
mL vial a solution of 3-(4-formyl-1-(6-nitroquinolin-2-yl)piperazin-2-yl)propyl4- 
methylbenzenesulfonate 63 (0.056 g, 0.11 mmol) in dry THF (0.30 mL) was 
treated with a solution of TBAF (0.16 mL, 1 M in THF, 0.16 mmol, Aldrich) to give 
a dark orange solution. The vial was capped and heated at 55 °C for 2 h. The 
reaction was concentrated in vacuo and then dissolved in C H C I 3 .  The crude 
material was purified by column chromatography over silica gel (2  g) eluting with 
1:1 EtOAc/hexanes followed by 1:19 MeOH/EtOAc and concentrated in vacuo to 
give 65 as a yellow foam (0.025 g, 64%): TLC Rf = 0.22 (1:19 MeOH/EtOAc); 1H 
NMR ( C D C I 3 ,  400 MHz) (mixture of amide rotamers) 5 1.60-2.00 (m, 4H), 2.90 
(dt, J = 3.6 and 12.3 Hz, 0.5H), 3.00 (dd, J = 4.2 and 13.3 Hz, 0.5H), 3.20-3.40 
(2m, 2H), 3.44-3.62 (m, 1.5H), 3.72 (bd, 0.5H), 4.32-4.60 (m, 3H), 4.83 (bs, 
0.5H), 5.07 (bs, 0.5H), 7.07 (dd, J = 3.2 and 9.4 Hz, 1H), 7.69 (m, 1H), 8.03 (d, J 
= 9.1 Hz, 1H), 8.10 (s, 0.5H), 8.25 (s, 0.5H), 8.32 (dd, J = 2.6 and 9.1 Hz, 1H), 
8.56 (d, J = 2.3 Hz, 1H).
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2-(2-(3-Fluoropropyl)piperazin-1-yl)-6-nitroquinoline (58). A solution of N- 
formyl-3-(3-fluoropropyl)-4-(6-nitroquinolin-2-yl)piperazine 65 (0.025 g, 0.072
mmol) in THF (0.5 mL) was treated with H2SO4 (4 M, 0.25 mL) and heated at 60 
°C for 1 hour. The reaction was quenched by pouring onto ice. The mixture was 
brought to a basic pH with 4 M NaOH, and buffered to pH 10 with sat. NaHC0 3 . 
The aqueous layer was extracted with CH2CI2 ( 3 x 1 0  mL), the organic portions 
were combined, dried (K2CO3) and concentrated in vacuo to give 58 as yellow oil 
(0.021 g, 90%): TLC Rf = 0.35 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 
6  1.56-2.10 (2m, 5H, CH2CH2CH2F and NH), 2.91 (dt, J = 3.3 and 12.3 Hz, 1H),
3.06 (dd, J = 3.9 and 12.3 Hz, 1H), 3.14-3.38 (3m, 3H), 4.40-4.60 (2m, 2H, 
CH2F), 4.81 (bs, 1H), 7.04 (d, J = 9.4 Hz, 1H), 7.64 (d, J = 9.1 Hz, 1H), 7.99 (d, J 
= 9.4 Hz, 1H), 8.31 (dd, J = 2.6 and 9.4 Hz, 1H), 8.54 (d, J = 2.6 Hz, 1H).
ferf-Butyl-3-(3-hydroxypropyl)-4-(6-nitroquinolin-2-yl)piperazine-1- 
carboxylate (66). A solution of 2-[2-(3-Methoxypropyl)-piperazin-1-yl]-6- 
nitroquinoline 50 (0.16g, 0.48 mmol) in dry CH2CI2 (50 mL) was cooled at -78 °C
BBr3, CH2CI2, -78 °C;
NH [(CH3 )3 COCO]20 , CH2CI2> 0 °C
O.
*
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in a dry ice acetone bath. A solution of BBr3 (2.4 mL, 1 M in CH2CI2, 2.4 mmol) 
was added dropwise under argon giving a dark purple suspension. After 3 h the 
reaction was warmed to RT °C and stirred for an additional 4 h giving a yellow- 
orange suspension. The reaction was quenched by the addition of sat. NaHCC>3 
(20 mL). The organic layer was separated and the aqueous layer was extracted 
3 x 2 0  mL CH2CI2. The organic portions were combined, dried (K2CO3), filtered 
and concentrated in vacuo. The yellow semi-solid was transferred to a 50 mL 
flask with 0 .5:9.5 MeOH/ChfeCh and concentrated. The residue was treated with 
CH2CI2 (45 mL) sonicated to suspend all the material, then cooled to 0  °C and 
treated with di-ferf-butyl dicarbonate (0.1g, 0.48 mmol). After 2.5 h the reaction 
was warmed to RT °C and allowed to stir an additional hour. The solution was 
concentrated in vacuo (25 °C) and suspended in CHCI3. The crude material was 
purified by column chromatography over silica gel ( 8  g) eluting with 3:2 
EtOAc/hexanes, concentrated in vacuo to give 6 6  as a yellow foam (0.088 g, 
44% yield, 2 steps): TLC Rf = 0.29 (6:4 EtOAc/hexanes); 1H NMR (CDCI3, 400 
MHz) 5 1.40-1.94 (1 s and 2m, 13H), 2.90-3.22 (bm, 2H), 3.24-3.42 (m, 1H), 3.66- 
3.88 (bs, 2H), 3.94-4.34 (bm, 3H), 4.76 (bs, 1H), 7.04 (d, J = 9.2 Hz, 1H), 7.67 (d, 
J = 9.2 Hz, 1H), 7.95 (d, J = 9.5 Hz, 1H), 8.25 (dd, J = 2.6 and 9.5 Hz, 1H), 8.47 
(d, J = 2.6 Hz, 1H); 13C NMR (CDCI3, 100 MHz) (mixture of amide rotamers) 5 
24.9, 25.2, 28.3, 40.0, 42.7, 43.8, 44.4, 45.5, 50.7, 51.5, 62.2, 80.3, 111.1, 121.1, 
123.8, 124.1, 126.7, 139.0, 141.9, 151.1, 154.9, 158.1; HRMS (ESI-TOF) m/z (M 
+ H)+ calcd. for C21H29N4O5 417.2138 found 417.2132.
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Tosyl-CI, pyridine
H
*
O.
*
3-(4-(ferf-Butoxycarbonyl)-1-(6-nitroquinolin-2-yl)piperazin-2-yl)propyl 4- 
methylbenzenesulfonate (69). A solution of tert-butyl 3-(3-hydroxypropyl)-4-(6- 
nitroquinolin-2 -yl)piperazine-1 -carboxylate 6 6  (0.040g, 0.097 mmol) in dry CH2CI2 
(1 mL) and dry pyridine ( 6  drops from 18 gauge needle) in an 8  mL vial, was 
cooled to 0 °C. To the solution was added tosyl chloride (0.078 g, 0.41 mmol), 
the vial was flushed with argon and sealed with a cap and Parafilm. The solution 
was allowed to stir warming to RT °C overnight. The crude reaction mixture was 
diluted with CH2CI2 (5 mL), washed with sat. NaHCC>3 (5 mL), dried K2CO3, 
filtered and concentrated in vacuo. The crude material was purified by column 
chromatography over silica gel ( 1 2  g) loaded with CHCI3, eluting with 2:3 
EtOAc/hexanes, concentration in vacuo gave 69 as a yellow foam (0.042 g, 76% 
yield): TLC Rf = 0.37 (6:4 EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.47 
(s, 9H), 1.60-1.82 (bm, 4H), 2.41 (s, 3H), 2.80-3.30 (2bm, 3H), 3.92-4.44 (bm, 
2H), 4.76 (bs, 1H), 7.00 (d, J = 9.5 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.58 (d, J =
9.1 Hz, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 9.5 Hz, 1H), 8.26 (dd, J = 2.6 
and 9.2 Hz, 1H), 8.50 (d, J = 2.6 Hz, 1H); 13C NMR (CDCI3, 100 MHz) (mixture 
of amide rotamers) 5 21.6, 24.6, 25.5, 28.3, 39.5, 42.7, 43.8, 44.9, 46.1, 50.7,
51.0, 70.0, 80.3, 110.6, 121.0, 123.6, 124.2, 125.8, 127.1, 127.8, 129.8, 132.8,
139.0, 141.9, 144.8, 151.2, 154.8, 158.0; HRMS (ESI-TOF) m/z (M + H)+ calcd. 
for C28H35N4O7S 571.2226 found 571.2222.
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2-(2-(3-Fluoropropyl)piperazin-1-yl)-6-nitroquinoline (58). A solution of 3-(4- 
(terf-butoxycarbonyl)-1-(6-nitroquinolin-2-yl)piperazin-2-yl)propyl-4- 
methylbenzenesulfonate 69 (0.042 g, 0.074 mmol) in dry THF (1 mL) in an 8  mL 
vial was treated with a solution of TBAF (0.11 mL, 1 M in THF, 0.11 mmol, 
Aldrich) to give a dark orange solution. The vial was capped and heated at 55 °C 
for 3 h. The reaction was concentrated in vacuo and dissolved in CHCI3. The 
crude material was purified by column chromatography over silica gel ( 8  g) 
eluting with 2:3 EtOAc/hexanes to give the product as a yellow foam (0.025 g, 
79%). TLC Rf = 0.49 (3:2 EtOAc/hexanes). A portion (4 mg) of the purified N- 
Boc-PROF-NQP 70 was treated with H2SO4 (0.5 mL, 16 M) at RT °C and stirred 
for 4 min. The reaction was quenched by pipetting the mixture onto ice, then 
rinsing the vial with ice cold water. The aqueous solution was brought to a basic 
pH (persistent yellow color) with 4 M NaOH at 0 °C then buffered to pH 10 with 
saturated NaHC03. The aqueous solution was extracted with CH2CI2 ( 3 x 5  mL), 
the organic portions were combined, dried (K2CO3), filtered, and concentrated in 
vacuo. The crude material was purified over silica gel (1 g) loading with CHCI3 
and eluted with 1 :49 MeOH/CHCh followed by 1 :9 MeOH/CHCh to give the final 
amine product 58 as a yellow oil (0.002, 78% yield): TLC Rf = 0.22 (1:9
MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 1.56-2.10 (2m, 5H, CH2CH2CH2F
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and NH ) ,  2.91 (dt, J = 3.3 and 12.3 Hz, 1H), 3.06 (dd, J = 3.9 and 12.3 Hz, 1H),
3.14-3.38 (3m, 3H), 4.40-4.60 (2m, 2H, Ctf2F), 4.81 (bs, 1H), 7.04 (d, J = 9.4 Hz,
1H), 7.64 (d, J = 9.1 Hz, 1H), 7.99 (d, J = 9.4 Hz, 1H), 8.31 (dd, J = 2.6 and 9.4
Hz, 1H), 8.54 (d, J = 2.6 Hz, 1H).
6.3 Chiral Propyl N-formyl Series.
e  ©
G 0 2 M © EDC«HCI, pentafluorophenol 
N-Boc-N-Bn-glycine
Cl H3N : OO2M6
Et3 N, CH2 CI2
i II j-'
Bn O H CO2M6
(R)-N-Boc-N-Benzyl-glycyl-L-glutamate Dimethyl Ester ((R)-133). N-Ethyl-N- 
(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (1.4 g, 7.1 mmol) was 
suspended with stirring in C H 2 C I 2  (30 mL), to the suspension was added a 
solution of pentafluorophenol (PFP) (1.75 g, 9.5 mmol) in C H 2 C I 2  (10 mL) and 
stirred for 20 min. N-Boc-N-Benzyl glycine (1.6 g, 5.9 mmol) in C H 2 C I 2  (20 mL) 
was added to the stirred solution. The mixture was allowed to stir for 1 hour, and 
EtaN (3.0 mL) was added followed by D-glutamate dimethyl ester hydrochloride 
D-132 in C H 2 C I 2  (20 mL). The reaction was allowed to stir for 24 h at 21 °C. The 
crude reaction mixture was washed with 1 M Na2C0 3  (120 mL), 1 M citric acid 
(120 mL), and water (60 mL). The organic layer was dried (K2C0 3 ), filtered, and 
concentrated in vacuo. The crude material was purified by column 
chromatography over silica gel (50 g) loaded with C H C I 3 ,  eluting with 1:3 
EtOAc/hexanes (1 column length) followed by 2:3 EtOAc/hexanes to elute PFP 
and then 3:2 EtOAc/hexanes, concentration in vacuo to elute (R)-133 as a clear
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oil (2.19 g, 87%): TLC Rf = 0.69 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3> 400 MHz)
(S)-N-Boc-N-Benzyl-glycyl-L-glutamate Dimethyl Ester ((S)-133). Clear oil; 
(2.28 g, 91%).
Ethyl 3-((/?)-4-benzyl-3,6-dioxopiperazin-2-yl)propanoate ((/?)-134). A cooled 
(0 °C) stirred solution of (R)-N-Boc-N-Benzyl-glycyl-L-glutamate dimethyl ester 
(fl)-133 (2.2 g, 5.2 mmol) in methanol (30 mL, HPLC grade) was treated with 
thionyl chloride (3.2 g, 27.1 mmol) dropwise, then allowed to stir at 0 °C for 15 
min and at RT °C for 2 h. The reaction was concentrated in vacuo and then 
placed under high vacuum for 10 min to give a white foam. The foam was 
triturated with ether (2 x 30 mL). The resultant white oily semi-solid was placed 
under high vacuum overnight to give a white foam. The foam was dissolved in
5 1.48 (s, 9H), 1.87 (bs, 1H), 2.00-2.43 (2bs, 3H), 3.65 (s, 3H), 3.71 (s, 3H), 3.80 
(m, 1H), 4.39 (d, J = 15.5 Hz, 1H), 4.48-4.72 (m, 2H), 6.56 and 6.91 (2bs, 1H), 
7.12-7.40 (m, 5H); 13C NMR (CDCI3, 100 MHz) 5 50.5, 51.3, 51.7, 52.4, 81.3,
127.6, 128.1, 128.6, 137.1, 169.2, 171.7, 172.9.
The opposing enantiomer was similarly prepared:
B n  o  H
o
1)SOCI2, MeOH
2) NH4OH, MeOH
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methanol (60 mL, HPLC grade) and stirred. Ammonium hydroxide (12 mL, 177 
mmol, 28-30%) was added and the mixture was stirred for 24 h. The crude 
mixture was concentrated in vacuo to give a white solid. The solid was dissolved 
in sat. NaHC03 (50 mL) and 4:1 CHCI3/IPOH (50 mL), the organic layer was 
separated, and the aqueous layer was extracted with 4:1 CHCI3/IPOH (3 x 30 
mL). The organic portions were combined, dried (K2CO3), filtered, and 
concentrated in vacuo to give a clear oil (R)-134 (1.25 g, 84% yield), which 
required no further purification: TLC R f  = 0.39 (1:9 MeOH/Ch^Cb); 1H NMR 
(CDCI3, 400 MHz) 5 2.16 (m, 2H), 2.44 (m, 2H), 3.61 (s, 3H), 3.79 (q, J = 6.5 and 
17.8 Hz, 2H), 4.1 (bt, 1H), 4.54 (m, 2H), 7.14-7.42 (m, 5H), 7.85 (s, 1H); 13C 
NMR (CDCI3, 100 MHz) 5 29.0, 29.3, 48.7, 49.5, 51.8, 54.3, 128.0, 128.2, 128.8,
135.0, 165.4, 166.1, 173.1.
The opposing enantiomer was similarly prepared:
o
Ethyl 3-((S)-4-benzyl-3,6-dioxopiperazin-2-yl)propanoate ((S)-134). Clear oil; 
(1.30 g, 81%).
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o
EtO
O O
Bn
UAIH4i THF
0 °C reflux
HO
H
Bn
3-((R)-4-Benzylpiperazin-2-yl)propan-1-ol ((/?)-135). A stirred and cooled (0 
°C) suspension of LiAIH4 (0.93 g, 24.5 mmol) in dry THF (30 mL) under argon, 
was treated with a solution of ethyl 3-((f?)-4-benzyl-3,6-dioxopiperazin-2- 
yl)propanoate (/?)-134 (1.42 g, 4.89 mmol) in THF (30 mL) by syringe, 
maintaining a gentle effervescence. The reaction flask was fitted with a water- 
cooled condenser and the reaction was heated at reflux for 2 h. The mixture was 
allowed to cool to room temperature and stir overnight. The reaction was 
quenched by consecutive addition of water (0.8 mL), NaOH (1.7 mL, 4 M), then 
water (0.8 mL). The inorganic solids were vacuum filtered (Celite pad) and the 
rinsed with EtOAc. The filtrate was concentrated in vacuo, giving (/?)-135 as a 
clear oil (1.16 g, quantitative): TLC R f  = 0.06 (1:9 MeOH/C^Cb)- The product 
was used without further purification, or characterization.
The opposing enantiomer was similarly prepared:
3-((S)-4-Benzylpiperazin-2-yl)propan-1-ol ((S)-135). Clear oil; (1.04 g, 98%).
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o
AC2 0 A
HO.
Bn 8 8 % formic acid HO.
H Bn
H
(R)-4-Benzyl-2-(3-hydroxypropyl)piperazine-1 -carbaldehyde ((/?)-136). A
cooled (0 °C) solution of 3-((R)-4-benzylpiperazin-2-yl)propan-1-ol (/?)-135 (1.16 
g, 4.95 mmol) in formic acid (23 M, 12.5 mL) was treated dropwise with acetic 
anhydride (4.2 mL, 44.6 mmol). The solution was allowed to stir for 5 min at 0 
°C, then allowed to warm to room temperature and stir overnight. The reaction 
was quenched by pouring onto ice, and then basified with 4 M NaOH to pH 12. 
The resultant mixture was buffered to pH 10 with a saturated solution of 
NaHCC>3. The aqueous layer was extracted with CH2CI2, the organic portions 
were combined, dried (K2CO3), filtered and concentrated in vacuo, to give a light 
brown oil 1.25 g (89% crude yield). The crude material was purified by column 
chromatography over silica gel (50 g) loaded with CHCI3 and eluted with 0.3:9.7 
MeOH/CH2CI2 to elute (/?)-136 as a clear oil (0.81 g, 63%): TLC Rf = 0.22 (1:9 
MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 1.25-1.58 (m, 2 H), 1.60-1.86 (m, 
1H), 1.89-2.27 (m, 3H), 2.65-3.05 (m, 2H), 3.20-3.80 (m, 6 H), 4.05-4.55 (2m, 
1H), 7.15-7.50 (m, 5H), 8.00 (s, 1H); 13C NMR (CDCI3, 100 MHz) (mixture of 
amide rotamers) 5 26.0, 26.6, 28.7, 29.1, 36.3, 42.2, 48.1, 52.6, 53.5, 54.7, 55.3, 
56.6, 62.0, 62.3, 62.5, 127.2, 128.3, 128.7, 137.7, 161.0, 161.3.
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The opposing enantiomer was similarly prepared:
o
H
(S)-4-Benzyl-2-(3-hydroxypropyl)piperazine-1-carbaldehyde ((S)-136). Clear 
oil; (0.73 g, 73%).
(/?)-4-Benzyl-2-(3-methoxypropyl)piperazine-1-carbaldehyde ((/?)-137). A
cooled (0 °C) stirred solution of (R)-4-benzyl-2-(3-hydroxypropyl)piperazine-1- 
carbaldehyde (/?)-136 (0.81 g, 3.11 mmol) in dry DMF (50 mL) was treated with 
NaH powder (0.22 g, 9.3 mmol) in a portion-wise fashion, giving an off-white 
suspension. The resulting suspension was allowed to stir for 45 min at 0° C. To 
the suspension was added (dropwise) iodomethane (0.19 mL, 3.11 mmol) with 
stirring at 0 °C for 5 min and then RT °C for 2.5 h. The reaction was quenched 
by the addition of water (40 mL). The aqueous solution was extracted with Et2 0  
(3 x 30 mL) and EtOAc (15 mL). The organic portions were combined, dried 
(K2CO3), and concentrated in vacuo to give a tan oil. The crude material was 
purified by column chromatography over silica gel (30 g) loaded with CHCI3 
eluting with 0.3:9.7 MeOH/CH2CI2, concentration in vacuo gave (R)-137 as a 
clear oil (0.51 g, 59%): TLC Rf = 0.5 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 
MHz) 5 1.30-1.54 (m, 2H), 1.60-1.75 (m, 1H), 1.86-2.20 (m, 3H), 2.66-2.99 (m,
O O
A NaH, DMF, 0°C; A
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2.5H), 3.22-3.56 (m, 8.5H, singlet at 3.28, 3H), 4.13 (bd, 0.5H), 4.25 (bs, 0.5H), 
7.18-7.40 (m, 5H), 8.00 (s, 1 H); 13C NMR (CDCI3, 100 MHz) mixture of amide 
rotamers) 5 25.9, 26.1, 26.9, 36.2, 42.1, 47.9, 52.5, 53.6, 54.6, 55.3, 56.6, 58.3,
58.4, 62.5, 72.1, 127.1, 128.2, 128.6, 137.8, 160.8, 160.9.
The opposing enantiomer was similarly prepared:
o
 " " A % n
(S)-4-Benzyl-2-(3-methoxypropyl)piperazine-1-carbaldehyde ((S)-137). Clear 
oil; (0.30 g, 72%).
H N
4 M H2S 0 4 
THF, 50 - 60 °C
(/?)-1-Benzyl-3-(3-methoxypropyl)piperazine ((/?)-138). A stirred solution of 
(R)-4-benzyl-2-(3-methoxypropyl)piperazine-1-carbaldehyde (R)-137 (0.51 g, 1.8 
mmol) in THF (4 mL) was treated with H2SO4 (4 M, 9 mL). The flask was fitted 
with a water-cooled condenser and heated to 60° C for 3 h. The reaction was 
cooled to RT °C and poured into ice cold 4 M NaOH and then buffered to pH 10 
with sat. NaHCC>3. The aqueous layer was extracted with CH2CI2 (4 x 30 mL). 
The organic portions were combined, dried (K2CO3), filtered and concentrated in 
vacuo giving (/?)-138 as a light tan oil (0.42 g, 93%), product was used without 
further purification: TLC Rf = 0.05 (1:9 MeOH/C^Ch); 1H NMR (CDCI3, 400
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MHz) 6  1.30-1.47 (m, 2H), 1.50-1.68 (m, 2H), 1.72 (t, J = 10.4 Hz), 1.96 (bs, 1H),
2.03 (dt, J = 3.2 and 11.0 Hz), 2.70-2.84 (m, 3H), 2.84-3.00 (2m, 2H), 3.30 (s, 
3H), 3.31-3.39 (m, 2H), 3.49 (dd, J = 12.9 and 15.2 Hz), 7.20-7.35 (m, 5H); 13C 
NMR (CDCI3, 100 MHz) 5 26.0, 31.0, 45.8, 53.8, 54.8, 58.5, 59.8, 63.4, 72.6,
127.0, 128.2, 129.2, 138.0.
The opposing enantiomer was similarly prepared:
N" Bn
13 H
(S)-1-Benzyl-3-(3-methoxypropyl)piperazine ((S)-138). Light tan oil; (0.25 g, 
92%).
H2, 5% Pd/C * 2HCI
12 M HCI, MeOH^
H H
(f?)-2-(3-Methoxypropyl)-piperazine dihydrochloride ((f?)-48). Starting
material (R)-1-benzyl-3-(3-methoxypropyl)piperazine (/?)-138 (0.42 g, 1.7 mmol)
was dissolved in MeOH (50 mL, HPLC) with stirring. To the stirred solution was
added 12 M HCI (0.28 mL, 3.4 mmol), followed by 5% Pd/C (0.063 g). Flask was
sealed with a septum and H2 was bubbled through the suspension by balloon.
The reaction was filtered over a pad of Celite, rinsing with MeOH. The filtrate
was concentrated giving (R)-48 as a white salt (0.36 g, 93%). 1H NMR (DMSO,
400 MHz) 5 1.40-1.85 (m, 4H), 2.92-3.62 (4m, 11H), 3.18 (s, 3H), 4.14 (bs, 1H),
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9.79-10.31 (2bs, 4H). 13C NMR (DMSO, 100 MHz) 5 24.3, 26.8, 39.3, 39.9, 43.4,
51.5, 57.9, 71.0.
The opposing enantiomer was similarly prepared:
• 2HCI H N ^
h3Ĉ , ĥ nh
(S)-2-(3-Methoxypropyl)-piperazine dihydrochloride ((S)-48). White solid; 
(0.22 g, 95%).
• 2  HCI H N ^ I  CIC(Ph)3, Et3N
H3C ' ° ^ ^ NH CH2CI2> 0 °C H3C " ° ^ ^ ^ ^ N "CPh3
(/?)-3-(3-Methoxypropyl)-1-tritylpiperazine ((/?)-49). A stirred suspension of 
starting material (R)-2-(3-methoxypropyl)-piperazine dihydrochloride (/?)-48 
(0.36 g, 1.56 mmol) in dry CH2CI2 (15 mL) was treated with EtsN (0.87 mL, 6.25 
mmol) under argon, giving a clear solution. The solution was cooled at 0 °C and 
trityl chloride (0.44 g, 1.56 mmol) in CH2CI2 ( 1 0  mL) was added drop-wise. The 
reaction was stirred overnight allowing it to slowly warm to RT °C. The crude 
reaction mixture was then transferred to a separatory funnel and washed with 
sat. NaHCOs (1 x 50 mL), water (1 x 30 mL), and then brine (1 x 30 mL). The 
organic layer was dried (K2CO3), filtered and concentrated in vacuo, to give (/?)- 
49 as a white foam (0.60 g, 97%): TLC Rf= 0.33 (1:9 MeOH/CH2Cl2); The crude 
product was used directly in the next reaction without further purification or 
characterization.
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The opposing enantiomer was similarly prepared:
(S)-3-(3-Bethoxypropyl)-1-tritylpiperazine ((S)-49). White foam; (0.37 g, 97%).
(R)-2-[2-(3-Methoxypropyl)-piperazin-1-yl]-quinoline ((/?)-50). A stirred and 
cooled (0 °C) solution of (R)-3-(3-methoxypropyl)-1-tritylpiperazine (/?)-49 (0.60 
g, 1.51 mmol) in dry EtaO (25 mL) was treated with n-BuLi (0.67 mL, 2.25 M in 
hexanes, 1.51 mmol) under an atmosphere of argon, giving a cloudy suspension. 
After 20 min a solution of 2-chloroquinoline (0.17 g, 1.01 mmol) in dry Et2<D (10 
mL) was added drop-wise to give initially a orange solution. The mixture was 
allowed to stir for 20 min and the ice bath was removed. The solution then 
darkened to a red wine color over 2 h. The reaction was allowed to stir under 
argon (4 h), where the solution returned to an orange color. The reaction was 
quenched by the addition of saturated NaHCC>3 (50 mL). The aqueous phase 
was separated and the organic layer was washed with brine (30 mL). The 
organic phase was dried (K2CO3), and concentrated in vacuo to give a yellow 
amorphous foam. The foam was purified by column chromatography over silica 
gel (50 g) loaded with CHCI3 and eluting with 1:3 EtOAc/hexanes to give the
h 3c
H
CPh3
1)n-BuLi, 2-chloroquinoline 
Et2 0 , 0 °C;
2) 6  M HCI, acetone h3C NH
H
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intermediate 2-((R)-2-(3-methoxypropyl)-4-tritylpiperazin-1-yl)quinoline as a clear 
yellow oil (0.44 g, 83% yield).
The trityl protected quipazine (0.44 g, 0.55 mmol) was dissolved in 
acetone (3 mL) with stirring. To the stirred solution was added 6 M HCI (0.7 mL,
4.2 mmol) giving an orange solution that slowly generated a white precipitate, 
stirring continued for 10 min. The reaction was diluted out in 1 M HCI (50 mL), 
the crude aqueous mixture was extracted with CH2CI2 (4 x 25 mL). The aqueous 
layer was then basified to pH 14 with 4 M NaOH, and then buffered to pH 10 with 
saturated NaHCC>3. The aqueous layer was extracted with CH2CI2 (4 x 30 mL). 
The organic portions were combined, dried (K2CO3), filtered, and concentrated in 
vacuo, giving a yellow oil (/?)-50 (0.22 g, 90%; 75% 2 steps overall): TLC R f =  
0.1 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 1.50-1.70 (m, 2H), 1.72-
2.00 (2m, 2H), 2.37 (bs, 1H), 2.88 (dt, J = 3.2 and 12.0 Hz, 1H), 2.95-3.25 (m, 
4H), 3.30 (s, 3H), 3.38 (m, 2H), 4.38 (bd, 1H), 4.52 (bs, 1H), 6.94 (d, J = 9.1 Hz, 
1H), 7.20 (ddd, J = 1.3 and 7.1 Hz, 1H), 7.52 (ddd, J = 1.7 and 6.8 Hz, 1H), 7.58 
(dd, J = 1.3 and 7.8 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H); 13C NMR (CDCI3, 100 
MHz) 6 24.7, 26.7, 40.0, 46.0, 47.9, 51.4, 58.6, 72.6, 109.3, 122.0, 122.8, 126.4,
127.1, 129.4, 137.4, 147.9, 157.0.
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The opposing enantiomer was similarly prepared:
(S)-2-[2-(3-Methoxypropyl)-piperazin-1-yl]-quinoline ((S)-50). Yellow oil; (0.13 
g, 73% 2 steps).
(/?)-2-[2-(3-Methoxypropyl)-piperazin-1-yl]-6-nitroquinoline ((/?)-51). A
cooled (0 °C) stirred solution of (R)-2-[2-(3-methoxypropyl)-piperazin-1-yl]- 
quinoline (/?)-50 (0.22 g, 0.76 mmol) in H2SO4 (6 mL, 16 M) was treated dropwise 
with HNO3 (0.20 mL, 3.0 mmol, 15.4 M). The reaction was stirred at 0° C for 20 
min and quenched by pouring over ice. The solution was brought to pH 14 by the 
addition of 4 M NaOH giving a bright yellow solution, and then buffered to pH 10 
with saturated NaHC03 followed by extraction with CH2CI2, until no yellow color 
was brought into the organic layer. The organic portions were combined, dried 
(K2CC>3), filtered, and concentrated in vacuo to give a dark yellow oil (/?)-51 (0.25 
g, quantitative): [a]20D = -136° (c = 0.0016, CH2CI2); TLC Rf = 0.14 (1:9
MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 1.46-1.68 (m, 2H), 1.78-2.00 (m, 
2H), 1.92 (bs, 1H), 2.82 (dt, J = 3.6 and 12.0 Hz, 1H), 2.96 (dd, J = 3.9 and 12.3 
Hz, 1H), 3.03-3.15 (m, 2H), 3.15-3.26 (m, 1H), 3.29 (s, 3H), 3.38 (m, 2H), 4.45 
(bd, 1H), 5.59 (bs, 1H), 7.01 (d, J = 9.4 Hz, 1H), 7.57 (d, J = 9.4 Hz, 1H), 7.87 (d,
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J = 9.4 Hz, 1H), 8.24 (dd, J = 2.6 and 9.4 Hz, 1H), 8.47 (d, J = 2.6 Hz, 1H); 13C 
NMR (CDCIs, 100 MHz) 6 25.6, 26.7, 40.1, 46.0, 48.1, 51.6, 58.8, 72.7, 111.0,
121.1, 123.8, 124.4, 127.2, 138.8, 141.9, 151.8, 158.6.
The opposing enantiomer was similarly prepared:
02n
h
(S)-2-[2-(3-Methoxypropyl)-piperazin-1-yl]-6-nitroquinoline ((S)-51). Dark 
yellow oil; [a]20D = +132° (c = 0.0011, CH2CI2); (0.15 g, 98%).
6.4 Chiral Propyl N-Boc Series.
(R)-ferf-Butyl-4-benzyl-2-(3-hydroxypropyl)piperazine-1-carboxylate ((/?)- 
140). 3-((R)-4-benzylpiperazin-2-yl)propan-1-ol (R)-iZ5 (1.68 g, 6.41 mmol) in 
NaOH (3 M, 6.4 mL) and THF (2 mL) was treated with di-te/t-butyl dicarbonate 
(Boc20 )  (1.54 g, 7.05 mmol) in THF (6.4 mL) at 0 °C. The reaction was allowed 
to stir for 15 min then warmed to RT °C and stirred for 2.5 hrs forming a white 
solid. The reaction was concentrated in vacuo to remove the THF. The resulting 
aqueous layer was extracted with EtOAc, dried (Na2S0 4 ), filtered, and 
concentrated. The crude material was purified by column chromatography over 
silica gel (80 g) loaded with CHCI3 and then elution using 2:3 EtOAc/hexanes to
BoC20, NaOH(aq)
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remove nonpolar impurities, followed by 3:2 EtOAc/hexanes, then flushed with 
EtOAc to elute (/?)-140 as a clear oil (0.94 g, 40%); TLC R f = 0.40 (6:4 
EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.43 (bs, 11H), 1.71 (bm, 1H), 
1.84-2.14 (3m, 3H), 2.68 (bd, J = 11.4 Hz, 1H), 2.75 (bd, J = 11.0 Hz, 1H), 3.06 
(bm, 1H), 3.46 (dd, J = 13.2 and 53.5, 2H, CH2-AxAr), 3.65 (m, 2H, CH2OH), 3.86 
(bs, 1H), 4.09 (bs, 1H), 7.18-7.40 (m, 5H); 13C NMR (CDCI3, 100 MHz) 5 26.2, 
28.4, 29.3, 39.1 (broad), 50.6 (broad) 53.4, 55.8, 63.0, 63.1, 79.8, 127.0, 128.2,
128.7, 138.2, 154.8.
The opposing enantiomer was similarly prepared:
Boo' n^
H
(S)-fe/t-Butyl-4-benzyl-2-(3-hydroxypropyl)piperazine-1-carboxylate ((S)-
140). Clear oil; (0.87 g, 42%).
NaH, CH3I 
% n DMF, 0°C  H3 < r °
H
(f?)-ferf-Butyl-4-benzyl-2-(3-methoxypropyl)piperazine-1-carboxylate ((/?)-
141). A stirred solution of (R)-ferf-butyl 4-benzyl-2-(3-hydroxypropyl)piperazine-
1-carboxylate (f?)-140 (0.89 g, 2.7 mmol) in dry DMF (15 mL) was treated with 
NaH powder (0.13 g, 5.3 mmol) at 0 °C and stirred for an additional 30 min. The 
resulting alkoxide intermediate was treated with CH3I at 0 °C and then allowed to 
warm to RT °C overnight. The reaction was quenched by the addition of water
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(15 mL) followed by the addition of sat. NaHC0 3  (15 mL). The aqueous layer was 
extracted with Et20, dried (K2C 03), filtered, and concentrated in vacuo. The 
crude material was purified by column chromatography over silica gel (35 g) 
loaded with CHCI3, eluting with 1:3 EtOAc/hexanes (1 column length) followed by 
2:3 EtOAc/hexanes to elute (R)-141 as a clear oil (0.63 g, 6 8 %): TLC R f = 0.55 
(6:4 EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.44 (s, 11H), 1.6 6  (bm, 1H),
1.80-2.12 (3m, 3H), 2.66 (bd, J = 11.4 Hz, 1H), 2.73 (bd, J = 10.6 Hz, 1H), 3.04 
(bm, 1H), 3.13 (s, 3H), 3.33-3.41 (m, 3H), 3.50 (d, J = 13.2 Hz, 1H, CH2Ar), 3.87 
(bs, 1H), 4.04 (bs, 1H), 7.20-7.36 (m, 5H); 13C NMR (CDCI3, 100 MHz) 5 26.2,
26.3, 28.4, 38.6 (broad), 51.2 (broad), 53.2, 55.7, 58.4, 62.8, 72.5, 79.3, 126.9,
128.1, 128.7, 138.2, 154.7.
The opposing enantiomer was similarly prepared:
(S)-ferf-Butyl-4-benzyl-2-(3-methoxypropyl)piperazine-1-carboxylate ((S)- 
141). Clear oil; (0.61 g, 70%).
(R)-1-Benzyl-3-(3-methoxypropyl)piperazine ((/?)-138). A stirred solution of 
(R)-tert- butyl 4-benzyl-2-(3-methoxypropyl)piperazine-1 -carboxylate (R)-141 
(0.58 g, 1.67 mmol) in THF (2 mL) was treated with H2S0 4  (4 M, 4 mL) and was
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allowed to stir at RT °C overnight. The reaction was cooled at 0 °C and treated 
with NaOH (4 M) then buffered to pH 10 with sat. NaHC0 3 - The aqueous layer 
was extracted with CH2CI2 (2 x 10 mL) and 4:1 CHCI3/IPOH (15 mL). The organic 
portions were combined, dried (K2C 03), filtered and concentrated in vacuo to 
give (/?)-138 as a clear oil (0.36 g, 87%): TLC Rf = 0.05 (1:9 MeOH/CH2CI2); 1H 
NMR (CDCI3, 400 MHz) 6  1.24-1.41 (m, 2H), 1.43-1.70 (m, 4H), 1.97 (dt, J = 3.7 
and 11.0 Hz, 1H), 2.64-2.94 (4m, 5H), 3.26 (s, 3H), 3.31 (m, 2H, CH2OCH3), 3.44 
(dd, J = 2.2 and 13.2 Hz, 2H, CH2.ABAr), 7.16-7.30 (m, 5H); 13C NMR (CDCI3, 
100 MHz) 6  25.8, 31.0, 45.7, 53.8, 54.6, 58.4, 59.9, 63.3, 72.5, 126.8, 128.0,
129.0, 137.9.
The opposing enantiomer was similarly prepared:
HN
H3C ^  I1. Bn
d H
....
(S)-1-benzyl-3-(3-methoxypropyl)piperazine ((S)-138). Clear oil; (0.32 g, 
80%).
N N
n-BuLi, 2-chloroquinoline 
‘Bn Et2 0 , 0 - RT °C
2-((/?)-4-Benzyl-2-(3-methoxypropyl)piperazin-1-yl)quinoline ((R)-142). A
stirred solution of (R)-1-benzyl-3-(3-methoxypropyl)piperazine (/?)-138 (0.17 g, 
0.69 mmol) in dry Et2 0  (20 mL) at 0 °C was treated with /i-BuLi (0.3 mL, 2.27M in
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hexanes, 0.69 mmol) giving a yellow-orange solution. The solution was allowed 
to stir at 0 °C for 20 min, then treated with a solution of 2-chloroquinoline in Et20 
(4 mL) to give an orange solution that was allowed to stir for 30 min. The mixture 
was warmed to RT °C and stirred overnight. The reaction was quenched by the 
addition water (10 mL). The organic portion was separated and washed with sat. 
NaHCC>3 (10 mL) and brine (10 mL). The organic layer was dried (K2CO3), 
filtered, and concentrated in vacuo. The crude material was purified by column 
chromatography over silica gel (8 g) loaded with CHCI3, eluting with 1:9 
EtOAc/hexanes (1 column length) followed by 1:3 EtOAc/hexanes, concentration 
in vacuo gave (/?)-142 as a light yellow oil (0.094 g, 55%): TLC R f=  0.35 (4:6 
EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.42-1.62 (m, 2H), 1.74-1.88 (m, 
1H), 1.92-2.08 (m, 1H), 2.14-2.32 (m, 2H), 2.82-3.04 (m, 2H), 3.20-3.50 (m, 7H, 
overlapped singlet at 3.30, 3H), 3.57-3.69 (d, 1H), 4.32-4.62 (bm, 2H), 6.92 (d, J 
= 9.2 Hz, 1H), 7.15-7.75 (m, 9H), 7.84 (d, J = 9.2 Hz, 1H); 13C NMR (CDCI3, 100 
MHz) 5 25.6, 26.6, 39.8, 51.9, 53.4, 55.0, 58.4, 62.8, 72.7, 109.3, 121.8, 122.6,
126.3, 127.0, 128.2, 128.8, 129.3, 137.2, 138.4, 147.9, 156.7.
The opposing enantiomer was similarly prepared:
2-((S)-4-Benzyl-2-(3-methoxypropyl)piperazin-1-yl)quinoline ((S)-142). Light 
yellow oil; (0.26, 80%).
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2-((R)-4-(2-Nitrobenzyl)-2-(3-methoxypropyl)piperazin-1-yl)quinoline and 2- 
((/?)-4-(4-Nitrobenzyl)-2-(3-methoxypropyl)piperazin-1-yl)quinoline mixture 
((/?)-143). A cooled (0 °C) stirred solution of 2-((f?)-4-benzyl-2-(3-
methoxypropyl)piperazin-1 -yl)quinoline (R)-142 (0.30 g, 0.80 mmol) in H2S0 4 (16 
M, 4 mL) was treated (dropwise) with HNO3 (15.4 M, 0.16 mL). The mixture was 
allowed to stir for 20 min. The reaction was quenched by pouring onto ice. The 
acid was neutralized with 4 M NaOH to give a bright yellow solution, and the 
resulting solution was buffered to pH 1 0  with sat NaHCC>3 and extracted with 
CH2CI2 until minimal yellow color persisted in the aqueous layer. The organics 
were dried (K2COs), and concentrated in vacuo to give a bright yellow oil (R)-143 
(0.022 g, 84% yield). The crude material was purified by column 
chromatography over silica gel (3 g) loaded with CHCI3 and eluting with 1:3 
EtOAc/hexanes followed by 2:3 EtOAc/hexanes, concentration in vacuo gave 
(R)-143 as a yellow oil (0.34 g, 92%)(mixture of regioisomers): TLC 0.21 (4:6 
EtOAc/hexanes): 1H NMR (CDCI3, 400 MHz) 5 1.40-1.52 (m, 2H), 1.80-2.08 (m, 
2H), 2.20-2.32 (m, 2H), 2.80-3.00 (bm, 2H), 3.29 (s, 3H), 3.32-3.40 (m, 2H), 3.49- 
3.73 (dd, J = 13.9 and 60.8 Hz, 2H, CH2.AMAr), 4.57 (bd, 2H), 7.03 (d, J = 9.5 Hz, 
1H), 7.46-7.64 (m, 2H), 7.70 (d, J = 7.7 Hz, 1H), 7.92 (d, J = 9.2 Hz, 1H), 8.10- 
8.30 (m, 3H), 8.50 (d, J = 2.9 Hz, 1H); 13C NMR (CDCI3, 100 MHz) (mixture of 
BnN02 regioisomers) 5 26.2, 26.5, 39.8, 51.9, 53.4, 55.1, 58.6, 61.8, 72.5, 110.8,
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120.9, 122.3, 123.4, 123.6, 124.2, 127.0, 129.3, 134.7, 138.6, 140.6, 141.7, 
148.4, 151.6, 158.2.
The opposing enantiomer was similarly prepared:
2-((S)-4-(2-Nitrobenzyl)-2-(3-methoxypropyl)piperazin-1-yl)quinoline and 2- 
((S)-4-(4-Nitrobenzyl)-2-(3-methoxypropyl)piperazin-1-yl)quinoline mixture 
((S)-143). Yellow oil; (0.30 g, 94%).
0,N
N N
-frN 02
HqC
Ace-CI, DCE 
0 - 80 °C;
MeOH, 80 °C
OoN
H ,C
‘N
H H
(/?)-2-[2-(3-Methoxypropyl)-piperazin-1-yl]-6-nitroquinoline ((/?)-51). To a
cooled (0 °C) stirred solution of 2-((/?)-4-(2 and 4-nitrobenzyl)-2-(3- 
methoxypropyl)piperazin-1-yl)quinoline (R)-143 (0.25 g, 0.54 mmol) in 1,2- 
dichloroethane (12 mL) was added dropwise 1-Chloroethyl chloroformate (Ace- 
CI) (0.3 g, 2.2 mmol) under argon. After the addition the reaction was stirred at 
80 °C for 3 h, then cooled giving a yellow precipitate and concentrated in vacuo. 
The residue was dissolved in MeOH (10 mL) and heated at 70 °C for 3 h. The 
crude reaction mixture was concentrated in vacuo and the residue was taken up 
in 1 M HCI and then extracted with CH2CI2 ( 3 x 1 0  mL). The resulting aqueous
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layer was brought to basic pH with 4 M NaOH and then buffered to pH 10 with 
sat. NaHCOa. The basic phase was extracted with CH2CI2 (3 x 15 mL), the 
organic portions were combined, dried (K2CO3), and concentrated in vacuo. The 
crude material was purified by flash chromatography (Biotage). The column was 
eluted by a 3 segment gradient elution; segment 1: 10% - 25% EtOAc/hexanes 
over 120 mL, segment 2: 25% - 100% EtOAc/hexanes over 120 mL, segment 3: 
100% EtOAc over 120 mL. The fractions containing product were combined and 
concentrated in vacuo to give (/?)-51 as a yellow foam (0.087 g, 49%): TLC Rf = 
0.14 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 1.46-1.68 (m, 2H), 1.78-
2.00 (m, 2H), 1.92 (bs, 1H), 2.82 (dt, J = 3.6 and 12.0 Hz, 1H), 2.96 (dd, J = 3.9 
and 12.3 Hz, 1H), 3.03-3.15 (m, 2H), 3.15-3.26 (m, 1H), 3.29 (s, 3H), 3.38 (m, 
2H), 4.45 (bd, 1H), 5.59 (bs, 1H), 7.01 (d, J = 9.4 Hz, 1H), 7.57 (d, J = 9.4 Hz, 
1H), 7.87 (d, J = 9.4 Hz, 1H), 8.24 (dd, J = 2.6 and 9.4 Hz, 1H), 8.47 (d, J = 2.6 
Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 25.6, 26.7, 40.1, 46.0, 48.1, 51.6, 58.8,
72.7, 111.0, 121.1, 123.8, 124.4, 127.2, 138.8, 141.9, 151.8, 158.6.
The opposing enantiomer was similarly prepared:
2-((S)-4-(2 and 4-nitrobenzyl)-2-(3-methoxypropyl)piperazin-1-yl)quinoline 
((S)-51). Yellow foam; (0.11, 62%).
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6.5 Racemic n-PROP-NQP Synthesis.
Bn
n-BuLi, [(Ph)3 P+Et]Br
THF, 0 °C Bn
H H
1,4-Dibenzyl-2-(prop-1-enyl)piperazine (149). A stirred suspension of ethyl 
triphenylphosphonium bromide (2.73 g, 7.34 mmol) in dry THF (15 mL) was 
cooled at 0° C and then treated with n-BuLi (2.9 mL, 7.28 mmol) giving an 
orange-red suspension. The mixture was stirred for one hour at 0° C. 1,4- 
dibenzyl-piperazine-2-carbaldehyde 44 (1.06 g, 3.64 mmol) in dry THF (4 mL) 
was added dropwise to the ylide solution. The reaction was allowed to warm to 
RT° C and stirred for 18 h. The reaction was quenched with water (20 mL). The 
solvent (THF) was removed in vacuo, and then treated with sat. NaHC0 3  (20 
mL). The aqueous phase was extracted with CH2CI2 ( 4 x 1 5  mL), the organic 
portions were combined, dried (K2CO3) and concentrated in vacuo to give a 
white/tan semi-solid (3.5 g). The crude material was purified by column 
chromatography over silica gel (80 g) loaded with CHCI3 and eluting with 2:3 
EtOAc/hexanes followed by 3:2 EtOAc/hexanes, concentration in vacuo gave 
149 as a light tan oil (0.78 g, 71%, 2 steps overall): TLC Rf = 0.57 (3:2 
EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.68 (dd, J = 1.8 and 7.0 Hz, 
3H), 1.98-2.25 (m, 3H), 2.60-2.78 (m, 3H), 3.08 and 4.06 (2d, J = 13.2 Hz, 2H), 
3.27 (dt, J = 2.9 and 9.5 Hz, 1H), 3.50 (dd, J = 13.2 and 38.5, 2H), 5.43 (bt, J =
9.5 Hz, 1H), 5.58-5.70 (m, 1H), 7.12-7.38 (m, 10H); 13C NMR (CDCI3, 100 MHz) 
5 13.6, 51.2, 52.8, 58.1, 58.3, 58.8, 62.9, 126.7, 126.9, 127.2, 128.0, 128.1,
129.1, 129.2, 131.4, 137.9, 138.8.
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2-Propylpiperazine dihydrochloride (150). 5% Pd/C (1.2 g) was added to a 
stirred solution of 1,4-dibenzyl-2-(prop-1-enyl)piperazine 149 (0.78 g, 2.6 mmol) 
in MeOH (25 mL) and HCI (0.45 mL, 12 M, 5.4 mmol) with stirring. The flask was 
sealed with a septum and hydrogen gas was bubbled through the solution at 
atmospheric pressure. The reaction mixture was filtered over a pad of Celite. 
The pad was rinsed with MeOH and concentrated in vacuo to give 150 (0.48 g, 
92%) as a white solid: 1H NMR (D20, 400 MHz) 5 0.76 (t, J = 7.3, 3H), 1.18-1.32 
(m, 2H), 1.46-1.60 (m, 2H), 3.02 (dd, J = 12.1 Hz, 1H), 3.18-3.30 (m, 2H), 3.39- 
3.49 (m, 1H), 3.51-3.61 (m, 3H); 13C NMR (D20, 100 MHz) 5 12.8, 17.5, 32.0,
40.1,40.5,44.5, 52.6.
3-Propyl-1-tritylpiperazine (151). To a stirred solution of 2-propylpiperazine 
dihydrochloride 150 (0.48 g, 2.4 mmol) in dry CH2CI2 (12 mL) under argon was 
added dry Et3N (1.3 mL, 9.5 mmol). The solution was cooled at 0° C, and trityl 
chloride (0.64 g, 2.28 mmol) in dry CH2CI2 (5 mL) was added drop-wise. Once 
the addition was complete the ice bath was removed and the reaction stirred 
overnight at room temperature. The reaction mixture was washed with saturated 
NaHC03 (75 mL), water (75 mL), and then brine (75 mL). The organic portions
CIC(Ph)3, Et3N
CH2 CI2, 0 °C
H
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were combined, dried (K2C 03), and concentrated in vacuo to give 151 (0.84 g, 
99% yield) as a white amorphous foam. The crude material was used without 
further purification or spectroscopic characterization: TLC Rf = 0.15 (1:9 
MeOH/CH2CI2).
2-(2-Propylpiperazin-1-yl)quinoline (152). A solution of 3-propyl-1- 
tritylpiperazine 151 (0.85 g, 2.28 mmol) in dry Et20  (30 mL) cooled at 0° C, was 
treated with n-BuLi (dropwise)(0.93 mL, 2.45 M in hexanes), generating a light 
orange solution. The solution was allowed to stir for 20 min. A solution of 2- 
chloroquinoline (0.25 g, 1.52 mmol) in dry Et20  (5 mL) was added drop-wise to 
the lithium amide. The resulting mixture was allowed to stir for 1 h at 0 °C then 
the ice bath was removed. The reaction was allowed to warm to RT °C and stir 
for 4 h, giving a brown colored solution. The reaction was quenched with 
saturated NaHCOa (30 mL). The organic layer was separated, and then washed 
with water (20 mL) and brine (20 mL). The organic portion was dried (K2C 03), 
filtered, and concentrated in vacuo to give a white foam. The foam was purified 
by column chromatography over silica gel (45 g) loaded with CHCI3 and eluted 
with 1:9 EtOAc/hexanes to give the N-trityl protected product as a clear yellow oil 
(0.54 g, 71% yield). The oil was dissolved in Acetone (8 mL) and HCI (6 M, 2.5 
mL), the mixture was allowed to stir 20 min. The reaction mixture was diluted 
with 1 M HCI (20 mL) and extracted with CH2CI2 (4 x15 mL), the aqueous layer
n-BuLi, 2-chloroquinoline 
Et20 , 0 °C;
6  M HCI, acetone
H
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was basified to pH 12 with 4 M NaOH and then buffered to pH 10 with saturated 
NaHCOs. The aqueous layer was then extracted with CH2CI2 ( 4 x 1 5  mL), dried 
with K 2 C O 3 ,  and concentrated in vacuo to give 152 (0.18 g, 64%) as a light 
yellow oil: 1H NMR ( C D C I 3 , 400 MHz) 5 0.93 (t, J  = 7.3 Hz, 3H), 1.20-1.46 (m, 
2H), 1.60-1.72 (m, 1H), 1.76-1.90 (m, 2H), 2.81-2.91 (m, 1H), 2.96-3.22 (m, 4H), 
4.34-4.46 (bm, 2H), 6.93 (d, J  = 9.2 Hz, 1H), 7.2 (m, 1H), 7.5 (m, 1H), 7.57 (d, J  
= 8.1 Hz, 1H), 7.66 (d, J  = 8.4 Hz, 1H), 7.85 (d, J  = 9.2 Hz, 1H).
2-(2-propylpiperazin-1-yl)-6-nitroquinoline (52). A stirred solution of 2-(2- 
propylpiperazin-1-yl)quinoline 152 (0.16 g, 0.64 mmol) in H2SO4 (16 M, 4 mL) 
was cooled at 0° C. To the cooled solution was added HNO3 (15.4 M, 0.17 mL) 
(dropwise). The reaction was stirred for 20 min, then quenched pouring onto ice. 
The acid was neutralized with 4 M NaOH to give a bright yellow solution, and the 
resulting solution was buffered to pH 10 with sat NaHC03. The aqueous solution 
was extracted with CH2CI2 until minimal yellow color persisted in the aqueous 
layer. The organic portions were combined, dried (K2CO3), and concentrated in 
vacuo to give a bright yellow oil 52 (0.20 g, quantitative yield): TLC Rf = 0.11 (1:9 
MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 0.94 (t, J = 7.3 Hz, 3H), 1.20-1.42 
(m, 2H), 1.63-1.91 (2m, 3H), 2.83 (dt, J = 3.3 and 12.1 Hz, 1H), 3.00-3.24 (m, 
4H), 4.50 (bs, 2H), 7.00 (d, J = 9.5 Hz, 1H), 7.57 (d, J = 9.2 Hz, 1H), 7.89 (d, J =
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9.2 Hz, 1H), 8.24 (dd, J = 2.6 and 9.2 Hz, 1H), 8.47 (d, J = 2.6 Hz, 1H); 13C NMR 
(CDCI3, 100 MHz) 6 14.0, 19.7, 30.7, 40.3, 46.2, 48.2, 51.8, 110.8, 120.7, 123.5,
124.1, 126.8, 138.4, 141.5, 151.6, 158.4; HRMS (ESI-TOF) m/z (M + H)+ calcd. 
for C16H21N4O2 301.1665 found 301.1655.
6 . 6  Racemic Pent-NQP Series.
n
n-BuLi, (Et0 )2 P(0 )CH2 (CH)2C0 2Et
< V ^ N' Bn--------------------1 Et°T H THF, 0 °C
H O
Ethyl 5-(1,4-dibenzylpiperazin-2-yl)penta-2,4-dienoate (76). A stirred solution
of n-BuLi (2.45 M, 5.6 mL in hexanes, 13.6 mmol) in dry THF (20 mL) was
treated with triethylphosphonocrotonate (2.8 g, 13.6 mmol) at 0 °C under argon,
to give a yellow solution. After 30 min a solution of the 1,4-dibenzyl-piperazine-2-
carbaldehyde 44 (2.0 g, 13.6 mmol) in dry THF (10 mL) was added dropwise to
the cooled ylide solution, and stirring was maintained for 45 min. The reaction
mixture was allowed to warm to room temperature, stir for 20 h. The reaction
was quenched by the addition of water (15 mL) and concentrated in vacuo to
remove THF. The resulting aqueous layer was treated with 20 mL of sat.
NaHCCh and extracted with Et2<D (3 x 30 mL). The combined organic extracts
were washed with brine (20 mL), dried ( K 2 C O 3 )  and concentrated in vacuo, to
give an orange oil. The crude oil was purified by column chromatography over
silica gel (70 g) loaded with C H C I 3  and eluting with 1:3 EtOAc/hexanes followed
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by 2:3 EtOAc/hexanes to give 76 as a light tan oil (1.8 g, 6 6 % 2 steps overall): 
TLC Rf = 0.36 (4:6 EtOAc/Hexanes); 1H NMR (CDCI3> 400 MHz) 5 1.29 (t, J =
7.1 Hz, 3H), 2.08-2.32 (2m, 3H), 2.60-2.80 (m, 3H), 3.00-3.18 (2m, 2H, 
overlapped doublet at 3.11, J = 13.6 Hz, 1H, C/-/2-AxAr), 3.49 (s, 2H, C/-/2Ar), 3.94 
(d, J = 13.6 Hz, 2H, CH2Ar), 4.20 (q, J = 7.1 Hz, 2H), 5.85 (d, J = 15.2 Hz, 1H), 
6.08-6.24 (m, 1H), 6.37 (dd, J = 11.0 and 15.2 Hz, 1H), 7.18-7.48 (m, 11H, 
overlapped, 10H Ar); 13C NMR (CDCI3, 100 MHz) 5 14.3, 50.7, 52.9, 58.5, 59.5,
60.3, 62.8, 63.6, 121.1, 126.9, 127.0, 128.1, 128.2, 128.9, 129.1, 130.7, 137.8,
138.4, 143.5, 143.8, 166.9.
H2, 5% Pd/C
ISL --------------------- ► EtO
H Bn AcOH, MeOH
Ethyl 5-(1,4-dibenzylpiperazin-2-yl)pentanoate (77). To a solution of ethyl 5- 
(1,4-dibenzylpiperazin-2-yl)penta-2,4-dienoate 76 (1.6 g, 4.1 mmol) in HPLC 
grade MeOH (20 mL) and acetic acid (1.2 g, 20.5 mmol) was added 5% Pd/C 
(0.32 g). The reaction flask was sealed with a septum, fitted with hydrogen 
balloon and a bleed needle. One balloon of hydrogen was bubbled through the 
stirred solution; the bleed needle was removed and a second balloon was 
attached and the reaction was stirred overnight. The reaction was filtered over a 
pad of Celite, the pad was rinsed with MeOH and the filtrate was concentrated in 
vacuo. The resulting oil was dissolved in CH2CI2, basified with 4 M NaOH and 
then buffered to pH 10 with sat. NaHC03. The organic layer was separated and 
the aqueous layer was extracted with CH2CI2 ( 3 x 1 0  mL). The organic portions
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were combined, dried (K2CO3) and concentrated in vacuo. The crude oil was 
purified by column chromatography over silica gel (60 g) loaded with CHCI3 and 
eluted 1.5 column lengths with 1:3 EtOAc/hexanes followed by 2:3 
EtOAc/hexanes to give the product 77 after concentration as clear oil (3.5 g, 
78%): product was visualized in two different TLC solvent systems; Rf = 0.27 
(2:3 EtOAc/Hexanes) and Rf = 0.6 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 
MHz) 5 1.16-1.50 (m, 5H, overlapped triplet at 1.25, J = 7.1 Hz, 3H, 
C02CH2CH3), 1.52-1.76 (m, 4H), 2.10-2.80 (m, 9H), 3.20 (d, J = 13.2 Hz, 1H, 
CH2.AxAr), 3.49 (dd, J = 13.2 and 41.7 Hz, 2H, CH2.AMAr), 4.00 (d, J = 13.2 Hz, 
1H, CH2.AxAr), 4.12 (q, J = 7.1 Hz, 2H, C 0 2CH2CH3), 7.18-7.45 (m, 10H); 13C 
NMR (CDCI3, 100 MHz) 5 14.2, 25.0, 25.4, 29.3, 34.2, 50.7, 52.8, 57.5, 57.6,
59.4, 60.1, 63.0, 126.7, 126.8, 128.1, 128.8, 128.9, 138.2, 139.0, 173.5.
5-(1,4-Dibenzylpiperazin-2-yl)pentan-1-ol (78). A solution ethyl 5-(1,4- 
dibenzylpiperazin-2-yl)pentanoate 77 (1.0 g, 2.5 mmol) in dry ether (20 mL) was 
treated at 0  °C with portions LiAIH4 powder (0 .1 2  g, 3.0 mmol), then placed under 
an atmosphere of argon. The ice bath was removed and the reaction was 
allowed to stir for 35 min at 25 °C. The reaction was quenched by the 
consecutive addition of H20  (0.12 mL), NaOH (0.24 mL 4 M), and H20  (0.12 mL). 
The inorganic salts were filtered over a pad of Celite and the pad was rinsed with 
EtOAc. The filtrate was concentrated in vacuo to give 78 (2.8 g, 95%): TLC R f =
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0.06 (2:3 EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.20-1.45 (m, 4H),
1H, CH2-AxAr), 3.49 (dd, J = 13.2 and 44.0 Hz, 2H, CH2.AMAr), 3.58-3.64 (bm,
1,4-Dibenzyl-2-(5-methoxypentyl)piperazine (79). A stirred solution of 5-(1,4- 
dibenzylpiperazin-2-yl)pentan-1-ol 78 (0.69 g, 2.0 mmol) in dry DMF (10 mL) at 0 
°C was treated with NaH powder (0.14 g, 5.9 mmol) to give a turbid white 
suspension. The flask was placed under argon and stirring was continued for 30 
min. lodomethane (0.30 g, 2.1 mmol) was added dropwise to the cooled 
solution. The reaction was allowed to stir on ice for 30 min, followed by stirring at 
room temperature for 3.5 h. The reaction was quenched by the addition of water 
(20 mL) followed by sat. NaHC03 (20 mL). The aqueous layer was extracted with 
Et20  (4 x 10 mL). The organic portions were combined, dried (K2C0 3 ), and 
concentrated in vacuo to give a tan oil. The oil was purified by column 
chromatography over silica gel (30 g) loaded with CHCI3 and eluted with 2:3 
EtOAc/hexanes to give 79 after concentration as a clear oil (0.44 g, 60%): TLC 
Rf = 0.39 (2:3 EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.22-1.48 (m, 4H), 
1.52-1.70 (m, 4H), 2.08-2.32 (m, 3H), 2.40-2.78 (3m, 4H), 3.20 (d, J = 13.2 Hz,
1.48-1.68 (m, 5H), 2.10-2.28 (m, 3H), 2.40-2.76 (m, 4H), 3.20 (d, J = 13.2 Hz,
2H), 4.00 (d, J = 13.2 Hz, 1H, CH2.AxAr), 7.20-7.35 (m, 10H); 13C NMR (CDCI3, 
100 MHz) 5 25.3, 26.2, 29.6, 32.6, 50.8, 52.7, 57.5, 59.5, 62.5, 63.0, 126.7,
126.9, 128.0, 128.9, 129.0, 137.9, 138.9(1 unresolved peak).
H
DMF, 0 °C
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1H, C/-/2-AxAr), 3.32-3.40 (m, 5H, overlapped singlet, 3.33, 3H, OCH3), 3.49 (dd, J 
= 13.2 and 43.6 Hz, 2H, CH2.AMAr), 4.02 (d, J = 13.2 Hz, 1H, CH2.AxAr), 7.20-7.40 
(m, 10H); 13C NMR (CDCI3, 100 MHz) 6  25.4, 26.6, 29.0, 29.5, 50.8, 52.8, 57.6,
58.5, 59.6, 63.0, 72.0, 72.7, 126.6, 126.8, 128.0, 128.9, 129.0, 138.2, 139.0.
H2, 5% Pd/C
N„
•2  HCI H N ^
Bn 12 M HCI, MeOH H3C
H
2-(5-Methoxypentyl)piperazine dihydrochloride (80). A solution of 1,4- 
dibenzyl-2-(5-methoxypentyl)piperazine 79 (0.23 g, 0.64 mmol) in HPLC grade 
MeOH (14 mL) and HCI (12 M, 1.92 mmol, 0.16 mL) was treated with 5% Pd/C 
(0.07 g). The flask was sealed with a septum and a balloon of hydrogen was 
bubbled through the stirred solution. The reaction mixture was filtered over a pad 
of Celite rinsing with MeOH and concentrated in vacuo to give a white solid 80 
(0.17 g, quantitative).
• 2 HCI H N ^ ^ i CIC(Ph)3, Et3N H N " ^
H3C ' ° ^ ^ ^ NH CH2CI2i 0 °C H3C ' ° v X 'Vs^ v X £ 'N- ' 'N 'C Ph 3 
H H
3-(5-Methoxypentyl)-1-tritylpiperazine (81). A solution of 2-(5-
methoxypentyl)piperazine dihydrochloride 80 (0.38 g, 1.5 mmol) in dry CH2CI2
(10 mL) and dry Et3N (0.59 g, 0.81 mL, 5.8 mmol) at 0 °C, was treated dropwise
with a solution of trityl chloride (0.41 g, 1.5 mmol) in dry CH2CI2 (5 mL). The ice
bath was removed and the reaction stirred for 20 h at room temperature. The
reaction mixture was transferred to a separatory funnel and diluted to 15 mL with
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CH2CI2. The organic portion was washed with saturated NaHC03 (25 mL), brine 
(25 mL). The organic portion was dried (K2C 03), filtered, and concentrated in 
vacuo to give an amorphous white foam 81 (0.62 g, 99% yield): TLC 0.34 (1:9 
MeOH/CH2CI2); 3-(5-Methoxypentyl)-1-tritylpiperazine 81 was used without 
further purification, or spectroscopic characterization.
N
1)n-BuLi, 2-chloroquinoline 
Et20 , 0 °C
CPh3 2) 6  M HCI, acetone .0.
H3C
2-(2-(5-Methoxypentyl)piperazin-1-yl)quinoline (82). A stirred solution of 3-(5- 
methoxypentyl)-1-tritylpiperazine 81 (0.40 g, 0.93 mmol) in dry Et20  (25 mL) at 0 
°C was treated with n-BuLi (0.38 mL, 2.45M in hexanes, 0.93 mmol) giving a pale 
orange-white suspension. The solution was allowed to stir at 0 °C for 20 min, 
then treated with a solution of 2-chloroquinoline (0.10 g, 0.62 mmol) in Et20  (4 
mL) to give an orange-white suspension. The mixture was allowed to stir for 30 
min, then warmed to RT °C and stirred overnight. The reaction was quenched by 
the addition water (10 mL). The organic portion was separated and washed with 
sat. NaHC03 (10 mL) and brine (10 mL). Then the organic layer was dried 
(K2C03), filtered, and concentrated in vacuo. The crude material was purified by 
column chromatography over silica gel (30 g) loaded with CHCI3 and eluted with 
1:9 EtOAc/hexanes to give the N-trityl protected product as a light yellow oil (0.23 
g, 6 6 %). TLC Rf = 0.57 (2:3 EtOAc/Hexanes). The product oil was dissolved in 
acetone ( 8  mL) and HCI ( 6  M, 4 mL) and allowed to stir (20 min). The reaction 
was diluted with 1 M HCI (20 mL) and extracted with CH2CI2 (4 x15 mL). The
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aqueous layer was brought to pH 12 with 4 M NaOH and then buffered to pH 10 
with saturated NaHC0 3 . The aqueous layer was extracted with CH2CI2 ( 4 x 1 5  
mL), dried with K2CO3 , and concentrated in vacuo to give 82 as a light yellow oil 
(0.11 g, 8 8 %, 58% 2 steps overall): 1H NMR (CDCI3, 400 MHz) 5 1.18-1.42 (m, 
4H), 1.44-1.58 (m, 2H), 1.60-1.72 (m, 1H), 1.76-1.90 (m, 1H), 2.11 (bs, 1H), 2.84 
(m, 1H), 2.94-3.18 (m, 4H), 3.24-3.34 (m, 5H, overlapped singlet, 3.28, 3H, 
OCH3), 4.38 (bd, 2H), 6.90 (d, J = 9.5 Hz, 1H), 7.18 (t, J = 8.06 Hz, 1H), 7.50 (t, J 
= 8.4 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 9.2 
Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 26.0, 26.4, 27.7, 29.4, 40.1, 46.0, 47.8, 
51.7, 58.4, 72.6, 109.3, 121.9, 122.7, 126.3, 127.0, 129.3, 137.2, 147.9, 157.0.
0 2N
h 2s o 4, h n o 3 
 ►
' NH 0  °C x0.
H3C"
2-(2-(5-Methoxypentyl)piperazin-1-yl)-6-nitroquinoline ((±)-83). A stirred 
solution of 2-(2-(5-methoxypentyl)piperazin-1-yl)quinoline 82 (0.11 g, 0.36 mmol) 
in H2SO4 (16 M, 4 mL) was cooled at 0° C. HNO3 (15.4 M, 0.09 mL) was added 
drop-wise, and the reaction stirred for 20 min at 0 °C. The reaction was 
quenched by pouring onto ice, the acid was neutralized with 4 M NaOH to give a 
bright yellow solution, and the resulting solution was buffered to pH 10 with sat. 
NaHCOs. The yellow aqueous solution was extracted with CH2CI2 until no yellow 
color was extracted into the organic layer. The organics were dried (K2C 03), 
filtered and concentrated in vacuo to give a bright yellow oil (±)-83 (0.13 g,
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quantitative yield): TLC Rf = 0.16 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 
MHz) 5 1.26-1.46 (m, 4H), 1.50-1.60 (m, 2H), 1.71-1.96 (m, 2H), 2.06 (bs, 1H), 
2.85 (dt, J = 3.6 and 12.3 Hz, 1H), 2.98 (dd, J = 3.6 and 12.3 Hz, 1H), 3.06-3.26 
(m, 3H), 3.29 (s, 3H), 3.33 (m, 2H), 4.52 (bs, 2H), 7.01 (d, J = 9.1 Hz, 1H), 7.61 
(d, J = 9.4 Hz, 1H), 7.93 (d, J = 9.4 Hz, 1H), 8.27 (dd, J = 2.6 and 9.4 Hz, 1H), 
8.51 (d, J = 2.6 Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 26.0, 26.2, 28.2, 29.4,
40.3, 46.1, 48.0, 51.8 58.4, 72.5, 110.7, 120.7, 123.4, 124.1, 126.8, 138.4, 141.4,
151.6, 158.3; HRMS (ESI-TOF) m/z (M + H)+ calcd. for C i9H27N40 3  359.2083 
found 359.2086.
N N '^ ' j
8 8 % formic acid 
Ac20
H,C H,C
N-Formyl-3-(5-methoxypentyl)-4-(6-nitroquinolin-2-yl)piperazine (84). A
stirred solution of 2-(2-(5-methoxypentyl)piperazin-1-yl)-6-nitroquinoline (±)-83 
(0.049 g, 0.14 mmol) in 8 8 % formic acid (0.35 mL) was treated with Ac20  (0.13 g, 
0.12 mL, 1.23 mmol) and the reaction was stirred for 30 min. The reaction was 
quenched by pouring onto ice, then brought to basic pH with 4 M NaOH, buffered 
to pH 10 with sat. NaHCOs, and then extracted with CH2CI2 ( 3 x 1 0  mL). The 
organic portions were combined, dried (K2COs), and concentrated in vacuo to 
give 84 as a yellow oil (0.053 g, 97%): TLC Rf = 0.55 (1:9 MeOH/CH2CI2).
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o K1 o2n
BBr3, CH2CI2
H3C'
N Br- Nr °H H
H
N-Formyl-3-(5-bromopentyl)-4-(6-nitroquinolin-2-yl)piperazine (85). A
solution of N-formyl-3-(5-methoxypentyl)-4-(6-nitroquinolin-2-yl)piperazine 84 
(0.038 g, 0.098 mmol) in dry CH2CI2 ( 8  mL) was cooled at -78 °C in a dry ice, 
acetone bath. A solution of BBr3 (0.59 mL, 1M in CH2CI2, 0.59 mmol) was added 
dropwise under argon giving a deep purple suspension. The reaction was 
allowed to warm to RT °C while stirring overnight, giving a tan suspension. The 
reaction was quenched by the addition of sat. NaHC03 (20 mL). The organic 
layer was separated and the aqueous was extracted with CH2CI2 (3 x 2 0  mL). 
The organic portions were combined, dried (K2C 03), filtered and concentrated in 
vacuo. The crude material was purified by column chromatography over silica 
gel (3 g) eluting with 4:1 EtOAc/CHCI3 to give 85 as a yellow oil (0.40 g, 93% 
yield): TLC Rf = 0.48 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) (mixture 
of amide rotamers) 5 1.25-1.90 (m, 8 H), 2.86-2.95 (m, 0.5H), 2.99 (dd, J = 4.2 
and 13.3 Hz, 0.5H), 3.16-3.39 (m, 4H), 3.44-3.60 (m, 1H), 3.68-3.75 (bm, 0.5H), 
4.40-4.52 (m, 1.5H), 4.70 (bs, 0.5H), 4.91 (bs, 0.5H), 7.06 (dd, J = 3.2 and 9.4 
Hz, 1H), 7.66 (d, J = 9.1 Hz, 1H), 8.01 (d, J = 9.4 Hz, 1H), 8.10 (s, 0.5H), 8.24 (s, 
1H), 8.30 (dd, J = 2.6 and 9.1 Hz, 1H), 8.54 (d, J = 2.6 Hz, 1H); 13C NMR 
(CDCI3, 100 MHz) (mixture of amide rotamers) 5 25.0, 25.2, 27.8, 28.0, 28.2,
32.3, 33.6, 33.7, 38.6, 39.6, 39.7, 42.3, 45.1, 47.9, 50.9, 51.5, 110.7, 121.2,
123.8, 124.2, 127.2, 139.1, 142.1, 151.1, 158.0, 161.3.
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o2n o 2n
AgOTs, CH3CN
Br- N 65 °C
H
TsO.
H
H
5-(4-Formyl-1-(6-nitroquinolin-2-yl)piperazin-2-yl)pentyl 4-methylbenzene- 
sulfonate (8 6 ). A cooled (0 °C) stirred solution of N-formyl-3-(5-bromopentyl)-4- 
(6-nitroquinolin-2-yl)piperazine 85 (0.040 g, 0.092 mmol) in dry acetonitrile (ACN) 
(0.5 mL) was treated with silver tosylate (AgOTs) (0.051 g, 0.18 mmol) giving a 
clear solution. The solution was stirred for 5 min at 0 °C, 4 h at 25 °C, and 4 h at 
65 °C, forming a silvery-black precipitate. The reaction was cooled and filtered 
over cotton, rinsing with ACN and concentrating in vacuo. The crude material 
was purified over silica gel (4 g) loading with CHCI3 and eluting with 2:3 
EtOAc/hexanes followed by 4:1 EtOAc/CHCI3, concentration in vacuo gave 8 6  as 
a yellow oil (0.042 g, 8 8 %): 1H NMR (CDCI3, 400 MHz) 5 1.21-1.49 (m, 4H),
1.51-1.80 (m, 4H), 2.43 (s, 3H), 2.84-3.02 (m, 1H), 3.12-3.26 (bm, 1H), 3.27-3.39 
(m, 0.5H), 3.42-3.60 (m, 1H), 3.65-3.77 (m, 0.5H), 3.91-4.02 (m, 2H), 3.36-4.51 
(m, 1.5H), 4.69 (bs, 0.5H), 4.86 (bs, 0.5H), 7.00-7.10 (m, 1H), 7.31 (d, J = 8.1 Hz, 
2H), 7.61-7.68 (bm, 1H), 7.74 (d, J = 8.1 Hz, 2H), 7.96-8.04 (m, 1H), 8.08 (s, 
0.5H), 8.23 (s, 0.5H), 8.25-8.32 (m, 1H), 8.52 (bs, 1H).
171
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
o 2n o 2n
TBAF, THF
TsO.
H
N
5 5  ° c
H
F-
H
Nr°
H
N-Formyl-3-(5-fluoropentyl)-4-(6-nitroquinolin-2-yl)piperazine (87). In an 8
mL vial a solution of 5-(4-formyl-1-(6-nitroquinolin-2-yl)piperazin-2-yl)pentyl 4- 
methylbenzene-sulfonate 8 6  (0.042 g, 0.080 mmol) in dry THF (0.4 mL) was 
treated with TBAF (0.12 mL, 1 M in THF, 0.12 mmol) to give a dark orange 
solution. The vial was capped and heated at 55 °C for 3.5 h. The reaction was 
cooled then concentrated in vacuo and dissolved in CHCI3. The solution was 
purified by column chromatography over silica gel (4 g) eluting with 3:2 
EtOAc/hexanes followed by 4:1 EtOAc/CHCh, concentration in vacuo gave 87 as 
a yellow oil (0.025 g, 84%): 1H NMR (CDCI3, 400 MHz) (mixture of amide 
rotamers) 5 1.26-1.82 (m, 8 H), 2.85-3.04 (2m, 1H), 3.15-3.39 (m, 1.5H), 3.43- 
3.63 (m, 1H), 3.67-3.77 (m, 0.5H), 4.06-4.18 (m, 1H), 4.30-4.37 (m, 0.5H), 4.40- 
4.54 (m, 2H), 4.71 (bs, 0.5H), 4.90 (bs, 0.5H), 7.00-7.10 (m, 1H), 7.66 (d, J = 9.1 
Hz, 1H), 8.01 (d, J = 9.1 Hz, 1H), 8.10 (s, 0.5H), 8.25 (s, 0.5H), 8.31 (dd, J = 2.6 
and 9.1 Hz, 1H), 8.54 (d, J = 2.6 Hz, 1H); 13C NMR (CDCI3, 100 MHz) (mixture 
of amide rotamers) 6  24.9, 25.06, 25.12, 25.6, 25.7, 28.1, 28.2, 28.3, 30.0, 30.2,
38.6, 39.5, 39.6, 39.8, 42.4, 45.2, 47.9, 51.0, 51.6, 83.0, 84.6, 110.7, 123.8,
124.2, 127.3, 139.1, 142.2, 151.2, 158.1, 161.4.
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2-(2-(5-Fluoropentyl)piperazin-1-yl)-6-nitroquinoline (8 8 ). A solution of N- 
formyl-3-(5-fluoropentyl)-4-(6-nitroquinolin-2-yl)piperazine 87 (0.025 g, 0.067 
mmol) in THF (0.25 mL) was treated with H2SO4 (16 M, 0.75 mL) and heated at 
60 °C for 2 h. The reaction was quenched by pouring onto ice, the solution was 
brought to a basic pH with 4 M NaOH, and buffered to pH 10 with sat. NaHC0 3 - 
The aqueous layer was extracted with CH2CI2 ( 3 x 1 0  mL), the organic portions 
were combined, dried (K2C 03), filtered and concentrated in vacuo to give 88 as 
yellow oil (0.021 g, 91%): 1H NMR (CDCI3, 400 MHz) 5 1.25-2.04 (m, 9H), 2.85 
(dt, J = 3.6 and 12.0 Hz, 1H), 2.98 (dd, J = 3.9 and 12.3 Hz, 1H), 3.06-3.28 (m, 
3H), 3.4703.64 (m, 1H), 4.35 (m, 0.5H), 4.42-4.66 (m, 2.5H), 7.01 (d, J = 9.4 Hz, 
1H), 7.61 (d, J = 9.4 Hz, 1H), 7.93 (d, J = 9.4 Hz, 1H), 8.27 (dd, J = 2.6 and 9.4 
Hz, 1H), 8.51 (d, J = 2.6 Hz, 1H).
6.7 Chiral Pent-NQP Series.
o o
Methyl (f?)-3-(1,4-dibenzyl-3,6-dioxopiperazin-2-yl)propanoate ((R)-145). A
stirred solution of methyl (R)-3-(4-benzyl-3,6-dioxopiperazin-2-yl)propanoate (/?)-
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134 (1.3 g, 4.6 mmol) in dry DMF (50 mL) at 0 °C was treated consecutively with 
BU4NI (0.68 g, 1.9 mmol), benzyl bromide (0.83 g, 4.9 mmol), and NaH (0.12 g, 
4.9 mmol). The flask was sealed with a septum and placed under an atmosphere 
of argon. The reaction was allowed to stir for 1 hour at 0 °C, then at 25 °C 
overnight. The reaction was quenched by the cautious addition of water (50 mL), 
then buffered to pH 10 using sat. NaHC03 (30 mL). The aqueous layer was 
extracted with Et20  (3 x 30 mL) and EtOAc (2 x 30 mL). The organic portions 
were combined, washed with water (30 mL) followed by brine (30 mL), dried 
(K2CO3), filtered, and concentrated in vacuo. The oil was purified by column 
chromatography over silica gel (90 g) loaded with CHCI3 and eluted with 0.4:19.6 
MeOH/CHCl3 to give a clear oil (/?)-145 (1.57 g, 89%): Product was visualized by 
two separate TLC solvent systems; R f  = 0.29 (6:4 EtOAc/Hexanes) or Rf = 0.73 
(1:9 MeOH/CHCIs); 1H NMR (CDCI3, 400 MHz) 5 1.98-2.10 (m, 1H), 2.16-2.28 
(m, 1H), 2.32-2.50 (m, 2H), 3.66 (s, 3H), 3.84 (d, J = 17.5 Hz, 1H, CH2.AJAr), 
3.92-4.02 (m, 3H), 4.42 (d, J = 14.6, 1H, CH2.AMAr), 4.69 (d, J = 14.6 Hz, 1H, 
CH2.AMAr), 5.26 (d, J = 14.9 Hz, 1H, CH 2-ax ), 7.18-7.40 (m, 10H); 13C NMR 
(CDCI3, 100 MHz) 6  26.5, 29.0, 46.9, 48.9, 49.4, 51.9, 58.2, 128.0, 128.1, 128.2,
128.8, 128.9, 135.1, 135.4, 163.9, 165.5, 172.6.
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The opposing enantiomer was similarly prepared:
o
Bn' u \
B0Y ^ " h c N'Bno o
Methyl (S)-3-(1,4-dibenzyl-3,6-dioxopiperazin-2-yl)propanoate ((S)-145).
Clear oil; (1.62 g, 93%).
(S?)-3-(1,4-Dibenzylpiperazin-2-yl)propan-1-ol ((/?)-56). A stirred suspension of 
UAIH4 (0.86 g, 22.6 mmol) in dry THF (90 mL) at 0° C was treated with a solution 
of methyl (R)3-(1,4-dibenzyl-3,6-dioxopiperazin-2-yl)propanoate (/?)-145 (1.57 g,
4.1 mmol ) in THF (20 mL) by syringe under argon maintaining a gentle 
effervescence. The reaction flask was fitted with a water-cooled condenser and 
the reaction was heated at reflux for 2 h. The solution was allowed to cool to 
room temperature and stir overnight. The reaction was quenched by consecutive 
addition of water (0.84 mL), NaOH (1.7 mL 4 M), and then water (0.84 mL). The 
inorganic solids were filtered off with a pad of Celite and the pad was rinsed with 
EtOAc. The filtrate was concentrated in vacuo, giving a clear oil (R)-56 (1.2 g, 98 
% crude). The oil was purified by column chromatography over silica gel (50 g) 
loaded with CHCI3 and eluted one column length with 0.4:19.6 MeOH/CHCl3 
followed by 1:19 MeOH/CHCl3, concentrated to give a clear oil (/?)-56 (1. 2 g,
o
Reflux
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92%): TLC Rf = 0.3 (1:9 MeOH/CHCI3); 1H NMR (CDCI3> 400 MHz) 5 1.52-1.95 
(3m, 4H), 2.12-2.37 (2m, 3H), 2.48-2.80 (3m, 4H), 3.20 and 4.19 (2d, J = 12.8, 
2H), 3.48 (dd, J = 17.9 and 13.2 Hz), 3.66 (m, 2H), 7.20-7.40 (m, 10H); 13C NMR 
(CDCI3i 100 MHz) 5 27.6, 28.6, 50.5, 52.2, 56.4, 57.8, 59.4, 62.8, 63.0, 126.9,
127.1, 128.1, 128.3, 129.0, 129.3, 137.8, 138.0.
The opposing enantiomer was similarly prepared:
Bn,
T i 
"L % „
(S)-3-(1,4-Dibenzylpiperazin-2-yl)propan-1-ol ((S)-56). Clear oil; (1.16 g, 
90%).
DMSO, (COCI) 2 Bn, N
-  N'Bn CH2CI2,E t3N ,-78«C  
H H H
(R)-3-(1,4-Dibenzylpiperazin-2-yl)propanal ((/?)-89). A solution of DMSO (0.33 
g, 4.3 mmol) and dry CH2CI2 (1 mL) was added dropwise to a solution of oxalyl 
chloride (2 M in CH2CI2, 1.1 mL, 2.1 mmol) in dry CH2CI2 (5 mL) at -78 °C (dry 
ice, acetone bath). After 5 min, a solution of (R)-3-(1,4-dibenzylpiperazin-2- 
yl)propan-1-ol (R)-56 (0.63 g, 1.9 mmol) in dry CH2CI2 (3 mL) was added 
dropwise. The mixture was allowed to stir for an additional 20 min. The reaction 
was treated with Et3N (0.98 g, 9.7 mmol), forming a tan precipitate. The 
suspension was allowed to stir for 5 min, then the reaction was warmed to room 
temperature and stirred for 1 hour. The reaction was quenched by the addition of
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water (25 mL). The organic layer was separated and the aqueous layer was 
extracted with an additional 15 mL of CH2CI2. The organic portions were 
combined, washed with saturated NaHC03 (20 mL), dried (K2C 03) and 
concentrated in vacuo. The aldehyde (/?)-89 was used in the next step without 
further purification: TLC R f=  0.54 (2:3 EtOAc/hexanes).
The opposing enantiomer was similarly prepared:
BrUN ^
H H
(S)-3-(1,4-Dibenzylpiperazin-2-yl)propanal ((S)-89). Used directly in the 
subsequent Horner-Emmons olefination.
n-BuLi, Triethylphosphono- BrUN ^ Y
l h  acetate, THF, 0 °C Y  H
H O
Ethyl (f?)-5-(1,4-dibenzylpiperazin-2-yl)pent-2-enoate ((R)-146). A stirred
solution of n-BuLi (2.25 M in hexanes, 2.6 mL, 5.9 mmol) in dry THF (10 mL) at 0
°C was treated with triethylphosphonoacetate (1.3 g, 5.9 mmol) under argon, to
give a light yellow solution. After 30 min, a solution of (R)-3-(1,4-
dibenzylpiperazin-2-yl)propanal (/?)-89 (0.6 g, 2.0 mmol) in dry THF (3 mL) was
added dropwise to the original solution. The reaction mixture was allowed to
warm to room temperature and was stirred for 20 h. The reaction was quenched
by the addition of water (25 mL) and concentrated in vacuo to remove the THF.
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The aqueous layer was treated with 20 mL of sat. NaHC03 and extracted with 
Et20  ( 3 x 1 5  mL) and EtOAc ( 1 x 1 5  mL). The organic fractions were combined, 
washed with brine (20 mL), dried (K2C 03), filtered and concentrated in vacuo. 
The resulting orange oil was purified by column chromatography over silica gel 
(30 g) loaded with CHCI3 and eluted with 3:2 EtOAc/hexanes and concentration 
in vacuo to give (/?)-146 as a light tan oil (0.46 g, 60% 2 steps overall): TLC R f =  
0.33 (3:2 EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.29 (t, J = 7.1 Hz, 3H), 
1.62-1.88 (bm, 2H), 2.06-2.34 (bm, 5H), 2.44-2.76 (bm, 4H), 3.26 (d, J = 13.3 Hz, 
1H, C H 2.AxAr), 3.49 (dd, J = 12.6 and 34.3 Hz, 2H, C H 2.AMAr), 4.18 (q, J = 7.1 Hz, 
2H), 5.78 (m, 1H), 6.88-6.98 (m, 1H), 7.18-7.36 (m, 10H); 13C NMR (CDCI3, 100 
MHz) 6 14.3, 27.5, 28.2, 50.2, 52.8, 56.7, 57.6, 58.7, 60.2, 63.0, 121.3, 126.9,
127.0, 128.2, 128.8, 129.0, 148.9, 166.6, 183.8.
The opposing enantiomer was similarly prepared:
Ethyl (S)-5-(1,4-dibenzylpiperazin-2-yl)pent-2-enoate ((S)-146). Light tan oil; 
(0.47 g, 66% 2 steps overall).
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AcOH, MeOH
Ethyl (/?)-5-(1,4-dibenzylpiperazin-2-yl)pentanoate ((/?)-77). To a solution of 
ethyl (R)-5-(1,4-dibenzylpiperazin-2-yl)pent-2-enoate (/?)-146 (0.46 g, 1.2 mmol) 
in HPLC grade MeOH (10 mL) and acetic acid (0.35 g, 5.9 mmol) was added 5% 
Pd/C (0.9 g). The reaction flask was sealed with a septum, fitted with hydrogen 
balloon and a bleed needle. One balloon of hydrogen was bubbled through the 
stirred solution, the needle was removed a second balloon was attached and the 
mixture was stirred overnight. The reaction was filtered over a pad of Celite. 
The pad was rinsed with MeOH and concentrated in vacuo. The resulting oil was 
dissolved in CH2CI2, free based with 4 M NaOH to a basic pH then buffered to pH 
10 with sat. NaHC03. The organic layer was separated and the aqueous layer 
was extracted with CH2CI2 (2 x 30 mL). The organic portions were combined, 
dried (K2C 03) and concentrated in vacuo to give an tan oil. The crude oil was 
purified by column chromatography over silica gel (15 g) loaded with CHCI3 and 
eluted with 1:3 EtOAc/hexanes followed by 2:3 EtOAc/hexanes, concentration in 
vacuo gave (/?)-77 as clear oil (0.28 g, 60%): The product was visualized by two 
separate TLC solvent systems; TLC Rf = 0.27 (2:3 EtOAc/Hexanes), Rf = 0.6 
(1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 1.16-1.50 (m, 5H, overlapped 
triplet at 1.25, J = 7.1 Hz, 3H, C 02CH2CH3), 1.52-1.76 (m, 4H), 2.10-2.80 (m, 
9H), 3.20 (d, J = 13.2 Hz, 1H, CH2.AxAr), 3.49 (dd, J = 13.2 and 41.7 Hz, 2H, 
CH2.AMAr), 4.00 (d, J = 13.2 Hz, 1H, CH2.AxAr), 4.12 (q, J = 7.1 Hz, 2H, 
C02CH2CH3), 7.18-7.45 (m, 10H); 13C NMR (CDCI3, 100 MHz) 5 14.2, 25.0,
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25.4, 29.3, 34.2, 50.7, 52.8, 57.5, 57.6, 59.4, 60.1, 63.0, 126.7, 126.8, 128.1,
128.8, 128.9, 138.2, 139.0, 173.5.
The opposing enantiomer was similarly prepared:
B" ' N ^
H
Ethyl (S)-5-(1,4-dibenzylpiperazin-2-yl)pentanoate ((S)-77). Clear oil; (0.27 g, 
57%).
LiAIH4, Et20
(/?)-5-(1,4-Dibenzylpiperazin-2-yl)pentan-1-ol ((/?)-78). A solution of ethyl (R)- 
5-(1,4-dibenzylpiperazin-2-yl)pentanoate (R)-77 (0.28 g, 0.7 mmol) in dry ether 
(10 mL) was treated with LiAlhU powder (0.03 g, 0.8 mmol) at 0 °C, then placed 
under an atmosphere of argon. The ice bath was removed and the reaction was 
allowed to stir overnight at 25 °C. The reaction was quenched by consecutive 
addition of H2O (0.03 mL), NaOH (0.06 mL 4 M) and then H20  (0.03 mL). The 
inorganic salts were filtered over a pad of Celite and the pad was rinsed with 
EtOAc. The filtrate was concentrated in vacuo to give (R)-78 (0.24 g, 99%): TLC 
Rf = 0.10 (2:3 EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.20-1.45 (m, 4H),
1.48-1.68 (m, 5H), 2.10-2.28 (m, 3H), 2.40-2.76 (m, 4H), 3.20 (d, J = 13.2 Hz, 
1H, CH2.AxAr), 3.49 (dd, J = 13.2 and 44.0 Hz, 2H, CH2.AMAr), 3.58-3.64 (bm,
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2H), 4.00 (d, J = 13.2 Hz, 1H, CH2-AxAr), 7.20-7.35 (m, 10H); 13C NMR (CDCI3) 
100 MHz) 5 25.3, 26.2, 29.6, 32.6, 50.8, 52.7, 57.5, 59.5, 62.5, 63.0, 126.7,
126.9, 128.0, 128.9, 129.0, 137.9, 138.9(1 overlapped peak).
The opposing enantiomer was similarly prepared:
Bn' N ^ |
H
5-((S)-1,4-Dibenzylpiperazin-2-yl)pentan-1-ol ((S)-78). Clear oil; (0.24 g, 
quantitative).
NaH, CH3l 
% n DMF, 0 °C H3 C " °
(R)-1,4-Dibenzyl-2-(5-methoxypentyl)piperazine ((/?)-79). A stirred solution of 
(R)-5-(1,4-dibenzylpiperazin-2-yl)pentan-1-ol (/?)-78 (0.24 g, 0.69 mmol) in dry 
DMF (5 mL) at 0 °C was treated with NaH powder (0.05 g, 2.1 mmol) to give a 
turbid white suspension. The reaction was placed under argon and stirring was 
continued for 20 min. lodomethane (0.10 g, 0.69 mmol) was added dropwise to 
the cooled solution and the reaction was allowed to stir on ice for 30 min followed 
by room temperature overnight. The reaction was quenched by the addition of 
water (10 mL) followed by sat. NaHC03 (10 mL). The aqueous layer was 
extracted with Et20  (4 x 20 mL). The organic portions were combined, dried 
(K2C 03), and concentrated in vacuo to give a tan oil. The oil was purified by 
column chromatography over silica gel (9 g) loaded with CHCI3 and eluted with
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2:3 EtOAc/hexanes followed by 3:2 EtOAc/hexanes, concentration of the product 
fractions gave (/?)-79 as a clear oil (0.14 g, 56%): TLC Rf = 0.39 (4:6
EtOAc/Hexanes); 1H NMR ( C D C I 3 , 400 MHz) 5 1.22-1.48 (m, 4H), 1.52-1.70 (m, 
4H), 2.08-2.32 (m, 3H), 2.40-2.78 (3m, 4H), 3.20 (d, J = 13.2 Hz, 1H, C H 2 -AxAr), 
3.32-3.40 (m, 5H, overlapped singlet, 3.33, 3H, O C / - / 3 ) ,  3.49 (dd, J = 13.2 and
43.6 Hz, 2H, C H 2 .AMAr), 4.02 (d, J = 13.2 Hz, 1H, C H 2 -AxAr), 7.20-7.40 (m, 10H); 
13C  NMR ( C D C I 3 ,  100 MHz) 5 25.4, 26.6, 29.0, 29.5, 50.8, 52.8, 57.6, 58.5, 59.6,
63.0, 72.0, 72.7, 126.6, 126.8, 128.0, 128.9, 129.0, 138.2, 139.0.
The opposing enantiomer was similarly prepared:
Bn' ^
H3(T  N '  Bn
6 H
(S)-1,4-Dibenzyl-2-(5-methoxypentyl)piperazine ((S)-79). Clear oil; (0.14 g, 
57%).
H,C'
H2, 5% Pd/C . 2  HCI HN/ 'V |
N' Bn 12 M HCI, MeOH h 3C '0 ^ ^ / ^ ŝ ^ NH 
H H
(R)-2-(5-Methoxypentyl)piperazine dihydrochloride ((/?)-80). A solution of 
(f?)-1,4-dibenzyl-2-(5-methoxypentyl)piperazine (R)-79 (0.14 g, 0.39 mmol) in 
HPLC grade MeOH (8 mL) and HCI (12 M, 0.77 mmol, 0.06 ml_) was treated 
with 5% Pd/C (0.021 g). The flask was sealed with a septum and three balloons 
of hydrogen were bubbled through the stirred solution. The reaction mixture was 
filtered over a pad of Celite, the pad was rinsed with MeOH and the combined
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organic portions were concentrated in vacuo to give a white solid (R)-80 (0.083 g, 
83%).
The opposing enantiomer was similarly prepared:
(S)-2-(5-Methoxypentyl)piperazine dihydrochloride ((S)-80). Clear oil; (0.10 
g, 98%).
(R)-3-(5-Methoxypentyl)-1-tritylpiperazine ((/?)-81). A solution of hydrochloride 
(/?)-80) (0.082 g, 0.32 mmol) in dry CH2CI2 (5 ml_) and dry EtsN (0.13 g, 0.18 ml_,
1.3 mmol) at 0 °C, was treated with a solution of trityl chloride (0.089 g, .32 
mmol) in dry CH2CI2 (2  mL) by dropwise addition. The ice bath was removed 
after one hour and the reaction stirred for 20 h at room temperature. The reaction 
mixture was transferred to a separatory funnel and diluted to 2 0  mL with CH2CI2. 
The organic portion was washed with saturated NaHCC>3 (1 0  mL), water ( 1 0  mL), 
brine (10 mL), dried (K2CO3) and concentrated in vacuo to give an amorphous 
white foam (R)-81 (0.14 g, 99% yield): TLC 0.34 (1:9 MeOH/CH2CI2). The 
product was used directly without further purification, or spectroscopic 
characterization.
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CIC(Ph)3, Et3N
CH2CI2, 0 °C H3C'
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The opposing enantiomer was similarly prepared:
H,C CPh,
(S)-3-(5-Methoxypentyl)-1-tritylpiperazine ((S)-81). White foam; (0.16 g, 
97%).
H,C CPh,
n-BuLi, 2-CI-quinoline 
Et2 0 , 0 °C;
6  M HCI, acetone
H,C
N
(R)2-(2-(5-Methoxypentyl)piperazin-1-yl)quinoline ((/?)-82). A solution of (R )-
3-(5-methoxypentyl)-1-tritylpiperazine (/?)-81 (0.14 g, 0.32 mmol) in dry Et20  (8 
mL) under argon at 0° C, was treated dropwise with n-BuLi (0.93 mL, 2.45 M in 
hexanes) generating an off-white suspension. The suspension was allowed to 
stir for 20 min. A solution of 2-chloroquinoline (0.034 g, 0.21 mmol) in dry Et20  
(2 mL) was added drop-wise, the mixture was allowed to stir for 1 h and then the 
ice bath was removed. The reaction was allowed to stir for a total of 4 h giving a 
red-brown colored suspension. The reaction was quenched with saturated 
NaHC03 (20 mL), diluted to 40 mL with Et20  and the organic layer was 
separated. The organic layer was washed with water (20 mL), brine (20 mL), 
dried (K2C 03), and concentrated in vacuo to give a white foam. The foam was 
purified by column chromatography over silica gel (9 g) loaded with CHCI3 and 
eluted with 1:9 EtOAc/hexanes followed by 1:3 EtOAc/Hexanes to give the N- 
trityl protected product (0.099 g, 85% yield) as a clear yellow oil. Rf = 0.3 (4:6
184
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
EtOAc/Hexanes). The purified oil was dissolved in acetone (1.5 mL) and HCI (6  
M, 0.5 mL) and allowed to stir for 15 min. The reaction was diluted with 1 M HCI 
(10 mL) and extracted with CH2CI2 ( 3x15  mL), the aqueous layer was basified to 
pH 12 with 4 M NaOH and then buffered to pH 10 with saturated NaHCOs. The 
aqueous layer was extracted with CH2CI2 ( 3 x 1 5  mL), the organic portions were 
combined, dried (K2CO3), and concentrated in vacuo to give (/?)-82 (0.035 g, 
53% 2 steps) as a light yellow oil: [a]25o = -39° (c = 0.001, CH2CI2); 1H NMR 
(CDCI3, 400 MHz) 6  1.18-1.42 (m, 4H), 1.44-1.58 (m, 2H), 1.60-1.72 (m, 1H), 
1.76-1.90 (m, 1H), 2.11 (bs, 1H), 2.84 (m, 1H), 2.94-3.18 (m, 4H), 3.24-3.34 (m, 
5H, overlapped singlet, 3.28, 3H, OCH3), 4.38 (bd, 2H), 6.90 (d, J = 9.5 Hz, 1H), 
7.18 (t, J = 8.06 Hz, 1H), 7.50 (t, J = 8.4 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.65 
(d, J = 8.4 Hz, 1H), 7.84 (d, J = 9.2 Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 26.0,
26.4, 27.7, 29.4, 40.1, 46.0, 47.8, 51.7, 58.4, 72.6, 109.3, 121.9, 122.7, 126.3,
127.0, 129.3, 137.2, 147.9, 157.0.
The opposing enantiomer was similarly prepared:
(S)2-(2-(5-Methoxypentyl)piperazin-1-yl)quinoline ((S)-82). Light yellow oil; 
(0.022 g, 29% 2 steps overall).
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o 2n
h n o 3, h 2 s o 4
NH 0 °C NH
H H
(R)-2-(2-(5-Methoxypentyl)piperazin-1-yl)-6-nitroquinoline ((/?)-83). A stirred 
solution of (R)-2-(2-(5-methoxypentyl)piperazin-1-yl)quinoline (R)-B2 (0.035 g, 
0.11 mmol) in H2SO4 (16 M, 2 mL) was cooled at 0° C. HNO3 (15.4 M, 0.03 mL, 
0.45 mmol) was added drop-wise, and the reaction stirred for 20 min at 0 °C. The 
reaction was quenched by pouring into ice water. The acid was neutralized with 
4 M NaOH to give a bright yellow solution, and the resulting mixture was buffered 
to pH 10 with sat. NaHC0 3 . The yellow aqueous solution was extracted with 
CH2CI2 until no yellow color was extracted into the organic layer. The organic 
portions were combined, dried (K2CO3), and concentrated in vacuo to give a 
bright yellow oil (/?)-83 (0.041 g, quantitative yield): TLC Rf = 0.16 (1:9
MeOH/CH2CI2); [a]25D = -105° (c = 0.0008, CH2CI2); 1H NMR (CDCI3, 400 MHz) 
51.26-1.46 (m, 4H), 1.50-1.60 (m, 2H), 1.71-1.96 (m, 2H), 2.06 (bs, 1H), 2.85 (dt, 
J = 3.6 and 12.3 Hz, 1H), 2.98 (dd, J = 3.6 and 12.3 Hz, 1H), 3.06-3.26 (m, 3H),
3.29 (s, 3H), 3.33 (m, 2H), 4.52 (bs, 2H), 7.01 (d, J = 9.1 Hz, 1H), 7.61 (d, J = 9.4 
Hz, 1H), 7.93 (d, J = 9.4 Hz, 1H), 8.27 (dd, J = 2.6 and 9.4 Hz, 1H), 8.51 (d, J =
2.6 Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 26.0, 26.2, 28.2, 29.4, 40.3, 46.1,
48.0, 51.8 58.4, 72.5, 110.7, 120.7, 123.4, 124.1, 126.8, 138.4, 141.4, 151.6,
158.3.
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The opposing enantiomer was similarly prepared:
o 2n
h 3c" A 1
H
(/?)-2-(2-(5-Methoxypentyl)piperazin-1-yl)-6-nitroquinoline ((/?)-83). Bright
yellow oil; (0.024 g, 95%); [a]D = +8 6 ° (c = 0.0005, CH2CI2).
6 . 8  Racemic BuM-NQP Series.
3-(1,4-Dibenzylpiperazin-2-yl)propanal (89). A solution of DMSO (0.55 g, 7.0 
mmol) in dry CH2CI2 (2.5 mL) was added dropwise to a solution of oxalyl chloride 
(2 M in CH2CI2, 1.75 mL, 3.5 mmol) in dry CH2CI2 ( 8  mL) at -78 °C (dry ice, 
acetone bath). After 5 min, a solution of 1,4-dibenzyl-2-(3-hydroxypropyl)- 
piperazine 56 (0.94 g, 2.9 mmol) in dry CH2CI2 (5 mL) was added dropwise. The 
combined mixture was allowed to stir for an additional 20 min at -78 °C. The 
reaction was treated with Et3N (1.6 g, 16 mmol) forming a tan precipitate. The 
suspension was allowed to stir for 5 min then warmed to room temperature and 
stirred for 1 hour. The reaction was quenched by the addition of water (25 mL). 
The organic layer was separated and the aqueous layer was extracted with 15 
mL of CH2CI2. The organic portions were combined, washed with saturated
HO
DMSO, (COCl)2
Bn CH2CI2, Et3N, -78 °C
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NaHCOs (20 mL), dried ( K 2 C O 3 ) ,  filtered, and concentrated in vacuo. The 
aldehyde 89 was used in the next step without further purification: TLC Rf = 0.54 
(2:3 EtOAc/hexanes).
1,4-Dibenzyl-2-(but-3-enyl)piperazine (90). A stirred suspension of methyl 
triphenylphosphonium iodide (2.4 g, 5.9 mmol) in dry THF (15 mL) cooled at 0° 
C, was treated with n-BuLi (2.4 mL, 2.45 M in hexanes, 5.8 mmol) giving an 
yellow-orange suspension. The suspension was stirred for an additional hour at 
0° C. A solution of 3-(1,4-dibenzylpiperazin-2-yl)propanal 89 (0.94 g, 2.9 mmol) 
in dry THF (5 mL) was added dropwise to the ylide. After 1 h, the reaction was 
allowed to warm to RT° C and stir for 18 h. The reaction was quenched with 
water (15 mL). The THF was removed in vacuo, and aqueous layer was treated 
with sat. NaHCC>3 (20 mL). The aqueous phase was extracted with CH2CI2 (3 x 
30 mL), the organic portions were combined, dried (K2CO3) and concentrated in 
vacuo to give a white/tan semi-solid (3.25 g). The crude material was purified by 
column chromatography over silica gel (60 g) loaded with CHCI3, eluting with 1:3 
EtOAc/hexanes followed by 2:3 EtOAc/hexanes, after concentration in vacuo 
gave (/?)-90 as a light tan oil (0.69 g, 74%, 2 steps overall): TLC R f = 0.54 (2:3 
EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.68-1.79 (m, 2H), 1.93-2.34 (m, 
5H), 2.45-2.79 (m, 4H), 3.24 (d, J = 13.3 Hz, 1H, CH2-AMAr), 3.51 (dd, J = 12.9 
and 34.9 Hz, 2H, CH2-ABAr), 4.02 (d, J = 13.3 Hz, 1H, CH2.AMAr), 4.91-5.03 (m,
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1H), 5.74-5.87 (m, 1H), 7.20-7.38 (m, 10H); 13C NMR (CDCI3, 100 MHz) 5 28.7,
29.8, 50.6, 52.9, 57.2, 57.6, 59.1, 63.1, 114.4, 126.7, 126.9, 128.1, 128.9, 129.0,
138.2, 138.7, 139.1.
Bn H20 2, NaOH, 0 °C HO
9-BBN THF, 50 °C;
N
BnH H
4-(1,4-Dibenzylpiperazin-2-yl)butan-1-ol (91). A cooled (0 °C) stirred solution 
of 1,4-dibenzyl-2-(but-3-enyl)piperazine 90 (0.58 g, 1.8 mmol) in dry THF (15 mL) 
was treated (dropwise) with a solution of 9-BBN (7.2 mL, 0.5 M in THF, 3.6 
mmol), and then heated at 55 °C for 1.5 h. The reaction was cooled to 0 °C and 
treated (dropwise) with a solution of NaOH (5.4 mL, 1 M), followed by 30% H20 2  
(5.4 mL). The reaction was concentrated in vacuo to remove the THF, then 
diluted with 1 M HCI (10 mL) and extracted with CH2CI2 (3 x 20 mL). The 
resulting aqueous layer was brought to basic pH with 4 M NaOH, buffered to pH 
1 0  with sat. NaHCOs, and extracted with CH2CI2 ( 4 x 1 5  mL). The combined 
organic portions were, dried (K2CO3), and concentrated in vacuo. The crude oil 
was purified by column chromatography over silica gel (37 g) loaded with CHCI3 
and eluted with 3:2 EtOAc/hexanes to give a clear oil 91 (0.45 g, 73%): The 
product was visualized using two separate TLC solvent systems; Rf = 0.06 (4:6 
EtOAc/Hexanes) and Rf = 0.42 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 
5 1.25-1.70 (m, 6 H), 2.12-2.32 (m, 3H), 2.41-2.76 (m, 5H), 3.22 (d, J = 13.3 Hz, 
1H, CH2-AMAr), 3.49 (dd, J = 12.9 and 42.7 Hz, 2H, CH2.ABAr), 3.62 (m, 2H, 
CH2OH), 4.01 (d, J = 13.3 Hz, 1H, CH2.AMAr), 7.20-7.36 (m, 10H); 13C NMR
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(CDCI3, 100 MHz) 6 21.8, 29.4, 33.1, 50.7, 52.7, 57.4, 57.6, 59.6, 62.5, 63.0
126.7, 126.9, 128.1, 128.9, 129.1, 138.0, 138.9.
HO Bn DMF, 0 °C
NaH, CH3I
h 3c.
O BnH H
1,4-Dibenzyl-2-(4-methoxybutyl)piperazine (92). A stirred solution of 4-(1,4- 
dibenzylpiperazin-2-yl)butan-1-ol 91 (1.6 g, 4.73 mmol) in dry DMF (40 mL) at 0 
°C was treated with NaH powder (0.34 g, 14.2 mmol) to give a white suspension. 
The flask was placed under argon and stirring was continued for 20 min. 
lodomethane (0.71 g, 4.97 mmol) was added (dropwise) to the cooled solution. 
The reaction was allowed to stir on ice for 30 min, followed by room temperature 
overnight. The reaction was quenched by the addition of water (40 mL) followed 
by sat. NaHC03 (40 mL). The aqueous layer was extracted with Et20  ( 4 x 1 5  
mL), the organic portions were combined, washed with ether, dried (K2C 03), 
filtered and concentrated in vacuo to give a tan oil. The oil was purified by 
column chromatography over silica gel (56 g) loaded with CHCI3 and eluted with 
2:3 EtOAc/hexanes, concentration in vacuo gave 92 as a clear oil (1.02 g, 61%): 
TLC Rf = 0.35 (2:3 EtOAc/Hexanes), Rf = 0.48 (1:9 MeOH/CH2CI2); 1H NMR 
(CDCI3, 400 MHz) 6 1.24-1.70 (m, 6H), 2.12-2.30 (m, 3H), 2.41-2.50 (bm, 1H),
2.52-2.60 (bm, 1H), 2.66-2.76 (m, 2H), 3.20 (d, J = 13.2 Hz, 1H, CH2Ar), 3.33 (s, 
3H), 3.36 (m, 2H), 3.49 (dd, J = 13.2 and 41.8, 2H, CH2.ABAr), 4.02 (d, J = 13.2 
Hz, 1H, CH2Ar), 7.20-7.40 (m, 10H); 13C NMR (CDCI3, 100 MHz) 5 22.2, 29.6,
190
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
30.1, 50.8, 52.8, 57.6, 58.5, 59.6, 63.1, 72.6, 126.7, 126.8, 128.1, 128.9, 129.0,
138.2, 139.1.
Bn 12 M HCI, MeOH
2-(4-Methoxybutyl)piperazine dihydrochloride (93). A solution of 1,4- 
dibenzyl-2-(4-methoxybutyl)piperazine 92 (1.0 g, 2.9 mmol) in HPLC grade 
MeOH (50 mL) and HCI (12 M, 6.1 mmol, 0.5 mL) was treated with 5% Pd/C 
(0.15 g). The flask was sealed with a septum and a balloon of hydrogen was 
bubbled through the stirred solution. The reaction mixture was filtered over a pad 
of Celite; the pad was rinsed with MeOH and concentrated in vacuo to give a 
white solid 93 (0.70 g, 98%): 1H NMR (D20, 400 MHz) 51.40-1.52 (m, 2H), 1.56- 
1.68 (m, 2H), 1.70-1.84 (m, 2H), 3.21 (m, 1H), 3.34 (s, 3H), 3.41 (m, 1H), 3.49 
(m, 2H), 3.56-3.80 (bm, 4H).
•2 HCI H N ^  CIC(Ph)3, Et3N
CH2CI2, 0 ° c  v  v sv ” 'CPh3
3-(4-methoxybutyl)-1-tritylpiperazine (94). A solution of 2-(4- 
methoxybutyl)piperazine dihydrochloride 93 (0.70 g, 2.8 mmol) in dry CH2CI2 (20 
mL) and dry Et3N (1.15 g, 1.6 mL, 11.4 mmol) at 0 °C, was treated (dropwise) 
with a solution of trityl chloride (0.79 g, 2.8 mmol) in dry CH2CI2 (10 mL). The ice 
bath was removed after one hour and the reaction stirred for 2 0  h at room 
temperature. The reaction mixture was transferred to a separatory funnel, diluted
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to 20 mL with CH2CI2. The organic fraction was washed with saturated NaHC0 3  
(20 mL), water (20 mL), brine (20 mL), dried (K2CO3) and concentrated in vacuo 
to give an amorphous white foam 94 (1.11 g, 94% yield). The product was 
directly used without further purification or characterization.
2-(2-(4-Methoxybutyl)piperazin-1-yl)quinoline (95). A solution of 3-(4- 
methoxybutyl)-1-tritylpiperazine 94 (0.54 g, 1.30 mmol) in dry Et2 0  (20 mL) under 
argon at 0° C, was treated (dropwise) with />BuLi (0.6 mL, 2.2 M in hexanes,
1.30 mmol) generating a creamy white suspension. The suspension was allowed 
to stir for 20 min. A solution of 2-chloroquinoline (0.14 g, 0.86 mmol) in dry Et2 0  
(5 mL) was added dropwise to the lithium amide and the reaction was allowed to 
stir for 1 h and the ice bath was removed. The reaction was allowed to stir for a 
total of 4 h giving a purple colored suspension. The reaction was quenched with 
saturated NaHCC>3 (20 mL), diluted to 40 mL with Et2<D and the organic layer was 
separated. The organic layer was washed with water (20 mL), brine (20 mL), 
dried (K2CO3), and concentrated in vacuo to give a white foam. The foam was 
purified by column chromatography over silica gel (9 g) loaded with CHCI3 and 
eluted with 1:9 EtOAc/hexanes followed by 1:3 EtOAc/Hexanes to give the N- 
trityl protected product (0.099 g, 85% yield) as a clear yellow oil. R f = 0.3 (4:6 
EtOAc/Hexanes). The purified oil was dissolved in acetone (1.5 mL) and HCI (6  
M, 0.5 mL) and the mixture was allowed to stir for 15 min. The reaction was
1) n-BuLi, 2-chloroquinoline 
  Et2Q, 0 °C
2) 6 M HCI, acetone
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diluted with 1 M HCI (10 mL) and extracted with CH2CI2 (3 x15 mL). The 
aqueous layer was basified to pH 12 with 4 M NaOH and then buffered to pH 10 
with saturated NaHCC>3 . The aqueous layer was extracted with CH2CI2 ( 3 x 1 5  
mL), the organic portions were combined, dried (K2CO3), and concentrated in 
vacuo to give 95 (0.035 g, 63%) as a light yellow oil: 1H NMR (CDCI3 , 400 MHz) 
5 1.28-1.46 (m, 2H), 1.54-1.76 (2m, 3H), 1.81-1.94 (m, 1H), 2.18 (bs, 1H), 2.86 
(m, 1H), 2.99 (dd, J = 4.0 and 12.5 Hz, 1H), 3.05-3.21 (m, 3H), 3.28 (s, 3H), 3.33 
(m, 2H), 4.36-4.44 (bm, 2H), 6.91 (d, J = 9.2 Hz, 1H), 7.18 (m, 1H), 7.50 (m, 1H), 
7.56 (m, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 9.2 Hz, 1H); 13C NMR (CDCI3 , 
100 MHz) 6  23.3, 27.6, 29.5, 40.1, 46.0, 47.7, 51.7, 58.5, 72.6, 109.3, 122.0,
122.8, 126.4, 127.1, 129.4, 137.3, 148.0. 156.9.
2-(2-(4-Methoxybutyl)piperazin-1-yl)-6-nitroquinoline ((±)-96). A stirred 
solution of 2-(2-(4-methoxybutyl)piperazin-1-yl)quinoline 95 (0.21 g, 0.70 mmol) 
in H2SO4 (16 M, 5 mL) was cooled at 0° C. Dropwise addition of HNO3 (15.4 M, 
0.18 mL) to the solution was followed by stirring for 20 min at 0 °C. The reaction 
was quenched by pouring into ice water, the acid was neutralized with 4 M NaOH 
to give a bright yellow solution and the resulting solution was buffered to pH 10 
with sat. NaHCOs. The aqueous solution was extracted with CH2CI2 until no 
yellow color was extracted into the organic layer. The organic portions were
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combined, dried (K2C 03), and concentrated in vacuo to give a bright yellow oil 
(±)-96 (0.21 g, 8 8 %): TLC Rf = 0 .2 2  (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 
MHz) 6  1.24-1.42 (m, 2H), 1.52-1.62 (m, 2H), 1.65-1.95 (2m, 3H), 2.79 (dt, J =
2.9 and 12.1 Hz, 1H), 2.88-2.96 (m, 1H), 3.00-3.20 (m, 3H), 3.23 (s, 3H), 3.26- 
3.32 (m, 2H), 4.46 (bs, 2H), 6.97 (d, J = 9.5 Hz, 1H), 7.54 (d, J = 9.2 Hz, 1H), 
7.86 (d, J = 9.5 Hz, 1H), 8.2 (dd, J = 2.6 and 9.5 Hz, 1H), 8.43 (d, J = 2.6 Hz, 
1H); 13C NMR (CDCI3, 100 MHz) 5 23.0, 28.1, 29.4, 40.3, 46.0, 47.9, 51.8, 58.4,
72.4, 110.7, 120.7, 123.5, 124.1, 126.7, 138.3, 141.3, 151.5, 158.3; HRMS (ESI- 
TOF) m/z (M + H)+ calcd. for Ci8H25N40 3 345.1927 found 345.1938.
1) BBr3, CH2 CI2, -78 °C
NH 2) [(CH3 )3 C0C0]2 0, CH2 CI2i 0 °C
HO'
A
ferf-Butyl-3-(4-hydroxybutyl)-4-(6-nitroquinolm-2-yl)piperazine-1- 
carboxylate (97). A solution of 2-(2-(4-methoxybutyl)piperazin-1-yl)-6- 
nitroquinoline (±)-96 (0.11g, 0.33 mmol) in dry CH2CI2 (33 mL) was cooled at -78 
°C in a dry ice, acetone bath. A solution of BBr3 (2.4 mL, 1M in CH2CI2, 2.4 
mmol) was added dropwise under argon giving a dark purple suspension. The 
suspension was warmed to RT °C and stirred overnight giving a yellow-orange 
suspension. The reaction was quenched by the addition of sat. NaHC03 (25 mL). 
The organic layer was separated and the aqueous layer was extracted with 
CH2CI2 (3 x 20 mL). The organic portions were combined, dried (K2C 03), filtered 
and concentrated in vacuo. The resulting yellow semi-solid was transferred to a
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50 mL flask with CH2CI2 and concentrated. The residue was treated with CH2CI2 
(15 mL) sonicated to suspend all the material, then cooled to 0 °C, and treated 
with di-ferf-butyl dicarbonate (0.07 g, 0.33 mmol). After 2.5 h, the reaction was 
warmed to RT °C. The solution was concentrated in vacuo (25 °C) and dissolved 
in CHCI3. The crude solution was purified by column chromatography over silica 
gel ( 8  g) eluting with 3:2 EtOAc/hexanes to give 97 as a yellow foam (0.088 g, 
44% yield 2 steps): 1H NMR (CDCI3, 400 MHz) 5 1.30-1.85 (m, 15H), 2.80-3.43 
(2bm, 4H), 3.63 (bs, 2H), 4.00-4.78 (3bm, 4H), 7.02 (d, J = 9.5 Hz, 1H), 7.63 (d, J 
= 9.2 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 8.28 (dd, J = 2.6 and 9.2 Hz, 1H), 8.52 (d, 
J = 2.6 Hz, 1H).
6.9 Chiral BuM-NQP Series.
(/?)-1,4-Dibenzyl-2-(but-3-enyl)piperazine ((/?)-90). A stirred suspension of 
methyl triphenylphosphonium iodide (3.0 g, 7.4 mmol) in dry THF (20 mL), cooled 
at 0° C, was treated with n-BuLi (3.3 mL, 2.2 M in hexanes, 7.3 mmol) giving an 
yellow-orange suspension. The mixture was stirred for 1 h at 0° C. A solution of
3-(1,4-dibenzylpiperazin-2-yl)propanal (/?)-89 (1.2 g, 3.7 mmol) in dry THF (5 mL) 
was added dropwise to the ylide. After 1 hour, the reaction was allowed to warm 
to RT° C and stir for 18 h. The reaction was quenched with water (15 mL). The
n-BuLi, [(Ph)3P+CH3]lBn
H
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THF was removed in vacuo, and the resulting aqueous solution was treated with 
sat. NaHCOs (20 mL). The aqueous phase was extracted with CH2CI2 (3 x 30 
mL), the organic portions were combined, dried (K2CO3) and concentrated in 
vacuo to give a white-tan semi-solid. The crude material was purified by column 
chromatography over silica gel (60 g) loaded with CHCI3 and eluted with 1:3 
EtOAc/hexanes followed by 2:3 EtOAc/hexanes to give (/?)-90 as a light tan oil 
(0.57 g, 49%, 2 steps): TLC Rf = 0.54 (4:6 EtOAc/hexanes); 1H NMR (CDCI3, 
400 MHz) 5 1.68-1.79 (m, 2H), 1.93-2.34 (m, 5H), 2.45-2.79 (m, 4H), 3.24 (d, J = 
13.3 Hz, 1H, CH2-AMAr), 3.51 (dd, J = 12.9 and 34.9 Hz, 2H, CH2.ABAr), 4.02 (d, J 
= 13.3 Hz, 1H, CH2-AMAr), 4.91-5.03 (m, 1H), 5.74-5.87 (m, 1H), 7.20-7.38 (m, 
10H); 13C NMR (CDCI3, 100 MHz) 6 28.7, 29.8, 50.6, 52.9, 57.2, 57.6, 59.1, 
63.1, 114.4, 126.7, 126.9, 128.1, 128.9, 129.0, 138.2, 138.7, 139.1.
The opposing enantiomer was similarly prepared:
(S)-1,4-Dibenzyl-2-(but-3-enyl)piperazine ((S)-90). Light tan oil; (0.56 g, 55% 2 
steps).
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" T
9-BBN THF, 50 °C;
Bn H20 2, NaOH, 0 °C HO'
(/?)-4-(1,4-Dibenzylpiperazin-2-yl)butan-1-ol ((/?)-91). A cooled (0 °C) stirred 
solution of (R)-1,4-dibenzyl-2-(but-3-enyl)piperazine (/?)-90 (0.57 g, 1.8 mmol) in 
dry THF (15 mL) was treated (dropwise) with a solution of 9-BBN (5.4 mL, 0.5 M 
in THF, 2.7 mmol), then heated at 55 °C for 1.5 h. The reaction was cooled to 0 
°C and treated (dropwise) with a solution of NaOH (4.5 mL, 1 M), followed by 
30% H2O2 (4.5 mL). The reaction was then concentrated in vacuo to remove the 
THF. The solution was subsequently diluted with 1 M HCI (10 mL) and extracted 
with CH2CI2 (3 x 20 mL). The resulting aqueous layer was brought to basic pH 
with 4 M NaOH, buffered to pH 1 0  with sat. NaHCOs, extracted with CH2CI2 (4 x 
15 mL). The organic portions were combined, dried (K2CO3), filtered and 
concentrated in vacuo to give a tan oil. The resultant crude oil was purified by 
column chromatography over silica gel (34 g) loaded with CHCI3 and eluted with 
0.4:9.6  MeOH/CHCb followed by 1:19 MeOH/CHCb to give a clear oil (/?)-91 
(0.58 g, 94%): TLC Rf = 0.06 (2:3 EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz) 
6  1.20-1.45 (m, 4H), 1.48-1.68 (m, 5H), 2.10-2.28 (m, 3H), 2.40-2.76 (m, 4H), 
3.20 (d, J = 13.2 Hz, 1H, CH2-AxAr), 3.49 (dd, J = 13.2 and 44.0 Hz, 2H, CH2. 
AMAr), 3.58-3.64 (bm, 2H), 4.00 (d, J = 13.2 Hz, 1H, CH2-AxAr), 7.20-7.35 (m, 
10H); 13C NMR (CDCI3, 100 MHz) 5 25.3, 26.2, 29.6, 32.6, 50.8, 52.7, 57.5,
59.5, 62.5, 63.0, 126.7, 126.9, 128.0, 128.9, 129.0, 137.9, 138.9 (1 overlapped 
peak).
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The opposing enantiomer was similarly prepared:
Bn' 0
H
4-((S)-1,4-dibenzylpiperazin-2-yl)butan-1-ol ((S)-91). Clear oil; (0.58 g, 99%).
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Appendix
Select NMR Spectra
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1H
NH
(±)-83
J V
1.0 0.59.0 6.5 6.0 5.0 3.0 2.5 2.0 1.5 0.08.5 8.0 7.5 7.0 5.5 4.5 4.0 3.5
13C
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
203
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
1H
T s O .
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
204
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
1H
NH
9.0 8.5 8.0 7.0 6.5 6.07.5 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
205
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
206
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Bibliography
(1) Emond, P.; Vercouillie, J.; Innis, R.; Chalon, S.; Mavel, S. et al.
Substituted diphenyl sulfides as selective serotonin transporter ligands: 
synthesis and in vitro evaluation. J Med Chem 2002, 4 5 ,1253-1258.
(2) Oya, S.; Choi, S. R.; Hou, C.; Mu, M.; Kung, M. P. et al. 2-((2- 
((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an 
improved serotonin transporter ligand. Nucl Med Biol 2000, 27, 249-254.
(3) Huang, Y.; Hwang, D. R.; Narendran, R.; Sudo, Y.; Chatterjee, R. et al. 
Comparative evaluation in nonhuman primates of five PET radiotracers for 
imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM,
[11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab 2002, 
22, 1377-1398.
(4) Rapport, M. M.; Green, A. A.; Page, I. H. Partial purification of the 
vasoconstrictor in beef serum. J Biol Chem 1948, 174, 735-741.
(5) Rapport, M. M.; Green, A. A.; Page, I. H. Serum vasoconstrictor 
(serotonin). IV. Isolation and characterization. J Biol Chem 1948, 176, 
1243-1251.
(6) Hamlin, K. E.; Fischer, F. E. The synthesis of 5-hydroxytryptamine. J Am 
Chem Soc 1951, 73, 5007-5008.
(7) Zifa, E.; Fillion, G. 5-Hydroxytryptamine receptors. Pharmacological 
Reviews 1992, 44, 401-458.
(8) Gaddum, J. H.; Picarelli, Z. P. Two kinds of tryptamine receptor. B rJ  
Pharmacol Chemother 1957, 12, 323-328.
(9) Peroutka, S. J.; Snyder, S. H. Multiple serotonin receptors: differential 
binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and 
[3H]spiroperidol. Mol Pharmacol 1979, 16, 687-699.
(10) Childers, W. E., Jr.; Robichaud, A. J. Recent Advances in Selective 
Serotonergic Agents. Annual Reports in Medicinal Chemistry, Elsevier:
San Diego, 2005; pp 17-33.
(11) Inoue, T.; Kusumi, I.; Yoshioka, M. Serotonin transporters. Curr Drug 
Targets CNS Neurol Disord 2002, 1, 519-529.
(12) Nelson, N. The family of Na+/CI- neurotransmitter transporters. J 
Neurochem 1998, 71, 1785-1803.
207
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(13) Elfving, B.; Bjornholm, B.; Ebert, B.; Knudsen, G. M. Binding 
characteristics of selective serotonin reuptake inhibitors with relation to 
emission tomography studies. Synapse 2001, 41, 203-211.
(14) Blakely, R. D.; Moore, K. R.; Qian, Y. Tails of serotonin and 
norepinephrine transporters: deletions and chimeras retain function. Soc 
Gen Physiol Ser 1993, 48, 283-300.
(15) Cortes, R.; Soriano, E.; Pazos, A.; Probst, A.; Palacios, J. M. 
Autoradiography of antidepressant binding sites in the human brain: 
localization using [3H]imipramine and [3H]paroxetine. Neuroscience 1988, 
27, 473-496.
(16) Laruelle, M.; Vanisberg, M. A.; Maloteaux, J. M. Regional and subcellular 
localization in human brain of [3H]paroxetine binding, a marker of 
serotonin uptake sites. Biol Psychiatry 1988, 24, 299-309.
(17) Backstrom, I.; Bergstrom, M.; Marcusson, J. High affinity [3H]paroxetine 
binding to serotonin uptake sites in human brain tissue. Brain Res 1989, 
486, 261-268.
(18) Frankie, W. G.; Huang, Y.; Hwang, D. R.; Talbot, P. S.; Slifstein, M. et al. 
Comparative evaluation of serotonin transporter radioligands 11C-DASB 
and C-McN 5652 in healthy humans. J Nucl Med 2004, 45, 682-694.
(19) Mariamaki, P.; Zessin, J.; Eskola, O.; Gronroos, T.; Haaparanta, M. et al. 
S-[ F]fluoromethyl-(+)-McN5652, a PET tracer for the serotonin 
transporter: evaluation in rats. Synapse 2003, 47, 45-53.
(20) Purselle, D. C.; Nemeroff, C. B. Serotonin transporter: a potential 
substrate in the biology of suicide. Neuropsychopharmacology 2003, 28, 
613-619.
(21) Arango, V.; Underwood, M. D.; Mann, J. J. Serotonin brain circuits 
involved in major depression and suicide. Prog Brain Res 2002, 136, 443- 
453.
(22) Mann, J. J.; Huang, Y. Y.; Underwood, M. D.; Kassir, S. A.; Oppenheim,
S. et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) 
and prefrontal cortical binding in major depression and suicide. Arch Gen 
Psychiatry 2000, 57, 729-738.
(23) Reivich, M.; Amsterdam, J. D.; Brunswick, D. J.; Shiue, C. Y. PET brain 
imaging with [11C](+)McN5652 shows increased serotonin transporter 
availability in major depression. J Affect Disord 2004, 82, 321-327.
208
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(24) Stein, M. B.; Seedat, S.; Gelernter, J. Serotonin transporter gene promoter 
polymorphism predicts SSRI response in generalized social anxiety 
disorder. Psychopharmacology (Berl) 2006.
(25) Helbecque, N.; Sparks, D. L.; Hunsaker, J. C., 3rd; Amouyel, P. The 
serotonin transporter promoter polymorphism and suicide. Neurosci Lett 
2006, 400, 13-15.
(26) Arato, M.; Tekes, K.; Tothfalusi, L.; Magyar, K.; Palkovits, M. et al. 
Serotonergic split brain and suicide. Psychiatry Res 1987, 21, 355-356.
(27) Naylor, L.; Dean, B.; Opeskin, K.; Pavey, G.; Hill, C. et al. Changes in the 
serotonin transporter in the hippocampus of subjects with schizophrenia 
identified using [3H]paroxetine. J Neural Transm 1996, 103, 749-757.
(28) Joyce, J. N. The dopamine hypothesis of schizophrenia: limbic 
interactions with serotonin and norepinephrine. Psychopharmacology 
(Berl) 1993, 112, S16-34.
(29) Laruelle, M.; Abi-Dargham, A.; Casanova, M. F.; Toti, R.; Weinberger, D.
R. et al. Selective abnormalities of prefrontal serotonergic receptors in 
schizophrenia. A postmortem study. Arch Gen Psychiatry 1993, 50, 810- 
818.
(30) Frankie, W. G.; Narendran, R.; Huang, Y.; Hwang, D. R.; Lombardo, I. et 
al. Serotonin transporter availability in patients with schizophrenia: a 
positron emission tomography imaging study with [11C]DASB. Biol 
Psychiatry 2005, 57, 1510-1516.
(31) Gorwood, P. Eating disorders, serotonin transporter polymorphisms and 
potential treatment response. Am J Pharmacogenomics 2004, 4, 9-17.
(32) Tammela, L. I.; Rissanen, A.; Kuikka, J. T.; Karhunen, L. J.; Bergstrom, K.
A. et al. Treatment improves serotonin transporter binding and reduces 
binge eating. Psychopharmacology (Berl) 2003, 170, 89-93.
(33) Lundquist, P.; Wilking, H.; Hoglund, A. U.; Sandell, J.; Bergstrom, M. et al. 
Potential of [11C]DASB for measuring endogenous serotonin with PET: 
binding studies. Nucl Med Biol 2005, 32, 129-136.
(34) Brust, P.; Zessin, J.; Kuwabara, H.; Pawelke, B.; Kretzschmar, M. et al. 
Positron emission tomography imaging of the serotonin transporter in the 
pig brain using [11C](+)-McN5652 and S-([18F]fluoromethyl)-(+)-McN5652. 
Synapse 2003, 47, 143-151.
(35) Davidson, R. J.; Pizzagalli, D.; Nitschke, J. B.; Putnam, K. Depression: 
perspectives from affective neuroscience. Annu Rev Psychol 2002, 53, 
545-574.
209
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(36) Gurevich, E. V.; Joyce, J. N. Comparison of [3H]paroxetine and 
[3H]cyanoimipramine for quantitative measurement of serotonin 
transporter sites in human brain. Neuropsychopharmacology 1996, 14, 
309-323.
(37) Talbot, P. S.; Laruelle, M. The role of in vivo molecular imaging with PET 
and SPECT in the elucidation of psychiatric drug action and new drug 
development. European Neuropsychopharmacology 2002, 12, 503-511.
(38) Halldin, C.; Gulyas, B.; Langer, O.; Farde, L. Brain radioligands--state of 
the art and new trends. Q J Nucl Med 2001, 45, 139-152.
(39) Laruelle, M.; Slifstein, M.; Huang, Y. Relationships between radiotracer 
properties and image quality in molecular imaging of the brain with 
positron emission tomography. Mol Imaging Biol 2003, 5, 363-375.
(40) Huang, Y.; Narendran, R.; Bae, S. A.; Erritzoe, D.; Guo, N. et al. A PET 
imaging agent with fast kinetics: synthesis and in vivo evaluation of the 
serotonin transporter ligand [11C]2-[2-dimethylaminomethylphenylthio)]-5- 
fluorophenylamine ([11C]AFA). Nucl Med Biol 2004, 31, 727-738.
(41) Madsen, J.; Merachtsaki, P.; Davoodpour, P.; Bergstrom, M.; Langstrom,
B. et al. Synthesis and biological evaluation of novel carbon-11-labelled 
analogues of citalopram as potential radioligands for the serotonin 
transporter. Bioorg Med Chem 2003, 11, 3447-3456.
(42) Hume, S. P.; Lammertsma, A. A.; Bench, C. J.; Pike, V. W.; Pascali, C. et 
al. Evaluation of S-[11C]citalopram as a radioligand for in vivo labelling of
5-hydroxytryptamine uptake sites. Int J Rad Appl Instrum B 1992, 19, 851- 
855.
(43) Hume, S. P.; Pascali, C.; Pike, V. W.; Turton, D. R.; Ahier, R. G. et al. 
Citalopram: labelling with carbon-11 and evaluation in rat as a potential 
radioligand for in vivo PET studies of 5-HT re-uptake sites. Int J Rad Appl 
Instrum B 1991, 18, 339-351.
(44) Suehiro, M.; Wilson, A. A.; Scheffel, U.; Dannals, R. F.; Ravert, H. T. et al. 
Radiosynthesis and evaluation of N-(3-[18F]fluoropropyl)paroxetine as a 
radiotracer for in vivo labeling of serotonin uptake sites by PET. Int J Rad 
Appl Instrum B 1991, 18, 791-796.
(45) Szabo, Z.; Kao, P. F.; Scheffel, U.; Suehiro, M.; Mathews, W. B. et al. 
Positron emission tomography imaging of serotonin transporters in the 
human brain using [11C](+)McN5652. Synapse 1995, 20, 37-43.
(46) Szabo, Z.; Scheffel, U.; Suehiro, M.; Dannals, R. F.; Kim, S. E. et al. 
Positron emission tomography of 5-HT transporter sites in the baboon 
brain with [11C]McN5652. J Cereb Blood Flow Metab 1995, 15, 798-805.
210
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(47) Suehiro, M.; Greenberg, J. H.; Shiue, C. Y.; Gonzalez, C.; Dembowski, B. 
et al. Radiosynthesis and biodistribution of the S-[18F]fluoroethyl analog of 
McN5652. Nucl Med Biol 1996, 23, 407-412.
(48) Kuna, M. P.; Hou, C.; Oya, S.; Mu, M.; Acton, P. D. et al. Characterization 
of [( )I]IDAM as a novel single-photon emission tomography tracer for 
serotonin transporters. Eur J Nucl Med 1999, 26, 844-853.
(49) Acton, P. D.; Kung, M. P.; Mu, M.; Plossl, K.; Hou, C. et al. Single-photon 
emission tomography imaging of serotonin transporters in the non-human 
primate brain with the selective radioligand [(123)I]IDAM. Eur J Nucl Med 
1999, 26, 854-861.
(50) Choi, S. R.; Hou, C.; Oya, S.; Mu, M.; Kung, M. P. et al. Selective in vitro 
and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. 
Synapse 2000, 38, 403-412.
(51) Huang, Y.; Bae, S.-A.; Zhu, Z.; Guo, N.; Roth, B. L. et al. Fluorinated 
Diaryl Sulfides as Serotonin Transporter Ligands: Synthesis, Structure- 
Activity Relationship Study, and in Vivo Evaluation of Fluorine-18-Labeled 
Compounds as PET Imaging Agents. J Med Chem 2005, 48, 2559-2570.
(52) Lee, B. S.; Chu, S.; Lee, B. C.; Chi, D. Y.; Choe, Y. S. et al. Syntheses 
and binding affinities of 6-nitroquipazine analogues for serotonin 
transporter. Part 1. Bioorg Med Chem Lett 2000, 10, 1559-1562.
(53) Se Lee, B.; Chu, S.; Lee, B. S.; Yoon Chi, D.; Song, Y. S. et al. Syntheses 
and binding affinities of 6-nitroquipazine analogues for serotonin 
transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett 
2002, 12, 811-815.
(54) Jagust, W. J.; Eberling, J. L.; Roberts, J. A.; Brennan, K. M.; Hanrahan, S. 
M. et al. In vivo imaging of the 5-hydroxytryptamine reuptake site in 
primate brain using single photon emission computed tomography and 
[123l]5-iodo-6-nitroquipazine. Eur J Pharmacol 1993, 242, 189-193.
(55) Jagust, W. J.; Eberling, J. L.; Biegon, A.; Taylor, S. E.; VanBrocklin, H. F. 
et al. Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the 
serotonin transporter. J Nucl Med 1996, 37, 1207-1214.
(56) Lundkvist, C.; Loc'h, C.; Halldin, C.; Bottlaender, M.; Ottaviani, M. et al. 
Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET 
studies of the serotonin transporter. Nucl Med Biol 1999, 26, 501-507.
(57) Karramkam, M.; Dolle, F.; Valette, H.; Besret, L.; Bramoulle, Y. et al. 
Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a 
radioligand for the in vivo serotonin transporter imaging with PET. Bioorg 
Med Chem 2002, 10, 2611-2623.
211
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(58) Sandell, J.; Halldin, C.; Sovago, J.; Chou, Y. H.; Gulyas, B. et al. PET 
examination of [(11)C]5-methyl-6-nitroquipazine, a radioligand for 
visualization of the serotonin transporter. Nucl Med Biol 2002, 29, 651- 
656.
(59) Sandell, J.; Yu, M.; Emond, P.; Garreau, L.; Chalon, S. et al. Synthesis, 
radiolabeling and preliminary biological evaluation of radiolabeled 5- 
methyl-6-nitroquipazine, a potential radioligand for the serotonin 
transporter. Bioorg Med Chem Lett 2002, 12, 3611-3613.
(60) Griffin, L. D.; Mellon, S. H. Selective serotonin reuptake inhibitors directly 
alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A  
1999, 96, 13512-13517.
(61) Oh, S. J.; Ha, H. J.; Chi, D. Y.; Lee, H. K. Serotonin receptor and 
transporter ligands - current status. CurrMed Chem 2001, 8, 999-1034.
(62) Rosen, R. C.; Lane, R. M.; Menza, M. Effects of SSRIs on sexual function: 
a critical review. J Clin Psychopharmacol 1999, 19, 67-85.
(63) Banov, M. D. Improved outcome in fluvoxamine-treated patients with 
SSRI-induced sexual dysfunction. J Clin Psychiatry 1999, 60, 866-868.
(64) Waldinger, M. D.; van De Plas, A.; Pattij, T.; van Oorschot, R.; Coolen, L. 
M. et al. The selective serotonin re-uptake inhibitors fluvoxamine and 
paroxetine differ in sexual inhibitory effects after chronic treatment. 
Psychopharmacology (Berl) 2002, 160, 283-289.
(65) Wilson, P. A. A Simple Methodology for the Production of Three- 
Dimensional Models: Serotonin Transporter as an Example; Doctor of 
Philosophy, Chemistry; The University of Montana: Missoula, 2004.
(66) Davis, E. S. Comparative analysis of serotonin and norepinephrine 
reuptake inhibitor pharmacophore constructs for ligand designs; Doctor of 
Philosophy, Chemistry; The University of Montana: Missoula, 2006.
(67) Gerdes, J. M.; DeFina, S. C.; Wilson, P. A.; Taylor, S. E. Serotonin 
transporter inhibitors: synthesis and binding potency of 2'-methyl- and 3'- 
methyl-6-nitroquipazine. Bioorg Med Chem Lett 2000, 10, 2643-2646.
(68) Rondu, F.; Le Bihan, G.; Wang, X.; Lamouri, A.; Touboul, E. et al. Design 
and Synthesis of Imidazoline Derivatives Active on Glucose Homeostasis 
in a Rat Model of Type II Diabetes. 1. Synthesis and Biological Activities of
N-Benzyl-NXarylalkyO^-^'.S'-dihydro-TH-imidazol^'-yOpiperazines. j .
Med. Chem. 1997, 40, 3793-3803.
212
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(69) Walker, M. A. Serotonin Transporter Inhibitors: Studies of 2'-Substituted-6- 
nitroquipzine agents; Master of Science, Chemistry; Central Washington 
University: Ellensburg, 2001.
(70) Le Bihan, G.; Rondu, F.; Pele-Tounian, A.; Wang, X.; Lidy, S. et al. Design 
and Synthesis of Imidazoline Derivatives Active on Glucose Homeostasis 
in a Rat Model of Type II Diabetes. 2. Syntheses and Biological Activities 
of 1,4-Dialkyl-, 1,4-Dibenzyl, and 1-Benzyl-4-alkyl-2-(4',5'-dihydro-TH- 
imidazol-2'-yl)piperazines and Isosteric Analogues of Imidazoline. J Med  
Chem 1999, 42, 1587-1603.
(71) Gilman, H.; Crounse, N. N.; Massie, S. P.; Benkeser, R. A. J.; Spatz, S. M. 
Rearrangement in the Reaction of alpha-Halogenonaphthalenes with 
Lithium Diethylamide. J Am Chem Soc 1945, 67, 2106-2108.
(72) Bolstad, D. B.; Chandler-Ferguson, D.; Davis, E. S.; DeFina, S. C.;
Gerdes, J. M. et al. Serotonin Transporter Inhibitor Ligands: Synthesis and 
Biochemical Studies of 2'-Methoxymethyl-6-nitroquipazine. American 
Chemical Society 221 National Meeting: Chicago, IL, 2001.
(73) Davis, E. S.; Gerdes, J. M.; Walker, M. A.; Weller, M. L.; Wilson, P. A. et 
al. Studies of the Serotonin Transporter: Synthetic, Pharmacological and 
Whole Animal Investigations of Inhibitor 2'-Methyl-6-nitroquipazine. 
American Chemical Society 221 National Meeting: Chicago, IL, 1999.
(74) Bolstad, D. B. Synthesis of Novel 6-Nitroquipazine Analogs for Imaging 
the Serotonin Transporter by Positron Emmission Tomography; Doctor of 
Philosophy, Chemistry; The University of Montana: Missoula, 2006.
(75) O'Neil, J. P.; VanBrocklin, H. F.; Bolstad, D. B.; Gerdes, J. M.; Kusche, B. 
K. Serotonin Transporter Ligands: Synthesis of (+/-)-[11C]2‘- 
Methoxymethyl-6-nitroquipazine. J Label Compd Radiopharm 2003, 46, 
S1-S403.
(76) Thompson, S. K.; Heathcock, C. H. Effect of Cation, Temperature, and 
Solvent on the Stereoselectivity of the Horner-Emmons Reaction of 
Trimethyl Phosphonoacetate with Aldehydes. J Org Chem 1990, 55, 3386- 
3388.
(77) Mancuso, A. J.; Brownfain, D. S.; Swern, D. Structure of the dimethyl 
sulfoxide-oxalyl chloride reaction product. Oxidation of heteroaromatic and 
diverse alcohols to carbonyl compounds. J Org Chem 1979, 44, 4148- 
4150.
(78) Mancuso, A. J.; Huang, S.-L.; Swern, D. Oxidation of long-chain and 
related alcohols to carbonyls by dimethyl sulfoxide "activated" by oxalyl 
chloride. J Org Chem 1978, 43, 2480-2482.
213
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(79) Epstein, W. W.; Sweat, F. W. Dimethyl sulfoxide oxidations. Chemical 
Reviews (Washington, DC, United States) 1967, 67, 247-260.
(80) Fadel, A.; Vandromme, L. Total synthesis of (-)-sporochnol A, the fish 
deterrent, from a chiral malonate. Tetrahedron: Asymmetry 1999, 10, 
1153-1162.
(81) Hudlicky, T.; Sinai-Zingde, G.; Natchus, M. G. Selective reduction of a,[3- 
unsaturated esters in the presence of olefins. Tet Lett 1987, 28, 5287- 
5290.
(82) Angelovski, G.; Costisella, B.; Kolaric, B.; Engelhard, M.; Eilbracht, P. 
Complexation of Metals with Piperazine-Containing Azamacrocyclic 
Fluorophores. J Org Chem 2004, 69, 5290-5294.
(83) Sheehan, J. C.; Yang, D. D. H. The Use of N-Formylamino Acids in 
Peptide Synthesis. J Am Chem Soc 1958, 80, 1154-1158.
(84) Kuduk, S. D.; DiPardo, R. M.; Bock, M. G. Tetrabutylammonium Salt 
Induced Denitration of Nitropyridines: Synthesis of Fluoro-, Hydroxy-, and 
Methoxypyridines. Org Lett 2005, 7, 577-579.
(85) Frederic Dolle, H. V., Michel Bottlaender, Frangoise Hinnen, Frangoise 
Vaufrey, llonka Guenther, Christian Crouzel, Synthesis of 2-[18F]fluoro-3- 
[2(S)-2-azetidinylmethoxy]pyridine, a highly potent radioligand for in vivo 
imaging central nicotinic acetylcholine receptors. J Label Compd 
Radiopharm 1998, 41, 451-463.
(86) Shozo Furumoto, R. I., Tatsuo Ido, Synthesis of 1-0-(8-
[18F]fluorooctanoyl)-2-0-palmitoyl-rac-glycerol for imaging intracellular 
signal transduction. J Label Compd Radiopharm 2000, 43, 1159-1172.
(87) Agranat, I.; Caner, H.; Caldwell, J. Putting chirality to work: the strategy of 
chiral switches. Nat Rev Drug Discov 2002, 1, 753-768.
(88) Eichelbaum, M.; Evert, B. Influence of pharmacogenetics on drug 
disposition and response. Clin Exp Pharmacol Physiol 1996, 23, 983-985.
(89) Agranat, I. I.; Caner, H. Intellectual property and chirality of drugs. Drug 
Discov Today 1999, 4, 313-321.
(90) Owens, M. J.; Knight, D. L.; Nemeroff, C. B. Second-generation SSRIs: 
human monoamine transporter binding profile of escitalopram and R- 
fluoxetine. Biol Psychiatry 2001, 50, 345-350.
(91) Sanchez, C.; Bergqvist, P. B.; Brennum, L. T.; Gupta, S.; Hogg, S. et al. 
Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin 
reuptake inhibitor with potent effects in animal models predictive of
214
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003, 
167, 353-362.
(92) Bedurftig, S.; Wunsch, B. Chiral, nonracemic (piperazin-2-yl)methanol 
derivatives with [sigma]-receptor affinity. Bioorganic & Medicinal 
Chemistry 2004, 12, 3299-3311.
(93) Naylor, A.; Judd, D. B.; Lloyd, J. E.; Scopes, D. I. C.; Hayes, A. G. et al. A 
Potent New Class of kappa-Receptor Agonist: 4-Substituted 1- 
(Arylacetyl)-2-[(dialkylamino)methyl]piperazines. J Med Chem 1993, 36, 
2075-2083.
(94) Dinsmore, C. J.; Bergman, J. M.; Bogusky, M. J.; Culberson, J. C.; 
Hamilton, K. A. et al. 3,8-Diazabicyclo[3.2.1]octan-2-one Peptide 
Mimetics: Synthesis of a Conformationally Restricted Inhibitor of 
Farnesyltransferase. Org Lett 2001, 3, 865-868.
(95) Tillement, J. P.; Testa, B.; Bree, F. Compared pharmacological 
characteristics in humans of racemic cetirizine and levocetirizine, two 
histamine H1-receptor antagonists. Biochem Pharmacol 2003, 66, 1123- 
1126.
(96) Kawachi, J.; Matsubara, H.; Nakahara, Y. Optical resolution of 2- 
methylpiperazine using dibasic acids: Japan, 2002, JP 2002080459.
(97) Yamazaki, H.; Kiyohara, M. Preparation of optically active 2- 
methylpiperazines: Japan, 2001, JP 2001131157.
(98) Weigl, M.; Wunsch, B. Synthesis of chiral non-racemic 3-(dioxopiperazin- 
2-yl)propionic acid derivatives. Tetrahedron 2002, 58, 1173-1183.
(99) Kukula, P.; Prins, R. Diastereoselective Hydrogenation of Pyrazine 
Derivatives: An Alternative Method of Preparing Piperazine-(2S)- 
Carboxylic Acid. Journal of Catalysis 2002, 208, 404-411.
(100) Eichhorn, E.; Roduit, J.-P.; Shaw, N.; Heinzmann, K.; Kiener, A. 
Preparation of (S)-piperazine-2-carboxylic acid, (R)-piperazine-2- 
carboxylic acid, and (S)-piperidine-2-carboxylic acid by kinetic resolution 
of the corresponding racemic carboxamides with stereoselective amidases 
in whole bacterial cells. Tetrahedron: Asymmetry 1997, 8, 2533-2536.
(101) Guosheng, W.; Zhao, H.; Luo, R. G.; Wei, D.; Malhotra, S. V. Chiral 
Synthesis and Enzymatic Resolution of (S)-(-)Piperazine-2-Carboxylic 
Acid Using Enzyme Alcalase. Enantiomer 2001, 6, 343-345.
(102) Velluz, L.; Anatol, J.; Amiard, G. Use of N-benzyl intermediates in peptide 
synthesis. II. Transition through mixed ethyl carbonic anhydrides of N,N-
215
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
dibenzyl-a-amino acids. Bulletin de la Societe Chimique de France 1954, 
1449-1454.
(103) Le Bail, M.; Aitken, D. J.; Vergne, F.; Husson, H. P. Alkylation of Chiral 2- 
(aminomethyl)oxazolines. J. Chem. Soc., Perkins Trans. 1 1997,1681- 
1689.
(104) Nefkens, G. H. L.; Zwanenburg, B. Boroxazolidones as simultaneous 
protection of the amino and carboxyl group in a-amino acids. Tetrahedron 
1983, 39, 2995-2998.
(105) Gong, B.; Lynn, D. G. Regioselective Reductions of Diacids: Aspartic Acid 
to Homoserine. J Org Chem 1990, 55, 4763-4765.
(106) Garcia, M.; Serra, A.; Rubiralta, M.; Diez, A.; Segarra, V. et al. Efficient 
method for the preparation of (S)-5-hydroxynorvaline. Tetrahedron: 
Asymmetry 2000, 11, 991-994.
(107) Graham, S. L. Inhibitors of farnesyl protein transferase: USA, 1992, 
92202923.6.
(108) Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis; 
Third ed.; John Wiley & Sons, Inc.: New York, 1999.
(109) Ishida, Y.; Aida, T. Homochiral Supramolecular Polymerization of an S- 
Shaped Chiral Monomer: Translation of Optical Purity into Molecular 
Weight Distribution. J Am Chem Soc 2002, 124, 14017-14019.
(110) Mathis, C. A.; Taylor, S. E.; Biegon, A.; Enas, J. D. [125l]5-iodo-6- 
nitroquipazine: a potent and selective ligand for the 5-hydroxytryptamine 
uptake complex. I. In vitro studies. Brain Res 1993, 619, 229-235.
(111) Habert, E.; Graham, D.; Tahraoui, L.; Claustre, Y.; Langer, S. Z. 
Characterization of [3H]paroxetine binding to rat cortical membranes. EurJ  
Pharmacol 1985, 118, 107-114.
(112) Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant 
(K1) and the concentration of inhibitor which causes 50 per cent inhibition 
(I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22, 3099-3108.
(113) http://www.davliqht.com/davcgi/cloqp.
(114) Gatley, S. J.; Ding, Y. S.; Brady, D.; Gifford, A. N.; Dewey, S. L. et al. In 
vitro and ex vivo autoradiographic studies of nicotinic acetylcholine 
receptors using [18F]fluoronochloroepibatidine in rodent and human brain. 
Nucl Med Biol 1998, 25, 449-454.
216
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(115) Matthews, J. C. Fundamentals of Receptor, Enzyme, and Transport 
Kinetics', CRC Press, Inc.: Boca Raton, 1993.
(116) McCortney, B. A.; Jacobsen, B. M.; Vreeke, M.; Lewis, E. S. Methyl 
Transfers. 14. Nucleophilic Catalysis of Nucleophilic Substitution. J Am 
Chem Soc 1990, 112, 3554-3559.
(117) Armarego, W. L. F.; Perrin, D. D. Purification of Laboratory Chemicals', 
Fourth ed.; Butterworth-Heinemann: Oxford, 1997.
(118) Kofron, W. G. A Convenient Method for Estimation of Alkyllithium 
Concentrations. J Org Chem 1976, 41, 1879-1880.
217
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
